
























This copy has been supplied by the Library of the University of Otago on the understanding that 
the following conditions will be observed: 
 
1. To comply with s56 of the Copyright Act 1994 [NZ], this thesis copy must only be used for 
the purposes of research or private study. 
 
2. The author's permission must be obtained before any material in the thesis is reproduced, 
unless such reproduction falls within the fair dealing guidelines of the Copyright Act 1994.  
Due acknowledgement must be made to the author in any citation. 
 




Natural antioxidants and susceptibility of low density 
lipoproteins to oxidation 
Jane E Upritchard 
A thesis submitted in fulfilment 
of the requirements for the degree of 
Doctor of Philosophy 





In patients with diabetes mellitus, increased oxidative stress may contribute to 
low density lipoprotein (LDL) oxidation and elevated levels of circulating products 
of inflammation. A randomised, placebo-controlled study was conducted in patients 
with type 2 diabetes mellitus to compare the effect of four weeks of supplementation 
with tomato juice (500 ml/day), alpha-tocopherol (800 IU/day) or vitamin C (500 
mg/day) on LDL oxidation, circulating levels of C-reactive protein (C-RP), soluble 
vascular cell adhesion molecule-I (sVCAM-1) and intercellular adhesion molecule-I 
(sICAM-1), and circulating products of lipid peroxidation. Plasma lycopene levels 
increased nearly three fold with the consumption of tomato juice and LDL resistance 
(lag time) to copper ion stimulated oxidation increased by 42% (P=0.001). The 
magnitude of the change with tomato juice was comparable to the corresponding 
increase during supplementation with a pharmacological dose of alpha-tocopherol 
(54%, P=0.001). Alpha-tocopherol also decreased plasma C-RP (-49%, P=0.004) 
and increased plasma cholesterol concentration (9%, P=0.022). Circulating levels of 
adhesion molecules, erythrocyte TBARS, plasma indices of lipid peroxidation and 
plasma glucose did not change significantly during the study. These findings 
indicate drinking tomato juice is an effective way to increase plasma lycopene levels 
and the intrinsic resistance of LDL to oxidation in diabetic patients. Alpha-· 
tocopherol increases the resistance of LDL to oxidation and reduces systemic 
inflammatory activity but these potentially anti-atherogenic actions are opposed by a 
concomitant increase in plasma cholesterol levels. 
The second study in this thesis focused on the development of a model which 
may reflect LDL oxidation in the arterial intima more closely than the frequently 
used copper ion induced oxidation of isolated LDL. Low density lipoproteins can 
bind to proteoglycans rich in heparin and chondroitin sulphate in the arterial intima 
and consequently may become a target for atherogenic modification by 
myeloperoxidase (MPO). Experiments were conducted to examine the susceptibility 
to peroxidase/hydrogen peroxide (H
2
0 2) catalysed oxidation of resolubilised LDL, 
that has been precipitated from serum with heparin and from native LDL with 
heparin, chondroitin sulphate, dextran sulphate, and polyethyleneglycol. In addition, 
the effects of antioxidants and components of human serum on the oxidation of 




system were investigated. The LDL from 
complexes with glycosaminoglycans and dextran sulphate were oxidised rapidly by 
horse radish peroxidase (HRP) and H20 2 (mean t14max for conjugated diene formation 
of 3-5 minutes) while there was little oxidation of native LDL and 
polyethyleneglycol-LDL during the 30 minute incubation period. Aggregated LDL 




• The formation of thiobarbituric acid reacting 
substances (TBARS) paralleled the change in conjugated dienes during oxidation of 





• Oxidation of heparin-LDL by peroxidases did not require free tyrosine 
and was almost totally inhibited by butylated hydroxytoluene (BHT) and ascorbate, 




betalipoprotein deficient serum (BLPDS) significantly (P<0.0001) inhibited the 
formation of TBARS during heparin-LDL oxidation catalysed by HRP and MPO. 
The inhibitory activity was removed by dialysis and gel-filtration of BLPDS and 
was not restored by addition of physiological levels of ascorbate, tyrosine and 
reduced thiols (cysteine) to gel-filtered BLPDS. These results indicate that LDL can 
form complexes with glycosaminoglycans rendering them particularly susceptible to 
oxidation by peroxidases. Furthermore LDL oxidation may be inhibited by small, 
water soluble compounds in the human serum but not by vitamin E. These findings 
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Oxidation of low density lipoprotein (LDL) that becomes trapped in the artery 
wall is regarded as an important step in the development of atherosclerosis.0,2) 
There is evidence that mildly oxidised LDL enhances the expression of 
inflammatory cytokines, chemokines and cellular adhesion moleculesO) by 
endothelial cells and monocytes. These molecules promote the adhesion of 
monocytes to the vascular endothelium followed by transmigration of adhered cells 
into the intima where they are retained and transformed into macrophages.0,2) 
Cultured macrophages avidly internalise oxidised LDL via unregulated receptors 
resulting in lipid-filled cells.0,2) A similar process may occur in the artery wall to 
generate foam cells, the hallmark of the early atherosclerotic lesion. Oxidative 
activities may also contribute to changes in plaque morphology, rupture and 
thrombus formation that can lead to angina pectoris, myocardial infarction (Ml) and 
ischIBmic stroke. (3-5) 
Reliable methods to determine the susceptibility of LDL to oxidation in vivo 
are not available. Monitoring the formation of conjugated dienes as a measure of 
intrinsic resistance of isolated LDL to copper ion mediated oxidation has emerged as 
a popular ex vivo modeI.(6,7) However models which more closely reflect LDL 
oxidation in vivo, by the inclusion of elements present in the artery wall and 
physiological pro-oxidants, are the current focus of investigation by a number of 
research groups.(8-16) 
Decreasing oxidative stress through the antioxidant protection of LDL is a 
strategy which may have significant consequences in reducing the development of 
atherosclerotic heart disease and its clinical sequelae.07-22) A number of studies 
indicate that dietary supplementation with high doses of vitamin E increases the 
resistance of isolated LDL to oxidation.(23-27) Also monocytes isolated from healthy 
subjects after supplementation with vitamin E show reduced adhesion to cultured 
endothelial cells and depressed release of interleukin- Ip (IL-1 P). (28) In people under 
increased oxidative stress, due to smoking, supplementation with high doses of 
vitamin C has been demonstrated to reduce the susceptibility of LDL to oxidation 
(29) and inhibit monocyte adhesion.(30) Lycopene, a major carotenoid in human 
plasma, inhibits the oxidative modification of isolated LDL.(31) Tomato products in 
the diet are a rich source of lycopene and drinking tomato juice has been 
demonstrated to increase plasma lycopene levels in healthy subjects. (32-35) Regular 
consumption of tomato juice appears to improve the resistance of isolated LDL to 
oxidation but this has not been tested in a randomised placebo-controlled trial. (33-36) 









Patients with type 2 diabetes are at increased risk of developing coronary heart 
disease (CHD) compared with the general population.(37) Increased oxidative 
stress(38) and enhanced LDL oxidationC39) are believed to contribute to this excess 
risk of arterial disease.(40) In diabetic patients, circulating levels of inflammatory 
cytokines,(41) C-RP,(41,42) soluble vascular cell adhesion molecule-1 (sVCAM-1) 
and intercellular adhesion molecule-1 (sICAM-1)(43,44) are elevated, suggesting 
pro-atherogenic inflammatory activity is increased. Furthermore, antioxidant 
protection may be inadequate and levels of some antioxidants including 
ascorbate(45-48) and lycopene(49) are low. Antioxidants may attenuate oxidative 
stress and inflammatory activity, however this has not been extensively tested in 
patients with type 2 diabetes. 
Outline of thesis 
A review of the current literature examining the interrelationship between 
natural antioxidants, LDL oxidation and diabetes is presented in Chapter 2. Some 
detail is also included on the methodology employed to investigate LDL oxidation 
and the relevance of these measures to atherosclerosis. Chapter 3 outlines an 
intervention trial which was conducted to examine the effect of natural antioxidants 
on LDL oxidation and inflammatory activity in patients with type 2 diabetes. A draft 
manuscript has been prepared from this chapter for submission to the journal 
"Diabetes Care."(Appendix A) Chapter 4 characterises a new model for assessing 
the susceptibility of LDL to oxidative modification ex vivo. A shorter version of this 
chapter was recently accepted for publication by in the journal "Atherosclerosis." 










2.1.1 Pathogenesis of atherosclerosis 
Atherosclerosis is the underlying primary cause of most cardiovascular 
diseases (CVD).(50,51) Atherosclerosis is a progressive multifactorial disease of large 
and medium sized arteries, whereby the arterial wall loses elasticity and the lumen is 
narrowed due to thickening of the intima. (50,52) In the development of 
atherosclerosis the lipid-filled fatty streak is the earliest lesion and this may progress 
via an intermediate lesion to a fibrous plaque. This plaque encroaching on the lumen 
may eventually rupture, resulting in occlusive thrombosis and subsequent 
myocardial infarction (MI) or ischremic stroke.(1,4,5,50-54) 
2.1.2 Role of oxidised LDL in atherosclerosis 
In the early stages of atherosclerosis, increased plasma LDL, endothelial 
dysfunction and permeability, and an imbalance between cholesterol influx and 
efflux result in the formation of foam cells in the artery waU.(55) The majority of the 
foam cells are derived monocyte-macrophages, and many of the properties exhibited 
by LDL which has been oxidatively modified could explain why monocytes migrate 
from the circulation into the subendothelial space, differentiate to macrophages and 
accumulate intracellular lipid to be converted to foam cells. 
Low density lipoprotein appears to be readily transported across the 
endothelium. Components of the extracellular matrix, namely proteoglycans and 
their long carbohydrate side-chains glycosaminoglycans, can interact with LDL, 
resulting in structural alterations and retention in the arterial wall. (56) The 
distribution of proteoglycans in the arterial intima varies with anatomical location 
and is increased in areas of intimal thickening associated with lesion development. (8) 
It is postulated that associations of LDL with proteoglycans and glycosaminoglycans 
increase both the susceptibility of LDL to oxidative modification and the 
opportunity for this modification to occur. (8) Subendothelial retention of LDL is an 
essential process in the development of the early lesion.(53,57,58) 
Oxidative waste and enzymes secreted from the vascular cells probably 
mediate LDL oxidation in the subendothelial space.(2) Initially LDL is minimally 
oxidised and the modified lipids formed are considered to have pro-inflammatory 
characteristics, upregulating inflammatory genes and the expression of cytokines and 
chemokines.(59,60) Several of these molecules participate in to the adherence of 








into the intima and transformation of monocytes into macrophages.(59) The 
expression of vascular cell adhesion molecule- I (VCAM- I) and intercellular 
adhesion molecule- I (ICAM- I) result in the firm adhesion of monocytes. Monocyte 
chemotactic protein-I, together with cell adhesion molecules, attract and guide 
monocytes into the arterial intima. Macrophage colony-stimulating factor causes 
monocyte differentiation into macrophages. Differentiation of monocytes also 
produces monocyte chemotactic protein-! that can stimulate further amplify the 
recruitment of monocytes.(61) Activated macrophages may continue to oxidise the 
lipids in LDL and modify apolipoprotein B, leading to a loss of recognition by the 
LDL receptor.(62-64) Oxidatively modified lipoprotein is taken up by unregulated 
receptors on macrophages, resulting in massive accumulation of cholesterol. Such 
cholesterol loaded cells are called foam cells and represent the first stage in fatty 
streak formation. 
In addition, oxidised LDL may be pro-atherogenic in other ways. Oxidised 
LDL may form immune complexes (65) and aggregates, and these are readily 
internalised by macrophages. (66,67) The release of cytotoxic lipid peroxidation 
products from oxidised LDL in the intima can be considered an irritant for the 
endothelial cell layer,(55,68) and may result in endothelial cell necrosis, platelet 
aggregation, release of growth factors that promote smooth muscle cell proliferation, 
accumulation of inflammatory cells and alterations to eicosanoid homeostasis. 
Furthermore, oxidatively modified LDL stimulate procoagulant activities by 
endothelial cells. ( 69, 70) 
2.1.3 Evidence for oxidised LDL in vivo 
Several lines of evidence provide support to the hypothesis that oxidatively 
modified LDL is an atherogenic agent.0,2,50,55,71,72) Oxidised LDL(73-75) and the 
major cytotoxin in oxidised LDL, 7~-hydroperoxycholest-5-en-3~-oI,06) have been 
isolated from atherosclerotic lesions. Low density lipoprotein isolated from aortic 
plaques, obtained at autopsy, share a number of structural and functional similarities 
with LDL which has been oxidised by incubation with copper ions. (74) Oxidised 
LDL forms auto-antibodies against oxidised-specific-lipid-protein epitopes(65,77) 
which have been reported as predictive markers of the progression of carotid 
atherosclerosis and MI.(78) Furthermore, a number of structurally unrelated 
antioxidants have been shown to retard lesion formation in hypercholesterolremic 
animals.09-81) 
2.1.4 Potential oxidants of LDL 
Low density lipoproteins circulating in the plasma are well protected from 
oxidation by a variety of antioxidant defence systems. (82,83) However in micro-
domains of the arterial wall, antioxidants may be depleted and the lipoproteins 
exposed to oxidative stress. The precise mechanism is uncertain although a number 
of candidates have been suggested as potential pro-oxidants of LDL. 
Vascular cells in the artery wall release enzymes, such as lipoxygenase(84) and 











) secreted by phagocytes convert 
chloride to hypochlorous acid(9I) and L-tyrosine to a tyrosyl radical,(92)and these 
products are capable of oxidising LDL. (88-90) Hypochlorous acid targets reactive 
amino groups on apolipoproten B,(90) and unsaturated fatty acids, and 
cholesterol,(93,94) modifying LDL to a form which is readily internalised by cultured 
macrophages.(95) There is strong evidence that myeloperoxidase is responsible for 
oxidation of LDL in vivo. Concentrations of a, a /-dityrosine, a marker of tyrosyl 
radical damage, (96,97) and 3-chlorotyrosine, a marker of MPO modified tyrosine, (98-
100) are markedly higher in atherosclerotic lesions compared with normal tissue or 
the circulation.001,102) 
During normal metabolism vascular cells also release a number of reactive 
oxygen species, including superoxide anion radicals and nitric oxide. Superoxide 
anion radicals may interact with nitric oxide to produce peroxynitrite,003) which is 
capable of promoting LDL peroxidation.004-107). Peroxynitrite reacts with tyrosine 
to form 3-nitrotyrosine.008) Levels of 3-nitrotyrosine are higher in atherosclerotic 
lesions than in the circulation(l09) indicating peroxynitrite may stimulate oxidative 
reactions in the LDL in vivo. 
Incubating LDL with vascular cells, such as macrophages, endothelial cells, 
smooth muscle cells, or neutrophils, has been demonstrated to stimulate the 
oxidation of the LDL in vitro. However this process requires low concentrations of 
transition metal ions, such as copper or iron. (110) Copper ions initiate LDL oxidation 
by first binding to the LDL and subsequently copper is reduced by the LDL.(111,112) 
In the case of iron, LDL cannot reduce iron so an external reductant such as a 
superoxide anion radical, hydrogen peroxide or thiol is required to initiate 
oxidation.011,113) Vascular cells could provide these reductants in vivo.(114-117) 
Metal containing proteins, such as creruplasmin(118) and hreminC8,12,13) also 
stimulate LDL oxidation in vitro. The metal is released from the protein by reactive 
oxygen species, hydrogen peroxide or glycation, and oxidation proceeds in a process 
which is similar to transition metal ion stimulated oxidation. Glucose may undergo 
auto-oxidation and also stimulate LDL oxidation in the presence of transition metal 
ions. (119-121) 
The oxidation of LDL by transition metal ions has been extensively studied in 
vitro however in the artery wall this process appears unlikely to be the major 
initiator of LDL oxidation. Proteins in the extracellular fluid of the artery wall 
would probably bind any free transition metal ions and prevent them from catalysing 
the oxidation of LDL.018,122,123) Transferrin, the major carrier of iron in the 
plasma, also binds iron and copper with high affinity.024,125) Free metal ions are 
unlikely to exist in the plasma or normal arterial tissue, (72) except in some situations 
they may be released as a result of cellular dissolution in injured tissueOOl,126) or 
with glycation of the creruplasmin027). The protein moiety on LDL forms a-tyrosine 
and m-tyrosine when oxidised by copper ions, thus levels of a-tyrosine and 
m-tyrosine in the atherosclerotic lesions provide a possible strategy to evaluate if 
transition metals ions are responsible for catalysing LDL oxidation in vivo.(101,128) 
In fatty streaks or intermediate atherosclerotic lesions levels of a-tyrosine and 







with diseases where high levels of trace metals are deposited in the tissues, such as 
hremochromatosis and Wilson's disease, do not appear to have an increased 
predisposition to premature atherosclerosis.029-131) Studies examining iron stores in 
the body and risk of CHD have not resulted in clear conclusions. (132-134) 
2.1.5 Oxidised LDL and inflammatory activity 
The oxidised lipids in minimally modified LDL may induce an inflammatory 
response through the stimulation of the transcription factor nuclear factor-kappa, B 
(NF-KB).035-139) The activation of NF-KB leads to a co-ordinated increase in the 
expression of many genes whose products mediate inflammatory and immune 
responses,040,141) including genes which encode pro-inflammatory cytokines, 
interleukin-I beta (IL-I~), interleukin-6 (IL-6), and tumour necrosis factor-alpha 
(TNF-a), macrophage colony stimulating factor; chemokines, in particular 
monocyte chemotactic protein- I; inflammatory enzymes; cellular adhesion 
molecules, ICAM-1, VCAM-1, E-selectin; and immune receptors. Interleukin-I~ 
and TNF-a may also cause the activation of NF-KB, thus amplifying and 
perpetuating local inflammatory responses. 
2.1.5.1 C-reactive protein 
Levels of C-reactive protein (C-RP), the classical acute-phase plasma protein, 
can rise by more than I 000 fold following tissue damage, infection or 
inflammation.(142,143) C-reactive protein is synthesised rapidly and exclusively by 
hepatocytes in response to increased levels of the pro-inflammatory cytokines, IL-I~ 
and TNF-a(142) and synergistically enhanced with IL-6.(144) The oxidised lipids 
from LDL have been demonstrated to increase pro-inflammatory cytokines and 
stimulate an acute phase response.(142) 
Inflammation may be elevated in response to the underlying atherosclerotic 
disease process and also as part of the disease.045) Inflammatory activity in arterial 
lesions may be an important component of changes in plaque morphology, rupture 
and thrombus formation leading to MI.(3,4) Deposits of C-RP have been isolated 
from lesions in human aortas.046,147) Plasma concentrations of C-RP are elevated in 
patients with acute ischremia048) or MI,049,150) and have been found to predict the 
progression of ischremia in patients with unstable angina.OSI) C-reactive protein is 
associated with both the propensities for MI in patients with angina and mortality in 
people with multiple risk factors for atherosclerosis.(152-155) Ridker and co-workers 
demonstrated plasma concentrations of C-RP predict the risk of future MI and 
stroke in healthy men056) and this prediction was independent of the other known 
CVD risk factors, including plasma lipid levels. (157) Furthermore, this risk was 
observed with apparently small elevations in plasma C-RP concentration (3 mg/I) 






2.1.5.2 Cell adhesion molecules 
The adhesion of leukocytes to endothelial cells and their subsequent 
transendothelial migration is mediated by adhesion molecules on both the 
endothelium and monocytes.058) Quiescent endothelial cells lack adhesion 
molecules whilst cells activated by cytokines, such as IL-1 ~ and TNF-a, have 
increased expression of these molecules.059,160) 
Strong associations between macrophage accumulation and adhesion 
molecules, in particular VCAM-1, expression have been reported.061) Soluble 
forms of VCAM-1 (162) and ICAM-1 (163) are present in the circulation, and appear 
to indicate cellular expression of these molecules. Recently sICAM-1 was reported 
to be an independent predictor of future MI in apparently healthy men.064) Also, 
Rohde and co-workers found levels of sVCAM-1 and sICAM-1 were correlated with 
early atherosclerosis, as assessed by intimal-medial thickness.(165) These findings 
are in agreement with case-control studies showing elevated levels of s VCAM-1 and 
sICAM-1 in patients with evidence of atherosclerosis compared with asymptomatic 
control subjects.062,166) In contrast, Peter and co-workers reported levels of 
sVCAM-1 were raised while sICAM-1 was normal in patients with peripheral artery 
vascular disease.067) Differences in the sensitivity of analytical methods and the 
inclusion of subjects with subclinical disease may have contributed to the variance in 
the findings. 
Dyslipidremia is associated with raised levels of sVCAM-1 and sICAM-1.(168) 
In particular, low HDL is associated with enhanced cytokine induced expression of 
endothelial cell adhesion molecules.(169) Also oxidised lipid,070) 
lysophosphatidycholine, and oxidatively modified LDL increase the expression of 
VCAM-1 and ICAM-1 on cultured endothelial cells.(171) However, Khan and co-
workers reported that oxidised LDL did not increase the expression of ICAM-1 
directly but increased the expression of TNF-a resulting in increased ICAM-1. (172) 
1he variance in findings may depend on differing methods for preparing oxidised 
LDL and cell culture conditions. Intercellular adhesion molecule-I and VCAM-1 
expression on human endothelial cells has been demonstrated to be increased when 
LDL oxidation is catalysed in the presence of low levels of copper ions, suggesting 
it is a specific product of mildly oxidised LDL which may be responsible for this 
expression. (171) 
2.2 Lipid oxidation products 
2.2.1 Formation of lipid oxidation products from polyunsaturated 
fatty acids 
Reactive oxygen species are constantly produced by metabolic reactions in the 
human body.(82,173) When an oxygen radical interacts with a polyunsaturated fatty 
acid, a hydrogen atom is abstracted from the fatty acid liberating a carbon radical 









turn may react with oxygen, resulting in a peroxyl radical. The peroxyl radical may 
have several possible fates including the abstraction of a hydrogen atom from an 
adjacent polyunsaturated fatty acid side chain, thereby propagating the oxidative 
injury. Further decomposition of the peroxyl radical catalysed by copper, iron and 
metal complexes (e.g. hreme, creruplasmin) results in additional radicals, and finally 
the formation of aldehydes (e.g. malondialdehyde (MDA)) and hydrocarbon gases. 
Rearrangement of conjugated dienes, after the addition of oxygen, results in the 
formation of isoprostanes F2o:. Thus attack by one oxygen radical may result in the 
production of many radicals and the propagation of peroxidation. 
2.2.2 Measurement of lipid oxidation products 
The measurement of lipid oxidation products in blood is difficult as LDL 
oxidation is likely to occur outside the circulation in the micro-domains of the 
arterial waU.074) Even if some oxidised lipoproteins are in the blood their 
concentration may not directly reflect those at the site of their formation in the artery 
wall. Extensively oxidised LDL is rapidly removed from the circulation by 
scavenger receptors so residence time in the plasma will be exceedingly short and 
levels are likely to be very low. Alternatively, the levels of oxidation products from 
isolated LDL or erythrocytes, provide a site-specific index of oxidative damage. 
However the isolation procedures may alter the concentration of lipid oxidation 
products.075,176) Numerous methods are available for the measurement of lipid 
oxidation products, however none are entirely satisfactory. 
Lipid peroxides are among the first peroxidation products to form from the 
oxidation of fatty acids in LDL. Levels can be quantified by iodimetry, whereby the 
peroxides oxidative capacity to convert iodide to iodine can be determined using a 
commercial reagent spectrophotometrically at 'A 365 nm.077) This method is 
convenient to perform but lacks specificity. Nevertheless this assay may provide a 
useful index of early lipoprotein peroxidation. A colourimetric assay using 
N-benzoyl methylene blue also provides a measure of lipid hydroperoxides in 
isolated lipids.(178) However, the extraction of lipids from the plasma may result in 
loss and an under estimation of peroxide levels. (176) Plasma concentrations of lipid 
hydroperoxides can be determined colourimetrically by ferrous iron oxidation in 
xylenol orange.079) Specificity in this assay is achieved by subtracting a 
background where lipid hydroperoxides are reduced by triphenyl-phosphine but the 
sensitivity of this measure is reduced due to the high background readings. A 
number of sophisticated procedures have also been developed to measure 
hydroperoxides and cholesterol hydroperoxides, including high performance liquid 
chromatography (HPLC) analysis with chemiluminescence,(180-183) fluorimetric 
post column detection084) and electrochemical detection.(185) These methods are 
extremely sensitive and specific. However when they are applied to plasma samples, 
the water soluble antioxidants must be removed or the lipid isolated prior to 
analysis, and this may result in the loss of peroxides. (176) The specialist equipment 
required for these procedures may also limit their use in many laboratories. 
Increased levels of lipoperoxides result in the rearrangement of the fatty acid 











absorbance at "A, 234 nm. However due to their transitory nature they are not a good 
index of peroxidation when measured at a single time point. (186) 
Isoprostanes are a marker of arachidonic acid peroxidation087,188) which form 
from esterified phospholipids and are subsequently released, presumably in the free 
form, through the action of phospholipases in vivo.(189) Isoprostanes are stable 
adducts which circulate in the plasma and are excreted in the urine. One of the most 
abundant F
2
-isoprostanes in the plasma is 8-epi PGF
2
a,(190-192) which is sensitive 
primarily to lipid oxidation and to a minor extent platelet cyclooxygenase.C193) 
Recently IPF2al was identified in urine and it appears to provide a sensitive marker 
of arachidonic acid oxidation which is independent of cyclooxygenase.(194) 
Isoprostanes can be quantified in these fluids by gas chromatography/ mass 
spectrometry.(190,191,195) 
As lipid peroxidation continues, lipid hydroperoxides decompose to form 
secondary products such as alkanes and aldehydic compounds. The reaction 
between MDA and TBARS yields a pink MDA-TBA adduct.096) This coloured 
complex can be quantified spectrophotometrically from its visible absorbance 
(A max 532 nm)(197) or by spectrofluorometry (excitation 532 nm, emission 553 
nm)098,199) and it is readily extractable into organic solvents such as butanoI.<200) 
However other aldehydes and substances, such as bilirubin, DNA, sugars, 
prostaglandins and thromboxanes, may interfere with determinations of MDA.(201-
203) Quantification of the MDA-TBA adduct by HPLC almost entirely eliminates 
this interference providing a specific and sensitive measurement of 
MDA-TBA.(204,205) However, this does not alleviate the problems associated with 
the conditions used to form the TBA-MDA adduct.C206) 
Many aldehydic products are highly reactive and can react with the E -amino 
groups of lysine residues in apolipoprotein B, forming Schiff bases and 
oxycholesterol derivatives. Schiff bases (FSB) may be quantified with 
fluorescence.(207) However advanced glycosylated end-products (AGE-products) 
also exhibit fluorescence over the same range(208) and may interfere with this 
measurement. Volatile hydrocarbons and aldehydes, such as pentane, ethane, hexane 
and 4-hydroxynoneal, may be determined by head-space gas chromatography of 
exhaled air.(209,210) These hydrocarbons have been linked with increased lipid 
peroxidation in vivo, however interference by other hydrocarbons and 
methodological difficulties may limit use. (211) 
Lysine residues are positively charged at physiological pH, hence the 
formation of Schiff s bases during the modification of LDL results in an increased 
net-negative charge of apolipoprotein B, which can be measured as increased anodic 
relative electrophotoretic mobility of LDL upon agarose gel electrophoresis. Thus 
the proportion of LDC to total LDL has been used as a measure of minimally 
modified LDL in vivo. (212) 
Auto-antibodies to epitopes of oxidatively modified LDL, such as MDA-LDL 
provide a very sensitive and specific measure of LDL oxidation. The relevance of 
this measure may be limited by the lack of information concerning the chemical 










2.3 Measurement of LDL susceptibility to 
oxidation 
Following the development of lipid oxidation products formed in isolated LDL 
when stimulated with a pro-oxidant, provides information on compositional changes 
which affect susceptibility to oxidation. A number of assays exist to evaluate this ex 
vivo oxidation, the most popular of these models uses copper ions to initiate the 
oxidation of isolated native LDL. Recently, other models which may better mimic 
the conditions believed to exist in the micro-domains of the arterial wall have also 
been studied. 
2.3.1 Copper ion stimulated oxidation 
2.3.1.1 Kinetics of LDL oxidation 
The susceptibility of LDL to copper ion stimulated oxidation may be 
determined by following the temporal profiles of the formation of conjugated dienes, 
TBARS, fluorescence at 'A, 430 nm, lipid peroxides, or relative electrophoretic 
mobility. During the lag and propagation phases these measurements are very 
similar, and only after the peroxide maximum is reached do the different indices 
separate producing dissimilar kinetic traces.(6,80,214) 
The duration of the lag time, as assessed by a change in absorbance at 
'A, 234 nm, provides a reliable and reproducible index of susceptibility to oxidation of 
the polyunsaturated fatty acids in LDL.(7,23,214-216) The kinetics of this oxidation 
are highly dependent on the experimental conditions, in particular temperature, pH, 
copper concentration, LDL preparation and concentration.(217-220) Low density 
lipoproteins appear to have a discreet number of copper binding sites, mainly on 
apolipoprotein B,012) which display either high or low affinity binding for copper 
ions depending on the concentration of copper ions. The characteristic lag phase is 
only present under experimental conditions in which the copper ions bind 
predominantly to the low affinity sites, when the copper concentration is high 
(~1.6 µmol/1) and the sites are not saturated. In contrast, at lower copper 
concentrations the high affinity sites bind copper ions and no lag phase is observed. 
Low density lipoprotein cholesterol is isolated in the presence of EDT A to limit 
artefactual oxidation.075) However, EDTA must be removed before copper 
stimulated oxidation of LDL and desalting columns are the preferred method of 
removing EDT A as prolonged dialysis has been associated with lipid oxidation and 
antioxidant depletion. (221) The temperature of the incubation medium must be stable 
throughout the assay to avoid variations in the rate of oxidation. Ideally the assay 
should be conducted at 37°C, although, lower temperatures may be used and the rate 
of oxidation will be reduced accordingly. Thus conducting copper ion induced 
oxidation of isolated LDL under standardised conditions is essential for comparisons 












2.3.1.2 Intrinsic factors influencing susceptibility of LDL to 
oxidation 
The duration of the lag time appears stable for an individuaI(222,223) but there 
is considerable variation between individuals.(224,225) A number of factors intrinsic 
to LDL are thought to be responsible for this variation, such as antioxidant 
concentrations, composition of fatty acids, distribution of LDL subfractions, 
intrinsic peroxides, protein to cholesterol ratio, and apolipoprotein B sulphydryl 
groups. (7,226) 
Low density lipoprotein contains a number of antioxidants including 
tocopherols, carotenoids and ubiquinol-10.(227) Alpha-tocopherol is the predominant 
antioxidant, with each LDL particle containing five to nine alpha-tocopherol 
molecules.(227,228) It has been reported that alpha- and gamma-tocopherol explain at 
least 30% of the variation in lag time with copper induced oxidation of 
LDL. (225,229) Lycopene, beta-carotene, and ubiquinol-10 are present in similar 
amounts, albeit substantially reduced compared with alpha-tocopherol, in the 
LDL.(229-231) Enriching LDL in vitro with antioxidants such as alpha-
tocopherol, (80,224,227,230,232,233) lycopene, (31) beta-carotene, (31,232) and ubquinol-
IQ(l 83) facilitates significant reductions in the susceptibility of LDL to copper ion 
stimulated oxidation. 
The fatty acid composition of LDL is primarily determined by diet. (234,235) 
Diets high in linoleate increase the levels of total oxidation products formed with 
copper ion oxidation.(235,236) However fatty composition does not appear to greatly 
influence the resistance of LDL to oxidative modification. Abbey and co-workers 
reported that lag time was identical when normolipidremic men consumed a 
linoleate-rich diet or an oleate-rich diet for several weeks.(237) In contrast, Reaven 
and co-workers reported increased oxidative modification of LDL in mildly 
hyperlipidremic men on a diet highly enriched with polyunsaturated fats but 
examination of their data suggested the lag time was not reduced. (236) 
Levels of small dense LDL are associated with lipoprotein abnormalities, such 
as increased total cholesterol, VLDL and low HDL. (238,239) Low density 
lipoproteins which are small and dense are more susceptible to oxidation.(240-244) 
Also this LDL subfraction is depleted in antioxidants, in particular vitamin E and 
carotenoids. (240,245) 
2.3.1.3 Extrinsic factors influencing susceptibility of LDL to 
oxidation 
The environment surrounding LDL in the micro-domains of the artery wall is 
believed to contain a number of compounds which also modulate LDL 
oxidation.(246,247) The composition of this fluid is known to vary with location and 
permeability of the endothelium. (248) These elements are usually removed during 
the isolation of LDL from plasma. Thus the complex composition of these 
components in the extracellular fluid and matrix are difficult to reproduce under 















Recently, the effects of some of these elements on copper ion stimulated 
oxidation of LDL has been studied in vitro. High density lipoproteins protect LDL 
from copper ion stimulated oxidation in vitro(249) and prevent the production of 
minimally modified LDL by vascular cells in a co-culture model. (250) High density 
lipoprotein contains enzymes, platelet activating factor acetylhydrolase and 
paraoxonase, which have been shown to protect against LDL oxidation in co-culture 
systems.(251) High concentrations of albumin and other plasma proteins, including 
transferrin, and creruplasmin, appear to sequester free copper ions and prevent 
copper induced oxidation.025). At physiological concentrations the water soluble 
antioxidant vitamin C has been demonstrated to scavenge free radicals(89,252-254) 
(aqueous peroxyl, tyrosyl and superoxide anion radicals) and oxidants083,255) 
(hypochlorite, peroxynitrite) in the fluids similar to those surrounding LDL in the 
micro-domains of the artery wall. Vitamin C may oxidise the histidine residues of 
apolipoprotein B rendering them unable to bind copper ions and thus limit LDL 
oxidation. (252,256,257) Furthermore, ascorbic acid can destroy lipid hydroperoxides 
in the LDL.(256) Ascorbic acid and several other water soluble antioxidants, 
glutathione and ubiquinol-10, are able to regenerate LDL associated alpha-
tocopherol from the alpha-tocopheroxyl radical at the water-lipid interface.(258,259) 
Kontush and co-workers have established a model which allows total 
lipoprotein oxidisability to be evaluated with the plasma components present; diluted 
plasma is oxidised by copper ions and the increase in conjugated dienes is 
monitored.00) In this system plasma albumin and thiol groups are strongly 
correlated with duration of lag phase and alpha-tocopherol, carotenoids and vitamin 
C, influence the maximal rate of oxidation. These results suggest antioxidants 
present in the extracellular fluid may have an important role in reducing LDL 
oxidation in vivo. Furthermore, antioxidant enrichment of plasma in vitro(260) or 
through supplementation of the diet of rabbitsOO) reduced the susceptibility of 
plasma to oxidation. However in this model of oxidation, the plasma was diluted 
extensively resulting in the components of the plasma in very low concentrations 
compared with the situation in vivo and a high ratio of copper ions to plasma 
lipoproteins. 
The formation of complexes between LDL and arterial proteoglycans, such as 
heparin and chondroitin sulphate has been found to make LDL more susceptible to 
oxidation in vitro.(14,122) Low density lipoprotein that has been precipitated with 
proteoglycans or glycosaminoglycans in vitro and then resolubilised is thought to 
imitate LDL which has formed reversible associations with proteoglycans in the 
arterial intima.(261,262) Low density lipoproteins which have been isolated from the 
plasma in this way show increased susceptibility to copper ion oxidation.(14) This 
precipitated resolubilised LDL has an altered structure04,263) and is bound and 
internalised more efficiently than native LDL by the apolipoprotein B/E receptor of 
cultured macrophages.(264) It is possible this LDL is structurally altered by this 
association resulting in increased access of the copper ions to the inner core 









2.3.1.4 Association of lag time with CHD 
A number of case-control studies have reported an association between 
increased susceptibility of LDL to copper ion oxidation, as assessed by lag time, and 
risk of CAD. Regnstrom and co-workers examined the susceptibility of LDL to 
oxidation in patients who had an acute MI and recorded that the duration of lag time 
was inversely related to the severity of coronary atherosclerosis.(216) De Rijke and 
co-workers reported oxidative resistance was lower in by-pass patients who 
displayed progression of their atherosclerosis compared with controls who remained 
stable. (265) Furthermore, CAD patients had significantly shorter lag times compared 
with control subjects(266) and this relationship was independent of other risk factors 
for CAD. This finding is in agreement with a number of other studies in CAD 
patients(267-269) although not alI.(270 763,271) Angiography is a sensitive technique 
for the diagnosis of CAD however studies which have used less sensitive 
methodology may result in the inclusion of asymptomatic patients with subclinical 
CAD in the control group, and this may obscure any differences between cases and 
controls. Several studies have reported LDL from patients with known risk factors 
for CVD, such as hypertension, hypercholesterolremia, display increased 
susceptibility to oxidation.(272-275) This provides further support to the hypothesis 
that the susceptibility of LDL to oxidation may be related to the rate of 
atherosclerosis. However, case-control studies can not determine cause and effect. 
Prospective studies are required to determine whether increased susceptibility of 
LDL to oxidation precedes the formation of arterial lesions. 
2.3.2 Other models of LDL oxidation 
At present there is considerable interest in the development of models which 
may more closely reflect LDL oxidation in the micro-domains of the artery wall 
than copper ion stimulated oxidation of isolated LDL. These models have focused 
on oxidative modification of LDL by physiological pro-oxidants and in the presence 
of extracellular components. Hremin is a iron-containing product of hremoglobin 
degradation. It is able to enter hydrophobic domains and oxidise LDL, in vitro, 
particularly in the presence of hydrogen peroxide.03) When native LDL is oxidised 
by hremin/H
2
0 2 there is a lag time in lipid peroxidation, measured by hremin 
degradation, and this can be prolonged by high concentrations of ascorbate and 




appears to be 
accelerated with low levels of betalipoprotein deficient serum (BLPDS) or human 
serum albumin.(12) Furthermore, elevated levels of TBARS are also formed when 




in the presence of low 
levels of BLPDS.02) Moreover the addition of physiological levels of ascorbate and 
vitamin E do not appear to influence the maximal rate of hremin degradation under 
these conditions. The low levels of albumin which stimulated peroxidation of native 
and glycosaminoglycan treated LDL in these in vitro experiments are comparable 
with the concentration in regions of the artery waU.(276) The action of BLPDS may 
be mediated through interactions between hreme and albumin, and it appears redox 












Activated phagocytes may release MPO, a hreme-containing enzyme, and 
hydrogen peroxide (H20 2). Atherosclerotic lesions contain products of LDL which 




,(98-100) supporting the hypothesis that 
MPO is a potential pro-oxidant of LDL in vivo. The mechanism underlying 
peroxidase-catalysed oxidation of LDL differs from LDL oxidation by copper ions. 
Peroxidases do not directly oxidise lipids(277) but radicals derived from protein, 
tyrosine or alpha-tocopherol appear to mediate oxidation. (11) 
Horse radish peroxidase (HRP), an enzyme derived from plants, also oxidises 
isolated LDL via a protein radical. (11) Horse radish peroxidase has been suggested as 
a model for transition metal ion independent oxidation of LDL in vivo(88) The role 
of alpha-tocopherol and other radical forming antioxidants in reducing LDL 




system has been controversial. Santanam 
and co-workers found lag time was reduced with increasing levels of alpha-
tocophero1<277) and this was consistent with a pro-oxidant role for alpha-
tocopheroI. (278) In contrast, Kalyanaraman and co-workers found alpha-tocopherol 
reduced the initial rate of conjugated diene formation in a concentration dependent 
manner.(11) The prevailing pro or antioxidant behaviours of alpha-tocopherol may 
reflect the levels of free alpha-tocopherol. The antioxidant behaviour of alpha-
tocopherol was predominant when LDL was enriched with alpha-tocopherol before 
isolation rather than when it was added directly to the LDL stock. In the HRP/H20 2 
system, the radical forming capacity of the antioxidant may be pivotal in 
determining its behaviour. ProbucoI(277) and butylated hydroxytoluene 
(BHT)(l 1,277) inhibited oxidation at very low concentrations whereas 
diphenylphenylenediamine increased oxidation.(277) All are powerful antioxidants, 
but probucol and BHT are incapable of forming propagating radicals. (277) In the 
HRP/H
2
0 2 system tyrosine also forms a radical (tyrosyl radical) and this may be 
capable of inducing oxidation. However tyrosine stimulated oxidation appears to be 
dependent on the levels of free tyrosine(89,96,97) and is also influenced by the 
concentrations of alpha-tocopherol in LDL. (277) The effect of other elements present 
in the serum and extracellular matrix have not been studied in a peroxidase 
stimulated model of LDL oxidation. 
2.4 Natural antioxidants 
The Mediterranean diet, rich in fruits, vegetables, fish and olive oil, is correlated 
with a lower incidence of CHD.(279 ,280) These diets contain a variety of anti-
atherogenic agents, including antioxidants such as carotenoids, tocopherols, vitamin 
C, flavonoids and other polyphenolic compounds.(281-283) Several of these 
antioxidants are the focus of this thesis, namely the carotenoid lycopene, vitamin E 












2.4.1.1 Antioxidant properties of lycopene 
The antioxidant and lipophilic properties associated with lycopene, along with 
its characteristic deep red colour, are a function of the structure of this carotenoid. 
(284) Lycopene has a polyene chain backbone, consisting of forty carbon atoms 
linked by a system of alternate double and single bonds, with flexible end groups. 
High performance liquid chromatography enables specific lycopene isomers to be 
separated and quantified.(285) In nature, lycopene occurs in the all-trans-isomer but 
undergoes trans-to-cis isomerisation if exposed to light, heat or during some 
chemical reactions.(285-287) Plasma mainly contains a mixture of all-trans and 5-cis-
lycopene isomers, whereas in the tissues cis-isomers predominate.(288) The 
biological significance of the various isomers of lycopene is uncertain.(289-291) 
Lycopene is one of the major carotenoids in LDL(292) where it is incorporated 
within the inner core probably due to its hydrophobic properties.(284) Lycopene is 
similar in structure to a polyunsaturated fatty acid, with an allylic methylene group 
at the C-4 position(284,293,294) and a high number of double bonds.(284,293-295) 
Thus, lycopene may be oxidised in preference to a polyunsaturated fatty acid. The 
rapid reaction of lycopene with reactive oxygen species may reduce the availability 
of free radicals to react with other molecules such as unsaturated lipids, and thereby 
reduce the level of damage caused to these molecules.(293,294) Studies have shown 
that lycopene effectively reduces LDL oxidation in vitro, by quenching singlet 
oxygen and scavenging peroxyl radicals(83,296-298) and this results in the formation 
of a lycopene carbon centred radical. (299) This carbon centred radical is stable but 
the lycopene radical formed from it by interaction with oxygen is not, and is capable 
of inducing peroxidation.(299) Therefore in the presence of oxygen, lycopene may 
behave as a pro-oxidant.(300) However, in healthy tissue the partial pressure of 
oxygen is low and antioxidant rather than pro-oxidant reactions are 
favoured.(300,301) Also other antioxidants in the immediate vicinity, such as vitamin 
E(31,302) and vitamin C(24,232,303) may limit the pro-oxidant behaviour of lycopene. 
In plasma the major oxygen radical of lycopene, lycopene-5,6-expoxide, is quickly 
removed. (304) 
Supplementing healthy people with lycopene has been demonstrated to reduce 
LDL oxidation. Agarwal and co-workers compared the effect of three high lycopene 
treatments (spaghetti with tomato sauce, tomato juice and Oleoresin®) with a 
placebo treatment on LDL oxidation in nineteen healthy subjects. (36) After seven 
days all of the lycopene regimens increased plasma lycopene three fold, and 
oxidation was reduced by 25%, as determined by TBARS, in the LDL and serum. 
Lycopene may improve the intrinsic resistance of LDL to oxidation. A preliminary 
uncontrolled study reported plasma lycopene increased three fold following seven 
days of tomato juice consumption in healthy people and this corresponded to a 50% 
increase in lag time.C34) A similar study by Steinberg and co-workers reported 
tomato juice supplementation over four weeks increased the resistance of LDL to 









may be an artefact of cigarette smoking, as previously smokers have been found to 
have lower levels of serum lycopene and higher levels of oxidation products 
compared with non smokers. (35) The potential reduction in LDL oxidation with 
increasing plasma lycopene is in agreement with a large study comparing risk 
factors for CHD in middle aged men. Intrinsic resistance of LDL to oxidation was 
15% shorter in the region with mean plasma lycopene levels which were two fold 
lower and CHD rates were higher.09) 
2.4.1.2 Dietary sources of lycopene 
Lycopene intake from the diet is estimated to be 1-4 mg a day and typically 
contributes 30% of the total carotenoid intake. (305-307) Dietary intake of lycopene 
reduces with age and cigarette smokingC308,309) and in some populations seasonal 
variations have been observed.(306,310,311) 
Tomatoes are rich in lycopene, with tomato products frequently supplying 
over 85 % of the lycopene in the diet.(312-315) The lycopene concentrations of 
tomato products depend on the variety of tomatoC3 l 4) and processing 
conditions.(316,317) The bioavailability of lycopene from tomato products is 
improved with heat treatment,(316) due to the release of lycopene from the plant cell 
wall components and improved lipid solubility.(288,317,318) Lycopene is also 
available as a dietary supplement, Oleoresin®, which contains 5% aH-trans-
lycopene in the extracted lipid components of tomatoes. 
Dietary intake of lycopene is the primary determinant of plasma levels in 
healthy people.(319,320). Increasing the consumption of tomato products in the diet 
has been shown to substantially increase blood levels of lycopene. (32,34-36) 
However, plasma lycopene levels often show poor correlations with total fruit and 
vegetable intake(321) or dietary lycopene.(320) Inadequacies with food composition 
databases and dietary assessment methodologies may be key factors in this apparent 
discrepancy. Many food composition databases do not have complete and accurate 
data for lycopene. (322) Historically carotenoids were included in food composition 
databases due to their role as precursors of vitamin A consequently carotenoid data 
was often absent if the carotenoid lacked provitamin A activity, as is the case with 
lycopene.(323) Furthermore, prior to the use of HPLC carotenoid analysis lacked 
specificity and sensitivity. (285) It has been demonstrated that dietary estimates of 
lycopene are almost three fold higher when dietary data is re-analysed with 
specialist carotenoid food composition databases.(324,325) However the New Zealand 
food composition database currently does not include lycopene data. (326) Therefore 
it would be difficult to accurately estimate lycopene intake in the New Zealand 
population. Researchers(305,306) have found good correlations between plasma 
lycopene and intake of dietary lycopene when estimated from a four day diet record 
and analysed by specialist carotenoid databases.(285,315) In contrast, food frequency 
questionnaires are often used to successfully estimate the intake of other carotenoids 
but this form of dietary assessment is unsuitable for lycopene as it is concentrated in 








2.4.1.3 Bioavai/ability, metabolism and regulation of lycopene 
In foods lycopene is tightly bound to macromolecules,(327) including proteins 
and fibre.(328) Mastication destabilises protein-lycopene complexes facilitating 
dispersion.(327,329) Co-ingestion of lycopene with lipid may extract it from the food 
matrix into the lipid phase of the chyme, (316,317) then as a result of the action of bile 
salts and pancreatic lipases, lycopene-containing lipid droplets enter the duodenum 
and form multilammellar lipid vesicles.(330) Studies have shown lycopene is better 
absorbed from tomatoes when consumed with lipid (spaghetti sauce verses tomato 
juice).(36) Conversely non-absorbable fat analogues, including sucrose 
polyesters(331) and drugs which affect cholesterol absorption(332) significantly 
reduce serum lycopene. The lycopene supplement, Oleoresin® appears to have 
lower bioavailability compared with tomato products especially those which are heat 
treated which may reflect differences in the bioavailability of isomers. (36) Other 
carotenoids may interact with lycopene during absorption although the effect has 
been inconclusive. Lycopene concentration in the blood increased by 176% after 
healthy volunteers took 20 mg/day of beta-carotene for two years in a large placebo-
controlled clinical trial. (333) Conversely, short term beta-carotene supplementation 
trials did not appear to significantly alter plasma lycopene. (334-336) It is unclear if 
other carotenoids facilitate or inhibit lycopene absorption. 
The movement of lycopene from the mixed lipid micelle into the mucosa! cells 
of the duodenum appears to take place via passive diffusion.(337) Lycopene is taken 
up into the mucosal cell and packaged into chylomicrons with phospholipids and 
triglycerides from the meal, thus lipid increases bioavailability.(36,316,317) Typically, 
only a small percentage of the lycopene from the meal will be taken up by the 
intestinal cell(327) and if this is not incorporated into chylomicrons within a few days 
it is lost when the mucosa! cells are sloughed off into the lumen of the 
gastrointestinal tract. Lycopene is incorporated into the chylomicrons and VLDL, 
and during the following 48 hours concentrations rise in the other lipoprotein 
fractions.(327,330) Three quarters of the lycopene in the blood is in LDL while the 
remainder is in HDL.(245,330,338,339) The transfer rate between beta-carotene and 
presumably lycopene, and native lipoproteins is very slow (more than 18 hours) 
compared to free cholesterol (20 minutes) and even alpha-tocopherol (70 
minutes).(340) Lycopene requires triglyceride lipolysis by lipase to transfer into 
biological lipid structures (mixed micelles, lipoproteins, membranes).(340) The exact 
mechanism in vivo is unclear but it is independent of lecithin: cholesterol acyl 
transferase, cholesteryl ester transfer protein or a specific carotenoid binding 
protein. (330,338,339) 
Lycopene in the blood of healthy individuals varies between 0.22-1.06 µmol/1 
and contributes between 21-43% of the total carotenoids.(341) There is wide 
variation in plasma lycopene between peopie(319,320,342) and levels reduce with 
age(308,309) probably reflecting different dietary patterns. Plasma levels are 
relatively stable in an individuaI(343) and in contrast to other carotenoids, lycopene 










menopausal status,(344) menstrual cycle,(345) or moderate alcohol 
consumption. (308,346) 
Lycopene accumulates in a number of tissues in the body, including the liver, 
adrenal glands, testes, ovary, adipose and kidney.(291,347,348) Levels oflycopene are 
higher in the tissues with more LDL receptors.(347) Mononuclear cells also appear to 
contain significant quantities of lycopene. (349) In feeding studies in healthy adults 
plasma lycopene levels reach a maximum in about three days(317) and lycopene 
stores appear to take twelve to thirty-three days to be depleted in healthy adults with 
non linear reduction suggesting that there are at least two significant body 
stores,(350,351) probably the liver and adipose tissue.(291) The regulatory mechanism 
for lycopene accumulation in tissues is unknown.(352) 
2.4.1.4 Relationship between lycopene and CHD 
Mortality from CHD has been inversely correlated with increased fruit and 
vegetable intake, and in particular tomato products demonstrate strong 
correlations.(353) Tomatoes contain a number of anti-atherogenic compounds with 
the antioxidant lycopene is in the highest concentration.(354) Palgi and co-workers 
reported total carotenoid intake is inversely correlated with CHD mortality.(355) 
Lycopene did not show a significant relationship, however in this study poor food 
compositional data may have obscured associations.(322) Recently, Kristenson and 
co-workers reported plasma lycopene was two fold higher in middle-aged men in 
Sweden compared with men in Lithuania where mortality from CHD is four times 
lower.(19) Also, in the ten European countries involved in the EURAMIC study high 
adipose lycopene was found to be protective against MI.(18) 
The Austrian Stroke Prevention Study reported that low plasma lycopene was 
significantly associated with subclinical ischremic brain damage. (356-358) In contrast, 
Street and co-workers found patients who had an MI did not have lower plasma 
lycopene than control subjects,(359) although lengthy storage of blood samples (15 
years) in this study may have influenced the findings as stability data is only 
available for samples stored up to four years at -70°C. (360-362) In summary 
epidemiological evidence appears to support a protective role for lycopene against 
CHD, which may be conferred from levels of lycopene obtained from the diet. 
Randomised controlled intervention trials are required to determine the effect of 
lycopene on risk of CHD. 
2.4.2 Vitamin E 
2.4.2.1 Antioxidant properties of vitamin E 
Vitamin E refers to eight compounds and their isomers, tocopherols and 
tocotrienols. These compounds share a similar 6-chromanol ring structure but differ 
in the methylene group positions and phytyl side-chain structure.(363) Alpha-
tocopherol and gamma-tocopherol are the predominant vitamin E homologues 














only in the methylene group substitutions on the chromanol ring and this is 
responsible for the differences in antioxidant potential observed between these 
homologues.(364,365) High performance liquid chromatography allows specific, 
sensitive and rapid analysis of vitamin E homologues and isomers.(366) 
Vitamin E is located near the surface of the LDL or membrane(367) with the 
chromanol head group orientated toward the outer surface while the phytyl side 
chain is buried within the hydrophobic region.(368-372) This orientation allows the 
chromanol ring to be in close proximity with the carbonyl groups of the fatty acids. 
As a result of its location and structure alpha-tocopherol may be oxidised in 
preference to the fatty acids. The reaction between alpha-tocopherol and a peroxyl 
radical results in the formation of a tocopheroxyl radical, and this radical may 
propagate further oxidation.(231,278,373,374) However water soluble antioxidants, 
such as ascorbate and ubiquinol-10, are capable of reducing tocopheroxyl radicals to 
tocopherol.(231,278,374-376) The orientation of the phenolic hydroxyl group is 
directed toward the surface at the water-lipid interface(367) and favours regeneration 
of tocopherol. (258,377) Tocopherol is in low concentrations compared with the fatty 
acids in LDL, thus regeneration of tocopherol may be criticaI.(373) However, under 
conditions of higher oxidative stress or as the tocopheroxyl radical penetrates the 
LDL core, tocopherol recycling may be insufficient to prevent oxidation. (378,379) 
A number of randomised placebo controlled clinical studies have shown that 
enriching LDL with alpha-tocopherol through supplementation extends the lag time 
to copper ion stimulated oxidation of LDL. Supplemental doses of alpha-tocopherol 
appear to be required to modify LDL oxidationC23-27) although dose response studies 
remain unclear. Several dose response studies (alpha-tocopherol 60-1200 IU/day) 
have reported levels of greater than 400 IU/day for more than two weeks are 
required to prolong lag time significantly.(27,28) Conversely, Princen and co-workers 
found a significant increase in lag time with supplementation of 25 IU/day, although 
the magnitude of this change was small (5.3 %).(26) 
Recently, vitamin E has been found to modulate endothelial cell interactions 
with immune cells. This effect has been demonstrated to be attenuated through 
stimulation of the genes for the expression of adhesion molecules on the endothelial 
cells and the expression of integrins on the surface of monocytes. Enrichment of 
human aortic endothelial cells with vitamin E significantly reduces the adherence of 
these cells in a dose-dependent manner.(380) Elevated levels of sICAM-1, due to 
increasing concentrations of native LDL, are also attenuated with vitamin E(380) 
Furthermore, when human endothelial cells are activated, the IL-1 p induced 
expression of cell adhesion molecules ICAM-1, VCAM-1, and E-selectin are 
increased significantly. This effect is attenuated in a dose-dependent manner if the 
cells are pre-enriched with vitamin E.(381,382) In response to oxidative stress 
monocytes produce cytokines and adhesion molecules (integrins). Supplementing 
healthy volunteersC28) and athletes(383) with high doses of alpha-tocopherol 
(~1200 IU/day) for several weeks reduces the release ofIL-lP by monocytes. In 
addition monocytes incubated with alpha-tocopherol displayed reduced expression 
of agonist stimulated integrins.(384) In summary, increasing cell and LDL content of 
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dietary supplementation with alpha-tocopherol reduces the cellular release of 
inflammatory cytokines. However the effect of supplementation with alpha-
tocopherol, and other antioxidants, on circulating levels ofICAM-1 and VCAM-1 is 
not yet well understood. 
2.4.2.2 Dietary sources of vitamin E 
Vegetable oils are the major dietary source of vitamin E(385) and this is 
primarily gamma-tocopherol. In oils, the contribution of alpha-tocopherol is usually 
only 7% to 15% with the exception of sunflower, canola, safflower and olive oils in 
which alpha-tocopherol predominates (e.g. sunflower oil, 48.7 mg/lOOg). Other 
important dietary sources of vitamin E are polyunsaturated margarines, some nuts 
and wheat germ. (326) A recommendation to increase intakes of vitamin E from the 
dietary sources would also result in a substantial increase in dietary fat due to the 
association of vitamin E with lipids in foods. 
Most countries have set recommended daily intakes of vitamin E between 7-10 
mg/day for adults(386) and this level is readily achieved from the New Zealand 
diet.(387) However, the dose of vitamin E which may be required to alter oxidative 
parameters may be significantly higher (40 fold) than usual dietary levels.(23-27,388) 
The safety of pharmacological doses of vitamin E has been extensively tested and a 
dose of up to 900 mg per day is considered to be safe and without side effects in 
healthy volunteers. (389-392) 
2.4.2.3 Bioavailabi/ity, metabolism and regulation of vitamin E 
Approximately 40% of alpha-tocopherol is absorbed at levels of vitamin E in 
the dietary range, but this percentage decreases with pharmacological doses. (393) 
Concurrent intake and digestion of dietary fat facilitates absorption of vitamin E 
through increasing pancreatic secretions and bile salts. Vitamin E is taken up 
directly by enterocytes in the intestine then secreted into the lymphatic system via 
chylomicra, before being taken up by the liver and released back into the circulation 
in association with VLDL.(394) Alpha-tocopherol which is secreted from the liver in 
VLDL may travel with the VLDL core during the conversion to LDL, or return to 
the liver in VLDL remnants. (395) In the plasma, almost all of the alpha-tocopherol 
circulates in association with lipoproteins (96% )(396) where it is able to transfer 
readily between LDL and HDL without the assistance of a transfer protein.(397-399) 
The liver is the primary site of regulation of circulating levels of vitamin 
E, (395,400,401) and it exhibits a distinct preference for the alpha-tocopherol 
homologue.(395,402,403) In addition, the RRR-alpha-tocopherol is favoured over 
other steroisomers and the synthetic form (racemic or all-rac-alpha-tocopherol).(403-
405) This discrimination between the tocopherol isomers and homologues is related 
to a specific tocopherol binding protein which recognises the fully saturated 
methylated aromatic ring, the saturated phytyl side chain and the stereochemical 
RRR-configuration of the methyl groups branching the side chain.(406-409) 
Tocopherol-binding protein appears to be critical for the regulation of plasma alpha-














alpha-tocopherol increasing levels by as little as two fold. (395) Excess vitamin E, 
including non alpha-tocopherol homologues are probably lost through excretion in 
the bile. (395,402,405) 
The uptake of tocopherol from plasma by the tissues occurs by both a LDL 
receptor mechanism(371,410) and also by receptor-independent pathways.(393) 
Adipose tissue is the major peripheral tissue depot, containing up to 90% of the 
alpha-tocopheroI.(411) Tissue levels can be increased in response to high-doses of 
alpha-tocopherol (800 IU/day), although the observed increase is relatively modest 
(10% to 20%).(412) Monocytes(28) and erythrocytesC413) have elevated levels of 
alpha-tocopherol with high dose supplementation, and it is presumed based on the 
available information that levels are concomitantly increased in endothelial 
cells.(380) 
2.4.2.4 Relationship between vitamin E and CHD 
Several large observational studies have reported dietary intake of vitamin E is 
inversely related to mortality from CHD.(414-416) Prospective studies also show 
higher vitamin E intakes are associated with reduced risk of CHD.(417-421) The 
largest of these studies, the Nurse's Health(418) and Health Professional's(421) 
studies found a 34% to 44% reduction with the highest quintile of vitamin E intake 
and the greatest benefit in people who consumed 100-250 IU per day for more than 
two years over the four to eight year follow-up. In agreement with these findings the 
cross-cultural MONICA Study(414,415,422) reported the incidence of CHD was 
inversely related to vitamin E concentration in the plasma. Furthermore, 60% of the 
difference between the high and low CHD regions in the MONICA study could be 
explained by plasma vitamin E. 
Low plasma vitamin E has been reported in patients with angina(423) and in 
elderly people with subclinical ischremic brain damage. (356-358) In contrast, several 
other case-control studies have reported less compelling findings between CVD and 
blood or adipose tissue levels of vitamin E.(359,422,424-426) However, the inclusion 
of control subjects with asymptomatic subclinical disease may confound the 
relationship between vitamin E and CVD in these studies. Also epidemiological data 
suggest the beneficial effects of vitamin E may be confined to high doses and a 
number of case-control studies did not include people who took vitamin E 
supplements. 
Case-control studies are unable to determine if an observed reduced risk is 
directly attributable to vitamin E or whether vitamin E is a biomarker for some other 
dietary or lifestyle factor that improves coronary risk. Randomised controlled 
intervention trials are required to determine the role of vitamin E in the development 
of coronary disease. The most significant trial showing a protective effect for 
vitamin Eis the Cambridge Heart Antioxidant Study (CHAOS).07) Nonfatal MI 
was reduced by 77% in CAD patients taking 400 or 800 IU alpha-tocopherol daily 
for an average of sixteen months. Comparing these findings with cholesterol 
lowering trials, the benefits of vitamin E on non fatal MI are observed in a shorter 
time. However fatal MI actually tended to increase in the CHAOS study in those 
patients taking vitamin E. Although it can not be completely dismissed that high 
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dose vitamin E may be harmful, other factors require consideration when 
interpreting this finding. In particular, few MI events occurred in the entire study 
population, especially fatal MI and the difference was not significant between the 
vitamin E and placebo groups for fatal MI (36 verses 26). In addition, most of the 
fatal MI events occurred early in the study and survival curves show the onset of 
treatment benefit was seen after 200 days. With respect to mortality from MI, the 
CHAOS study may have been underpowered and not of sufficient duration to 
evaluate vitamin E treatment. In agreement with findings of the CHAOS study 
another trial in patients with CAD found supplementing with 100 IU of vitamin E 
daily for two years was independently associated with a reduction in progression of 
CAD, as determined by angiography.(20,21) In contrast to these findings, two large 
intervention trials have reported no benefit of vitamin E supplementation on CVD in 
healthy populations. The Alpha-tocopherol/Beta-Carotene Cancer (ATBC) 
Prevention Study reported CAD events in apparently healthy male smokers did not 
change over six years with supplementation of 50 mg daily of vitamin E.(427) 
Similarly, a large vitamin E supplementation trial in 29, 000 people in Linxian, 
China, found no reduction in CVD after five years of supplementation with 
30 IU/day of alpha-tocopherol (428). In the latter study the population had a poor 
nutritional status at baseline, including low plasma levels of vitamin E. In addition, 
the level of supplementation used in both studies may have been too low, as doses 
were lower than the level reported to offer protection in the health professional 
studies (418,421) Furthermore, the primary objective of both the ATBC study and 
Linxian trial was cancer prevention and this may have influenced the selection of 
subjects in these studies. Moreover, in the case of the Linxian trial, the prevalence of 
CVD was extremely low in this region of China. In summary, vitamin E may play a 
protective role in the development of CVD, but pharmacological doses of vitamin E 
may be required to achieve this protection. 
2.4.3 Vitamin C 
2.4.3.1 Antioxidant properties of vitamin C 
A number of compounds exhibit the biological activity of ascorbic acid and 
these are collectively known as vitamin C.(429) The predominant form of vitamin C 
in the tissues and foods is ascorbic acid. Also the steroisomer of ascorbic acid, 
erythorbic acid, is often added during food processing as an antioxidant.(430) 
Dehydroascorbic acid is the most significant oxidised product of ascorbic acid often 
present in low concentrations in the tissues. 
While there are numerous methods available for the analysis of vitamin C in 
the plasma, HLPC and fluorescent methods are the most sensitive and specific.(431) 
High performance liquid chromatography can readily identify ascorbic and 
dehydroascorbic acid.(432) Metaphosphoric acid is usually added to serum or plasma 
when the sample is collected to stop degradation of vitamin C. However, the 
addition of metaphosphoric acid to the sample coupled with the time delay 















number of automated fluorescent methods have been developed measuring the 
fluorescent product which forms when dehydroascorbic acid is coupled with 
o-phenylenediamine.(433,434) Total vitamin C may be reliably quantified using 
fluorescence after the conversion of ascorbic acid to dehydroascorbic acid by the 
ascorbic acid oxidase. These methods more cost effective and convenient than 
HPLC while still retaining the specificity and sensitivity for total vitamin C. 
Ascorbic acid is part of a complex system providing protection against free 
radical damage both in extracellular fluids and cells. Vitamin C has been shown to 
scavenge aqueous superoxide and hydroxyl radicals and act as a chain-breaking 
antioxidant in lipid peroxidation.Cl83,255) Free radicals in the aqueous phase react 
with ascorbic acid to produce ascorbyl free radicals. The ascorbyl free radical is 
relatively stable and is an effective free radical scavenger, by reacting with a second 
ascorbyl radical forming one molecule of ascorbic acid and a second of 
dehydroascorbic acid which is subsequently reduced. Conversely, the addition of 
vitamin C to extensively oxidised LDL in the presence of metal ions may actually 
stimulate lipid peroxidation via the formation of the alkoxyl radical. (113,435-437) 
Vitamin C may reduce the oxidation of LDL, especially when oxidative stress 
is high. Resistance of LDL to copper ion stimulated oxidation was significantly 
increased after subjects who were habitual smokers when given pharmacological 
doses of vitamin C.(29,438) In contrast, vitamin C did not alter LDL oxidation in a 
similar study in non smoking men.C303) Smokers have lower natural antioxidant 
levels and increased free radical activity which may result in elevations of 
hydroperoxides in LDL.(29) The effect of vitamin Con oxidative resistance of LDL 
is difficult to determine using oxidation procedures where LDL is isolated from 
plasma however added vitamin C completely inhibits LDL oxidation in 
vitro.(252,256) 
Vitamin C may also affect monocyte adhesion through specific actions on cell 
adhesion molecules. Cultured monocytes isolated from smokers had elevated 
expression of the integrin CD 11 b( 439) and supplementing these people with high 
doses (500 mg/day) of vitamin C reduced CD1 lb expression and reduced monocyte 
adhesion to the endothelial cells. (30) The expression of other cell adhesion 
molecules, including ICAM-1 and VCAM-1, are decreased with vitamin C treatment 
in subjects under oxidative stress due to smoking. The effect of vitamin C on these 
adhesion molecules in other people under oxidative stress has not be studied. 
2.4.3.2 Dietary sources of vitamin C 
Most of the vitamin C in the New Zealand diet is obtained from foods of plant 
origin, primarily citrus fruits, green vegetables, peppers, tomatoes, berries and 
potatoes. (387) The recommended daily intakes for vitamin C vary between 30-80 mg 
daily(440) and most people in New Zealand would consume in excess of this 














2.4.3.3 Bioavailability, metabolism and regulation of vitamin C 
Vitamin C is nearly completely absorbed at low doses (less than 30 mg/day) 
and this only reduces slightly with increasing intakes under 180 mg/day. Above this 
amount absorption decreases dramatically. Delaying gastric emptying or dividing the 
dose over several hours will increase the total level absorbed.(441) Ascorbic acid is 
absorbed by active transport, driven by ATP hydrolysis, or indirectly via a sodium 
gradient. Also the absorption of ascorbic acid and its entry into cells may be 
facilitated by conversion into dehydroascorbic acid, which penetrates membranes 
better than ascorbic acid at physiologic pH.(442) After entry into the cell, 
dehydroascorbic acid can be reduced to ascorbic acid.(443) It is not known whether 
this.regeneration is chemically or enzymatically driven under physiological 
conditions. 
Absorbed ascorbic acid equilibrates rapidly with the extracellular pool. 
Ascorbic acid is present in all tissues in the body, and generally is in higher 
concentrations in tissues than in the plasma. Levels are particularly high in the 
glandular organs, including adrenals, pituitary and spleen, although muscle provides 
the largest reservoir due to its mass.(444) Maximum body pool for vitamin C is a 
little over two grams and this is achieved with an intake of 120 mg/day in healthy 
adults. Vitamin C body pool size increases with intake up to this maximal size, and 
as the renal threshold is exceeded (approximately 45 µmol/1) an increased proportion 
of the intake is excreted.(445) 
2.4.3.4 Relationship between vitamin C and CHD 
Several prospective studies have shown an inverse relationship between high 
vitamin C intakes and risk of mortality from CVD.(416,446,447) Conversely, other 
prospective studies have found either no association between vitamin C intake and 
risk(421,448) or a weak non significant trend.(417,418) A contributing factor to these 
inconsistent findings may be the methods of dietary assessment. A plasma vitamin C 
concentration of less than 12 µmol/1 has been significantly associated with increased 
CVD mortality(449) and levels of greater than 26 µmol/1 appear protective.(450) 
These findings have also been supported by case-control studies examining vitamin 
C in the blood and CHD.(422,423,451) Leukocyte vitamin C is thought to reflect 
vitamin C status better than plasma, and reduced leukocyte vitamin C was reported 
in CAD patients compared with healthy controls.(451) In a preliminary intervention 
study, supplementation with 500 mg/day of ascorbate significantly reduced coronary 
angiographic restenosis. (22) 
2.5 Diabetes and atherosclerotic disease 
Diabetes mellitus is a heterogeneous condition comprising of several distinct 
pathophysiologic disorders of carbohydrate metabolism, each of which ultimately 
manifests with hyperglycremia. Type 1 diabetes mellitus is primarily due to auto-
immune destruction of the pancreatic islet beta cells. The more prevalent form of 
















relative insulin deficiency. Type 2 diabetes mellitus in New Zealand has been 
estimated to affect 10.4 people per 100, 000, which is similar to rates in the USA, 
Britain and Europe(452,453) 
Type 2 diabetes directly caused 373 deaths in NZ in 1987,(454) although 
mortality statistics probably underestimate the importance of diabetes, as most 
deaths related to diabetes result from complications, particularly coronary heart 
disease (CHD). Seventy-five to 80% of adult diabetic patients die from CHD, 
cerebrovascular disease, or peripheral vascular disease.(455) 
2.5.1 Risk factors 
Mortality from atherosclerotic vascular diseases is two to three fold higher in 
diabetic populations compared with non diabetic populations.(37,456-460) Diabetic 
patients have numerous cardiovascular risk factors, such as hypertension, obesity 
and hyperlipidremia (37,40,461) however epidemiological data indicate that traditional 
risk factors account for less than half of the excess risk of CHD in this group.(37) 
People with type 2 diabetes may have other risk factors which increase their risk of 
developing atherosclerosis. 
Hyperglycremia induces a number of adverse biochemical reactions which may 
be responsible for atherogenic complications.(462,463) Recently, attention has 
focused on the role of increased oxidative stress generated by hyperglycremia and 
protein glycation.C38,119,464) Raised levels of glucose in the blood have been 
demonstrated to react non-enzymatically with amine groups on proteins forming a 
Schiff base followed by Amadori rearrangement to fructoselysine. ( 465) This 
reversible glycosylation of the amino group underlies the formation of glycated 
hremoglobin, a marker of chronic glycremic control. Lipoproteins, apolipoproteins 
and collagen in the arterial wall are also vulnerable to glycation as a result of 
hyperglcremia,(465) and glycation is elevated even when metabolic control is good in 
diabetic patients.(466) Numerous metabolic abnormalities are associated with 
glycation of LDL, including diminished recognition of LDL by the regulated LDL 
receptor,(467,468) retardation of the clearance of LDL from the plasma,(469,470) 
enriched uptake of LDL by macrophages, increased platelet aggregation,(471) 
increased binding of the LDL in the vessel walls,(472) and generation of oxygen free 
radicals.C121) Glycation may also result in the oxidation of fructoslysine to form an 
irreversible AGE-product, such as Ne -( carboxymethyl)lysine, pentosidine, and 
pyrroline. In diabetic patients AGE-products have been significantly correlated with 
vascular complications.(473) 
Diabetic patients frequently have raised plasma triglycerides and this may 
result in changes to their lipoproteins and an increase coagulation activities. (40,474) 
The diabetic dyslipidremia which is associated with hypertriglyceridremia is 
characterised by chylomicronremia, increased VLDL and remnants both with raised 
levels of apolipoprotein E and triglyceride enriched LDL and HDL. 
Chylomicronremia and increased VLDL and remnants are associated with increased 
cholesterol deposition in the artery wall. Triglyceride enriched LDL tends to be 



















non diabetic populations.(475) Hypertriglyceridremia increases the coagulation 
activities(476) of thrombogenic factors and reduces the concentrations of tissue 
plasminogen activator inhibitor.(477) Also, platelet aggregation and concentrations of 
lipoprotein (a) are increased in diabetic patients and these may further contribute to 
coagulation. ( 40) 
Insulin resistance and hyperinsulinremia appear to play an important role in the 
pathogenesis of atherosclerosis in diabetes. (37) Central adiposity is associated with 
insulin resistance and compensatory hyperinsulinremia.(40) Insulin, with other 
growth factors,(478) can potentially promote cell cholesterol ester accumulation. 
Also high levels of insulin may have a direct affect on arterial wall function. (40) 
Patients with type 2 diabetes have multiple pro-atherogenic risk factors and a 
number of these may increase oxidative stress in these patients. 
2.5.2 Oxidative stress 
2.5.2.1 Products of oxidation 
Oxidative stress is increased in patients with type 2 diabetes, as evidenced by 





a, were found to be three fold higher in the plasma 
of diabetic patients.087,479) In agreement with these findings, circulating levels of 
TBARS have been reported to be elevated in diabetic patients compared with 
healthy controis(43,49,480-484) and levels were further increased if metabolic control 
was poor or cholesterol levels were raised. Higher levels of lipid 
hydroperoxides(485) and cholesterol peroxides(486) have been measured in the 
plasma of diabetic patients compared with healthy control subjects. Lipid 
hydroperoxides are predominantly associated with lipoproteins in the plasma and 
mainly carried by HDL in healthy individuals.(374) Lipid hydroperoxides are 
reported to be higher in the HDL fraction of diabetic patients(487). Increased levels 
of auto antibodies to MDA-LDL(39) and an increased proportion of negatively 
charged LDL,(488)a small oxidised fraction of LDL, provide support for the 
presence of oxidatively modified LDL in diabetic patients. Erythrocytes in diabetic 
patients also have raised levels of MDA (482,489) and show increased susceptibility 
to oxidation.(490) 
2.5.2.2 Antioxidants 
Patients with type 2 diabetes appear to have inadequate antioxidant protection. 
Plasma lycopene levels were reported to be 50% lower in diabetic patients compared 
with age-matched control subjects. ( 49) All of the lycopene in the plasma is 
associated with lipoproteins thus it is probable that LDL lycopene levels are also 
significantly reduced. Duration of diabetes(319) rather than dietary intake appears to 
predict the lower levels of lycopene observed in diabetic patients.(491) 
Vitamin E in the plasma is primarily associated with the lipoproteins.(396) 









distribution of vitamin E.(492) Low density lipoprotein isolated from diabetic 
patients has been found to be depleted in alpha-tocopherol.(493,494) However raised 
levels of LDL in the plasma of diabetic patients may restore vitamin E 
concentrations to the normal range.(49,481,495) 
Total vitamin C in diabetic patients is often similar to healthy individuals but 
the proportion of ascorbic acid is reduced.(45-48) Hyperglycremia may reduce the 
renal reabsorption of ascorbic acid. Continuous infusion of glucose in people 
without diabetes has been demonstrated to increase urinary ascorbic acid(496) and 
diabetic patients with microalbuminuria have elevated ascorbic acid excretion.(497) 
Also intracellular ascorbate is reduced in rats with diabetes.(498) 
Consistent with reduced antioxidant levels in the plasma, total antioxidant 
capacity was reported to be lower in diabetic patients compared with non diabetic 
subjects.(490,499,500) These alterations in the levels of important intrinsic 
antioxidants in the LDL, including vitamin E and lycopene, and altered levels of 
ascorbic acid in the extracellular fluid may critically undermine the antioxidant 
defence system in diabetic patients. 
2.5.3 LDL susceptibility to oxidation 
Diabetic patients often have higher levels of small dense LDL (488,501-503) and 
the proportion may increase with poor blood glucose controI.(504) This LDL 
subfraction is more susceptible to oxidation(244,501,503) and depleted in intrinsic 
antioxidant levels.(493,494) Yoshida and co-workers(SOS) and Lintott(506) have 
reported the decreased resistance of isolated LDL to copper ion stimulated oxidation, 
indicated by a 20% shorter lag time in diabetic patients. In contrast Mol and co-
workers( 481) using similar experimental procedures did not report a significant 
difference in lag time. However, the LDL isolated in the latter study contained very 
high levels of vitamin E and these levels were similar among the patients and the 
healthy control subjects. The ratio of vitamin E to peroxides in the LDL isolated 
from diabetic patients is a strong determinant of lag time.(505) Several studies have 
also reported levels of TBARS from LDL oxidation are increased in diabetic 
patients compared with healthy controls.(481,482,507) 
The increased oxidative stress associated with diabetes may be attenuated by 
antioxidants. In a randomised placebo-controlled trial, conducted in twenty-one men 
with type 2 diabetes, supplementation with 1600 IU/day of alpha-tocopherol for ten 
weeks increased plasma and LDL alpha-tocopherol four fold and reduced the 
susceptibility of LDL to copper ion stimulated oxidation by 60%.(494) Fuller and co-
workers reported comparable findings in a similar study in patients with diabetes 
after taking 1200 IU/day alpha-tocopherol for eight weeks compared patients 
following the placebo treatment. (508) Plasma and LDL alpha-tocopherol increased 
2.4 fold and lag time increased by 41 %. This study included twenty-eight patients 
with type 1 (46%) and type 2 (54%) diabetes mostly men and four women, who 
were slightly younger, slimmer but with higher glycated hremoglobin levels than the 
patients in the previous study. The doses of vitamin E taken in these studies were 











LDL oxidation in non diabetic subjects.(23-27) Moland co-workers recently reported 
600 IU/day of alpha-tocopherol supplemented for four weeks increased lag time by 
52% in eleven patients with type 2 diabetes.(481) However, this study was not 
placebo-controlled and the basal alpha-tocopherol levels were extremely high. 
2.5.4 Inflammation markers and cell adhesion molecules 
Hyperglycremia may increase inflammatory proteins by altering signal 
transduction pathways which increase the expression of genes for these proteins 
through the activation of NF-KB.(463) Studies in animals have established the signal 
transduction pathways, diacylglycerol (DAG) and protein kinase C (PKC) can be 
sustained chronically in a number of vascular cells in response to 
hyperglycremia.(509,510) Advanced glycosylation end-products may modulate 
cellular functions through a specific cell surface receptor (RAGE) or RAGE which 
has complexed with a lactoferrin-like polypeptide.(463) The binding of AGE-
products to these receptors results, probably through multiple pathways, in the 
induction of cellular oxidative stress.(463) Receptors for AGE-products are present 
on endothelial cells, mononuclear phagocytes and smooth muscle cells.(511) 
Furthermore, the identification of RAGE as a member of the immunoglobin 
superfamily suggests that in addition to interacting with AGE-products, it might 
serve other functions, such as mediation of cell-cell recognition growth factors, 
cytokine or other immune responses.(463,512) Lipid peroxidation and AGE-product 
formation appear to be mutually reinforcing(38,513) therefore the generation of a 
variety of epitopes of oxidised, Amadori, and AGE-product modified LDL may 
occur in diabetic patients. 
Consistent with these activities, diabetic patients have elevated levels of some 
of the acute phase response proteins and cell adhesion molecules. Levels of plasma 
C-RP have been reported to be higher in patients with diabetes,(42) especially those 
with syndrome X. ( 41) The expression of VCAM-1 and ICAM-1 is raised on the 
vascular endothelial cells of diabetic rabbits.(514) Diabetic patients have elevated 
levels of sVCAM-1 and sICAM-1.<43,515,516) Furthermore, during an oral glucose 
tolerance test when blood glucose levels increase acutely, there is a corresponding 
increase in circulating sICAM-1 in diabetic and non diabetic subjects.(515) 
Consistent with this finding, high glucose induces ICAM-1 over expression in 
cultured human endothelial cells and increased ICAM-1 mediated adhesion of 
monocyte binding to human aortic endothelial cells.(517) Also cultured human 
endothelial cells exposed to AGE-products show increased expression of 
VCAM-I.<518) It has been reported the accumulation of AGE-products on the vessel 
walls of diabetic patients may trigger the increase in VCAM-1 expression and the 
subsequent release of sVCAM-1.(519) 
2.5.5 Summary 
Overall, it is evident that high dose alpha-tocopherol supplementation 









there is little information on the comparative effects of increased intake of other 
dietary antioxidants on LDL susceptibility to oxidation and circulating levels of cell 
adhesion molecules and marker of systemic inflammation, C-RP. 
2.6 Aims 
The studies in this thesis were designed to: 
(a) Compare the effect of tomato juice, or supplementation with high doses of 
vitamin E or vitamin C on the susceptibility of LDL to oxidation and 
circulating levels of a marker of systemic inflammation and cell adhesion 
molecules in patients with type 2 diabetes mellitus. 
(b) Establish a model of LDL oxidation which incorporates several factors that 
may be involved in the oxidation of LDL in the artery wall and determine 

















Antioxidant supplementation, LDL 
oxidation and products of inflammatory 
activity in patients with type 2 diabetes 
3.1 Introduction 
Patients with type 2 diabetes are at greater risk of developing CHD(37) and 
commonly measured risk factors for CHD account for only part of this increased 
risk.(40) Recently, attention has focused on the role of increased oxidative stress 
generated by hyperglycremia and protein glycation. (38,119,464) Diabetic patients 
show evidence of enhanced susceptibility of LDL to oxidation, (505,506,520) chronic 
systemic inflammation(41,42) and elevated levels of circulating cell adhesion 
molecules. ( 43 ,44,521) 
There is epidemiologic and clinical evidence that high intake or levels of 
vitamin E, vitamin C and lycopene may be associated with a decreased risk of 
coronary heart disease.(17,18,423) Laboratory studies have also demonstrated 
potentially antiatherogenic activities of these compounds. Supplementing people 
with high doses of alpha-tocopherol reduces susceptibility of LDL to oxidation ex 
vivo (23-27,481,494,508) and decreases the release of pro-inflammatory cytokines from 
isolated monocytes. (28,383) Also, enriching cultured monocytes with vitamin E 
decreases the LDL-induced production of cell adhesion molecules, including 
ICAM-1 and VCAM-1, and their adhesion to human endothelial cells in vitro.(380-
382) In individuals who are under increased oxidative stress, due to smoking, high 
doses of vitamin C have been demonstrated to lead to a small increase in the 
resistance of LDL to oxidation(29) and reduce monocyte adhesion to cultured 
endothelial cells. (30) The regular consumption of tomato juice markedly increases 
the resistance of LDL oxidation in healthy people. (34) Tomatoes and tomato 
products are the main source oflycopene in the dietC315) and this increased 
resistance of LDL to oxidation may be due to the nearly three fold increase in 
circulating levels of the antioxidant lycopene after consumption of tomato 
juice.(33,34,36) Lycopene is a lipophilic antioxidant present in plasma lipoproteins, 
including LDL,(245,338,339,341) and it has been shown to inhibit LDL oxidation 
when added to lipoproteins in vitro.(31) Plasma levels of lycopene appear to be low 



















juice and supplementation with high levels of vitamin E or vitamin C on 
susceptibility of LDL to oxidation and plasma concentrations of cellular adhesion 
molecules in diabetic patients has not been extensively studied. The present study 
was designed to compare the effect of dietary supplementation with tomato juice, 
vitamin E or vitamin C on the susceptibility of LDL to oxidation and circulating 




Patients with type 2 diabetes were recruited from the Diabetes Clinic, Dunedin 
Hospital, local general practitioners and by advertisement in the newspaper. 
Inclusion criteria were (a) age less than 75 years and (b) glycated haemoglobin 
< 10% and fasting plasma glucose< 11 mmol/1. Exclusion criteria included (a) 
presence of hepatic or renal disease and (b) cigarette smoking, ( c) use of dietary 
supplements, including antioxidants or (d) treatment with insulin, lipid-lowering 
drugs or hormone-therapy currently or during the preceding 6 months. The protocol 
was approved by the Southern Regional Health Authority Ethics Committee and all 
participants gave informed consent. 
At entry to the study patients provided a full clinical history of their 
hypertension and CVD. Clinical details pertaining to the duration of their diabetes 
and treatment regimen were obtained. Past smoking habits, medication use, blood 
pressure and BMI were also recorded. 
3.2.2 Study design 
The study was a randomised, placebo-controlled parallel trial. A total of 57 
patients were randomised to receive either: 800 IU/day a-tocopherol (natural source 
d-a-tocopherol, Red Seal) n=12; 500 mg/day vitamin C (Redoxin, Roche) n=12; 
250 ml twice daily commercial tomato juice (Campbells Foodstuffs, Australia) 
n=16; or a placebo supplement (gelatine capsule containing pharmaceutical starch) 
n= 17. The tomato juice did not contain added sugar but erythorbic acid (steroisomer 
of ascorbic acid) had been added as a preservative. Randomisation was carried out 
independently using a computer generated scheme with stratification by gender 
(Excel, Microsoft Office for Windows 95, Microsoft Office Inc.). All patients were 
instructed not to change their usual dietary habits for the duration of the study and 
four day checklists were used to estimate the frequency of consumption of tomato 
products during the study. Patients were asked to take the study supplements with 
meals. Supplement compliance was evaluated during the study by counting unused 
supplements. 
During the initial four weeks all patients received the placebo supplement and 
then proceeded to their assigned treatment for the following four weeks. Blood 
samples, blood pressure and BMI measurements were taken on two occasions at 
















values was used as a more reliable measure of the variables during the study. Blood 
samples were collected for analysis: plasma concentrations of glucose, total 
cholesterol, HDL, HDL2, HDL3, triglycerides, apolipoprotein Al, apolipoprotein B, 
a-tocopherol, a-carotene, ~-carotene, lycopene, vitamin C, FSB, TBARS, 
sVCAM-1, sICAM-1, C-RP; LDL levels of a-tocopherol, peroxides, protein, free 
cholesterol, cholesterol ester, phospholipid, triglyceride; erythrocyte TBARS; 
Conjugated diene and TBARS formation in response to copper stimulated oxidation 
of isolated native LDL. 
3.2.3 Plasma, lDL and erythrocyte preparation 
Patients reported to the study centre early in the morning, after an overnight 
fast. Venous blood was collected into tubes containing disodium EDT A, sodium 
fluoride or heparin. Blood was kept on ice, for a maximum of two hours, before 
plasma and erythrocytes could be isolated by slow speed centrifugation at 4 °C. 
Several aliquots of sodium fluoride and EDT A plasma were stored at -80°C and 
samples were later analysed for concentrations of glucose and lipids, respectively. 
Butylated hydroxytoluene was added to aliquots of EDTA plasma and heparin 
plasma to be assayed for lipid soluble antioxidants and TBARS, respectively. 
Samples were stored at -80°C until analysis. The remaining EDT A plasma was 
flushed with argon and stored at 4 °C (for a maximum of 24 hours) until it could be 
isolated rapidly at 291110 x g by ultracentrifugation on a single-step discontinuous 
gradient in a Beckman NVT 65 rotor.(217) The LDL isolated by this procedure did 
not contain appreciable levels of albumin. (522) Several aliquots of LDL were stored 
at -80°C and this was later analysed for the concentrations of alpha-tocopherol, 
cholesterol, triglyceride, cholesterol ester, phospholipid, and protein. Concentrations 
of LDL peroxides, the formation of conjugated dienes and levels of TBARS were 
determined on the remaining LDL, which had been stored for up to 72 hours at 4 °C 
under a layer of argon. Native LDL, for conjugated diene or TBARS determinations, 
were desalted into phosphate buffered saline (PBS) by gel-filtration in Ecocnopac 
PD-10 columns (Bio Rad) immediately preceding the assay (within 60 minutes). The 
PBS had been Chelex treated to remove any metal ions. Packed erythrocytes were 
prepared, immediately after removal of plasma and buffy coat, by washing 
erythrocytes 3 times with PBS. All laboratory analyses were determined without 
knowledge of the antioxidant regimen of the patient. 
3.2.4 Composition of plasma, LDL and erythrocytes 
Commercial enzymatic kits and calibrators (Boehringer Mannheim) were used 
to determine concentrations of plasma glucose, cholesterol, triglycerides, and LDL 
cholesterol, free cholesterol, cholesterol esters, phospholipids and triglycerides. 
Plasma apolipoprotein Al and apolipoprotein B were measured by 
immunoturbidimetry. (523) High density lipoprotein cholesterol was measured in the 
supernatant after precipitation of apolipoprotein B-containing lipoproteins with 
dextran/magnesium chloride.(524) Glycated h~moglobin was determined in whole 
blood using a commercial kit (Piece, Glycotest 2). The protein content of LDL was 
















measured using an iodometric method(l 77) with hydrogen peroxide standards and the 
addition of BHT and EDT A. 
High performance liquid chromatography was used to determine 
concentrations of plasma a-tocopherol, lycopene, a-carotene, P-carotene(526) and 
LDL a-tocopherol. (527) All sample preparation for lipid-soluble antioxidant analyses 
were performed under low level lighting. The six samples collected from each 
patients were stored at -80°C for several months, to allow analysis in a single batch. 
Each sample was extracted in duplicate from the plasma sample. 
When the plasma lipid-soluble antioxidants were measured, a thawed EDT A 
plasma sample (0.25 ml) containing BHT (0.1 mmol/1) was mixed with 0.25 ml of 
sodium dodecyl sulphate (10 mmol/1), and deproteinised with 0.5 ml of ethanol 
containing an internal standard (tocopherol acetate, 40 µmol/1). The lipid phase was 
extracted with 1 ml of hexane, and 0. 7 ml of this upper phase was evaporated to 
dryness under oxygen-free nitrogen at 40°C. The evaporated organic layer was 
reconstituted with 0.25 ml of mobile phase (methanol/acetonitrile/chloroform 
47:47:6 by volume). The chromatographic system consisted of a Waters 501 pump 
(Millipore Waters Chromatography Division), a 5 µm prepacked guard column 
(Spherisorb ODS-2, Alltech Associates Ltd.) with a 0.5 µm stainless steel frit, a 
150 x 4.60 mm 5 µm (Phenomenex Prodigy ODS-3) analytical column at 30°C with 
an isocratic mobile phase with a flow rate of 2.0 ml/minute, UVNIS detection (Jasco 
UV-975 Intelligent Detector) at "A 292 nm (a-tocopherol), 474 nm (lycopene), 
450 nm ( a-carotene and P-carotene) and quantification by integrated peak areas 
(Shimadzu C-R3A chromatopac). The integrator was calibrated by 15 replicate 
injections of a-tocopherol, lycopene, a-carotene, ~-carotene and tocopherol acetate 
standards. The calibration standards (Roche) were quantified by spectrophotometry 
(Ultrospec 2000 UV Visible Spectrophotometer, Pharmacia Biotech) using the 
specifications presented in Table 3.1. The quantity of antioxidant detected at the 
following times, a-tocopherol Rt= 4.7 minutes, lycopene Rt= 8.1 minutes, a.-
carotene R
1 
= 13.1 minutes, ~-carotene Rt= 14.0 minutes, was adjusted by recovery 
of the internal standard measured at Rt= 5.8 minutes. The intra-sample (n=25) and 
inter-sample (n=30) coefficients of variation were as follows; 3.1 %, 5.5 % 
a-tocopherol; 5.6%, 7.1 % lycopene; 7.3%, 8.2% a-carotene; 5.7%, 6.8% 
~-carotene. Recovery experiments were performed on a pooled plasma sample, 
spiked with the various antioxidants across the expected concentration range, and the 
mean results (n=8); 99.1 % a-tocopherol, 98.4% lycopene, 96.9% a-carotene and 
95.9 % ~ carotene. 
When the LDL a-tocopherol was measured, 0.1 ml of thawed LDL sample 
containing BHT (0.1 mmol/1) was combined with 0.1 ml of ethanol and 0.1 ml of 
ethanol containing 0.1 mg/ml of internal standard (tocopherol acetate dissolved in 
ethanol, 0.21 mmol/1). This mixture was vortexed and partitioned twice against 
0.2 ml of hexane, the organic supernatants were pooled and evaporated to dryness 
under oxygen-free nitrogen at 40°C. The evaporated organic layer was reconstituted 
with 0.1 ml of ethanol. The chromatographic system consisted of a 10 x 4.60 mm 
guard column (Direct-Connect, Alltech Associates Ltd.) and a 250 x 4.60 mm 10 µm 
(Versapack) C18 analytical column and with a 97% methanol mobile phase at 2.5 
ml/minute, UV detection (Shimadzu SPD-6A V) at A 294 nm and quantification by 




















calibrated by 10 replicate injections of a-tocopherol and tocopherol acetate 
quantified by spectrophotometry (Ultrospec 2000 UV visible Spectrophotometer, 
Pharmacia Biotech) (Table 3.1). The quantity of vitamin E detected at R
1 
= 4.2 
minutes was corrected by recovery of the internal standard measured at R
1 
= 5.8 
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TABLE 3.1 Tocopherol and carotenoid extinction coefficients and absorptivity 







Tocopherol acetate 0.447 
E Tocopherol and tocopherol acetate were measured in ethanol 
c Lycopene was measured in chloroform 





























Plasma vitamin C was determined by fluorimetry on a Cobas Fara autoanalyser 
(Roche) as described by Vuilleumier and Peck.(433) Measurements were performed 
on the clear supernatant obtained from thawed samples of heparin plasma which had 
been stored with 5% metaphosphoric acid (plasma/ MPA 1:9 by volume) and 
centrifuged at 4000 x g for 4 minutes at 4 °C. The ascorbate oxidase was purchased 
from Boehringer Mannheim Biochemica (10 mg lyophilisate, approximately 
1700 U), the lyophilisate was dissolved in 5 ml of acetate buffer (2 mol/1, pH 6.2) 
and stored in aliquots of 0.25 ml at -80°C until required. Recovery experiments were 
performed on a pooled plasma sample which had been spiked with ascorbic acid 
across the expected concentration range, and the mean result was 92.4% (n= 10). 
Samples for each patient were analysed in a single run and in triplicate. The intra-
sample (n=25) coefficient of variation for the assay was 1.7%. 
Circulating plasma fluorescent Schiff bases were determined essentially by the 
method developed by Tsuchida and co-workers.(207) First the proteins were 
separated from the lipid components by adding 4 ml of ethanol/diethyl ether (3: 1 by 
volume) to 0.1 ml of EDT A plasma. This mixture was shaken for 5 minutes, 
centrifuged at 1310 x g for 5 minutes ( 4 °C) and the solvents were discarded, this 
procedure was repeated with the resulting sediment. The sediment was dissolved in 
2 ml of distilled water and the fluorescence intensity of this solution was measured at 
an excitation A 350 nm and an emission of A 460 nm (Aminco-Bowman 
Spectrophotofluorometer), with the sample sensitivity set at 10 and both slit widths 
at 5 nm. The instrument was calibrated daily to read 100 relative fluorescence units 
against a quinine sulphate solution (0.1 µg/ml of 0.1 sulphuric acid). 
Plasma concentrations of MDA were determined by HLPC.099) A 0.5 ml 
aliquot of thawed heparin plasma containing BHT (18.9 µmol/1) was combined with 
6 ml of chloroform and 3 ml of methanolic BHT (0.25 g/1) and the mixture was 
shaken for 15 minutes at room temperature. Aqueous sodium chloride (2 ml of 0.9% 
weight by volume) was added and centrifuged at 1200 x g for 15 minutes at room 
temperature. A salt layer formed at the interface of the two phases, the upper phase 
was discarded and the chloroform layer was transferred to another tube, and the 
procedure was repeated on the chloroform layer, before the chloroform was removed 
under oxygen-free nitrogen at room temperature. The residue was taken up in 0.3 ml 
of dimethyl sulphoxide (DMSO) (containing 2.5 g/BHT) and then 0.5 ml of aqueous 
Triton X-100 (0.5% weight by volume, prepared daily) in 50% (by volume) 




0) (1.5 g/1 in 
50% by volume aqueous aldehyde-free acetic acid) were added sequentially, with 
vortex mixing between each addition. The capped tube was heated in boiling water 
for 60 minutes, then cooled rapidly on crushed ice. A further 2 ml of 50% Triton 
X-100 and 0.5 ml sodium hydroxide (8 mol/1) were added before application on the 
C
18 
mini-cleanup columns (500 mg Bond-Elut, Alltech Associates Ltd.) 
preconditioned with 10 ml propan-2-ol followed by 2 rinses of distilled water 
(10 ml). Non-binding substances were eluted with distilled water and bound adduct, 
malondialdehyde(thiobarbituric acid\ (MDA(TBA)
2
) was eluted in 3.0 ml of 70% 
(by volume) aqueous methanol, 50 µl of this eluate was subjected to HPLC 
separation using the following chromatographic system: a 100 x 4.60 mm i.d. C18 
(Alltech Associates Ltd.) analytical column with 70% (by volume) methanol mobile 
phase at 3.0 ml/minute, and a fluorescence detector (Shimadzu RF-530, excitation 















Integrated peak areas for samples were quantified by a MDA(TBA\ standard which 
was prepared by acid hydrolysis of 1,1,3,3-tetraethoxypropane.(528) Chromic acid 
washed glassware was used throughout this assay. 
Thiobarbituric acid reacting substances in erythrocytes were determined in 
triplicate essentially by the method developed by Jain et al (1989).(489) Butylated 
hydroxytoluene and EDT A were added to the samples to be assayed for TBARS 
prior to heating with acid to protect the polyunsaturated fatty acids from 
oxidation. (200,529) 
Plasma sVCAM-1 (sVCAM-1, R&D Systems), sICAM-1 (sICAM-1, R&D 
Systems) and C-RP (Hemagen CRP 150 Kit, Hemagen Diagnostics) were measured 
by an immunoassay. Due to economic constraints, only one sample at each phase of 
the trial was analysed for C-RP, sICAM-1 and sVCAM-1 for each patient. However 
all the samples from each patient were analysed in the same batch in duplicate. The 
intra-sample coefficients of variation for the assays were as follows: 4.9% 
sVCAM-1; 3.3% sICAM-1; 8% C-RP. 
3.2.5 Oxidation of LDL 
The oxidation of isolated LDL was monitored by the formation of conjugated 
dienes or TBARS. When conjugated dienes were measured, isolated LDL (100-
300 µl, 0.39 µmol cholesterol) was added to Chelex treated PBS (final volume was 
2 ml). An aliquot of copper sulphate (32 µl, final concentration 1.6 µmol/1) was 
added with rapid mixing and the absorbance at ').., 234 nm (Ultrospec 2000 UV 
Visible Spectrophotometer, Pharmacia Biotech) was monitored every 60 seconds 
over 4 hours. The temperature of the sample during this incubation was 25 ± 1 °C. 
The lag phase was defined, from the plot of absorbance values against time, as the 
intercept of the lag and propagation phase tangents. The inter-assay coefficient of 
variation for the lag time in LDL oxidation was 5% (n=l2). Maximal and rate of 
propagation of conjugated diene formation were also determined. 
When TBARS were measured, the LDL (100-200 µl, 0.2 µmol cholesterol), 
and copper sulphate (30 µI, final concentration 2.5 µmol/1) were added to Chelex 
treated PBS and the final volume was adjusted to 1.2 ml. The mixture was incubated 
at 37°C for 3 and 5 hours. At the end of this period, BHT (10 µl of 4 mmol/1 in 
methanol) and EDTA (50 µl of 4 mmol/1) were added and TBARS measured 
essentially by the method of Beuge and Aust. (197) Thiobarbituric acid solution 
(2 ml), containing 0.375% thiobarbituric acid in 15% trichloracetic acid and 
0.25 mol/1 hydrochloric acid, was added to the incubation mixture and to the 
standards containing 1,1,3,3-tetraethoxypropane (1.84-4.60 nmol). Tubes were 
heated on a boiling water bath for 30 minutes and after cooling were centrifuged at 
2800 x g for 30 minutes. The optical density of the clear supernatant was read at 
').., 532 nm (Ultrospec 2000 UV Visible Spectrophotometer, Pharmacia Biotech) 
against the blank and amount of TBARS formed was calculated using standards. 












3.2.6 Statistical analysis 
The study was able to detect a change in lag time in LDL oxidation of 10 
minutes at a power of 90% and P=0.05. Variables required logarithmic 
transformation to give approximately symmetrical distributions for statistical 
analysis. Analysis of variances with repeated measures were used to investigate the 
association between parameters of oxidative stress and markers of inflammation with 
the antioxidant regimens. Baseline values were used as a covariate in these analyses. 
When a significant difference was present among the treatment groups, unadjusted 
paired t-tests were used to test for within-group changes during the study. Multiple 
linear regression, adjusting for baseline LDL lag time, was performed to evaluate the 
relative impact of the antioxidant treatments on final lag time. Pearson's product-
moment correlation analysis was used to test C-RP levels, at baseline and at the end 
of the placebo phase and sICAM-1 and sVCAM-1. Two-sided tests of significance 
were used and a P value of less than 0.05 was considered statistically significant. 
Baseline differences between the treatment groups were examined using analysis of 
variances for continuous variables and x2 for categorical variables. The statistical 
analysis was carried out using SPSS release 6.1 (SPSS for Windows, SPSS Inc.). 




TABLE 3.2 Characteristics of the patients at entry to the study (mean ± SD ) 
a-Tocopherol Vitamin C Tomato Juice Placebo 
n=12 n=12 n=15 n=l3 
Age, years 56± 14 56±9 63 ± 8 60±6 
Gender, male/female 6/6 6/6 10/5 10/3 
Median duration of diabetes, years 3 1.5 3 2 
BMI, Kg/m2 31.5 ± 7.4 30.7 ± 6.3 30.9 ± 7.0 31.8±4.1 
Systolic blood pressure, mmHg 84 ± 11 89 ± 12 89 ± 8 87 ± 11 
w Diastolic blood pressure, mmHg 141 ± 10 140 ± 12 144 ± 13 142 ± 16 
\0 
Glycated haemoglobin (HbAc1) , % 6.73 ± 0.93 6.68 ± 0.98 6.00 ± 0.69 6.62 ± 1.66 
Fructosamine, µmol/1 270 ± 36 258 ± 21 269 ± 32 264 ± 20 
Fasting plasma glucose, mmol/1 8.3 ± 2.1 8.7 ± 1.5 8.2 ± 1.3 9.1± 2.4 
.i:,.. 
0 
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TABLE 3.3 Medication, prevalence of IHD, obesity and raised blood pressure 
(numbers and percentages) 
cx-Tocopherol Vitamin C Tomato Juice 
n=12 n=12 n=15 
Ischremic heart disease 8 (67) 5 (42) 10 (67) 
Obesity (BMI >30, Kg/m2) 6 (50) 5 (42) 6 (40) 
Systolic blood pressure;:,: 90 mmHg 6 (50) 2 (17) 4 (27) 
Control of hyperglycaemia 
Diet only 4 (33) 5 (42) 6 (40) 
Oral hypoglycaemics 8 (67) 7 (58) 9 (60) 
Biguanides 2 (17) 0 4 (27) 
Sulehon~lureas 8 (67) 7 (58) 7 (47) 























TABLE 3.4 Concentrations of plasma lipids and lipoproteins 
(mean± SD) 
a-Tocopherol Vitamin C Tomato Juice Placebo P" 
n=12 n=l2 n=15 n=13 
Cholesterol, mmol/1 
Baseline 5.65 ± 1.16 5.96± 0.97 5.87 ± 1.02 6.48 ± 1.14 
End of placebo 5.57 ± 1.30 5.92± 0.94 5.82 ± 1.00 6.49 ± 1.19 
End of study 6.07 ± 1.50:j: 5.97 ± 0.88 5.73 ± 0.97 6.52 ± 1.09 0.022 
HDL, mmol/1 
Baseline 1.16 ± 0.22 1.13 ± 0.23 1.04 ± 0.29 0.95 ± 0.16 
End of placebo 1.16 ± 0.22 1.15 ± 0.25 1.02 ± 0.30 0.96± 0.16 
End of study 1.20 ± 0.23 1.15 ± 0.22 1.07 ± 0.35 0.98 ± 0.20 0.693 
Triglycerides, mmol/1 
Baseline 2.09 ± 1.01 1.95 ± 0.93* 2.49 ± 0.74 3.03 ± 1.76 
End of placebo 2.00 ± 1.02 1.97 ± 1.00 2.57 ± 0.63 2.99 ± 1.52 
End of study 2.28 ± 1.20 2.14 ± 1.10 2.53 ± 1.04 2.83 ± 1.46 0.070 
Apolipoprotein Al, g/1 
Baseline 1.24 ± 0.21 1.19 ± 0.22 1.14 ± 0.28 1.12 ± 0.17 
End of placebo 1.26 ± 0.14 1.24 ± 0.26 1.28 ± 0.40 1.11 ± 0.10 
End of study 1.37 ± 0.21 1.27 ± 0.25 1.21 ± 0.29 1.14 ± 0.21 0.316 
Apolipoprotein B, g/1 
Baseline 0.95 ± 0.31 0.86 ± 0.17 0.95 ± 0.24 1.13 ± 0.31 
End of placebo 0.94 ± 0.33 0.92 ± 0.23 1.00 ± 0.22 1.17 ± 0.19 
End of study_ 1.04 ± 0.37 1.06 ± 0.18t 0.92 ± 0.19 1.20 ± 0.34 0.027 
* ANOV A comparing vitamin C group with placebo group, with level of significance P<0.05. 
t Unadjusted paired t-tests comparing the placebo phase with vitamin C supplementation, 
with level of significance P<0.05. 
:j: Unadjusted paired t-tests comparing the placebo phase with vitamin C supplementation, 
with level of significance P<0.01. 
41 
'( '( 
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TABLE 3.5 Concentrations of plasma antioxidants {mean ± SD) 
a-Tocopherol Vitamin C Tomato Juice Placebo pa 
n=12 n=12 n=15 n=13 
a-tocopherol, µmol/1 
Baseline 24.44 ± 8.57 22.69 ± 4.13 26.13 ± 4.88 23.89 ± 5.34 
End of placebo 24.34 ± 8.78 22.21 ± 5.01 25.49 ± 4.46 25.36 ± 5.75 
End of study 56.71 ± 23.66 t 22.55 ± 4.76 26.74 ± 5.97 24.36 ± 6.54 0.001 
Lycopene, µmol/1 
Baseline 0.35 ± 0.24 0.41 ± 0.27 0.39 ± 0.23 0.31 ± 0.26 
End of placebo 0.31 ± 0.19 0.41 ± 0.27 0.39 ±0.26 0.33 ± 0.28 
End of study 0.41 ± 0.23 0.44 ± 0.32 1.08 ± 0.39 t 0.28 ± 0.21 0.001 
.j:,,. 
Vitamin C, µmol/1 N 
Baseline 39.57 ± 19.51 40.74 ± 15.43 38.87 ± 25.50 24.96 ± 15.64 
End of placebo 42.71 ± 18.03 37.70 ± 12.37 43.83 ± 28.56 27.34 ± 15.35 
End of studl 39.96 ± 13.71 64.74 ± 14.34 t 55.96 ± 23.40 29.68 ± 21.10 0.089 
a Repeated measures ANOV A by treatment and group with baseline covariate correction. 
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TABLE 3.7 Concentrations of circulating lipid peroxidation products (mean ± SD) 
o:-Tocopherol Vitamin C Tomato Juice Placebo p• 
n=l2 n=l2 n=15 n=13 
Plasma FSB, U/ml 
Baseline 9.00 ± 2.05 9.24 ± 2.43 10.84 ± 1.76 11.13 ± 2.32 
End of placebo 9.83 ± 2.74 9.95 ± 2.35 11.72 ± 2.47 11.51 ± 2.72 
End of study 9.41 ± 2.03 9.88 ± 2.37 11.38 ± 3.25 10.62 ±2.29 0.614 
Plasma TEARS, ng/ml 
Baseline 90.49 ± 27.03 96.45 ± 19.83 109.84 ± 23.32 111.22 ± 35.80 
End of placebo 83.72 ± 21.60 94.03 ± 18.78 103.17 ± 22.83 109.21 ± 29.23 
End of study 87.88 ± 25.45 88.93 ± 19.70 108.09 ± 23.52 110.69 ± 32.27 0.206 
.i:,. RBCTBARS, .i:,. 
nmol MDA/ml PC 
Baseline 1.12 ± 0.25 1.20 ± 0.19 1.17 ± 0.25 1.12 ± 0.22 
End of placebo 1.17 ± 0.15 1.14 ± 0.22 1.18 ± 0.24 1.23 ± 0.20 
End of study 1.20 ± 0.19 1.23 ± 0.25 1.20 ± 0.27 1.29 ± 0.18 0.731 
Abbreviations: MDA, malondialdehyde; PC, packed cells. 




~ \,' •/ ,. " 
TABLE 3.8 Concentrations of plasma C-RP and soluble cell adhesion molecules (mean ± SD) 
a-Tocopherol Vitamin C Tomato Juice 
n=12 n=l2 n=15 
Plasma C-RP, mg/1 
Baseline 4.5 ± 3.8 2.9 ± 3.3 3.8 ±2.2 
End of placebo 5.6 ± 3.1 3.1 ± 3.3 3.5 ± 2.2 
End of study 2.9 ± 3.6 t 3.1 ± 2.9 4.1 ± 2.1 
Plasma sICAM-1, ng/ml 
Baseline 257 ± 85 256 ± 59 244 ±70 
End of placebo 276 ± 66 244± 55 246± 60 
End of study 272 ± 55 243 ± 62 240 ±49 
Plasma sVCAM-1, ng/ml 
Baseline 533 ± 148 582 ± 353 619 ± 179 
End of placebo 526 ± 139 584 ± 370 632 ± 189 
End of studx_ 534 ± 153 585 ± 354 632 ± 160 
• Repeated measures ANOV A by treatment and group with baseline covariate correction. 
Placebo 
n=13 
3.1 ± 2.6 
2.9 ± 1.9 
3.1 ± 2.5 
297 ± 131 
289 ± 112 
287 ± 112 
626 ± 232 
635 ± 244 
640 ± 256 
















Five people withdrew during the study, due to difficulties donating a blood 
sample (n=2), alterations in medication (n=2) and problems tolerating the tomato 
juice (n=l). The baseline characteristics of the participants are detailed in Tables 3.2 
and 3.3. The mean age of the patients was 58 ± 9 years. Forty percent of the patients 
were female and four were less than 50 years of age. Patients had been diagnosed 
with diabetes mellitus for a median of 2.5 years and the majority (86%) of patients 
had been diagnosed with diabetes for less than six years. Patients had elevated 
fasting plasma glucose, blood glycated haemoglobin and BMI at baseline and these 
remained stable during the study. A third of the study group controlled their 
diabetes by diet alone and the remainder were treated with oral hypoglycremic drugs. 
Nine patients ( 17%) controlled their hyperglycremia with gliclazide. Many of the 
participants had multiple risk factors for atherosclerosis and more than half had 
clinical evidence of coronary heart disease (60%). Consequently a number of the 
patients were taking medications regularly, including ACE inhibitors (37%), calcium 
blocking agents (19%) and low-dose aspirin (21 % ). The proportion of patients 
regularly taking calcium blocking agents, aspirin or gliclazide was similar between 
the treatment groups, however ACE inhibitor medication use was significantly lower 
(P<0.05) in the patients randomised to receive alpha-tocopherol and vitamin C 
compared with those on placebo. Medication regimens were unchanged during the 
study. 
Plasma lipids, lipoproteins and apolipoproteins concentrations were similar 
between the treatment groups at baseline (Table 3.4), with the exceptions of plasma 
triglyceride which were lower in the patients randomised to receive vitamin C 
(P<0.05) and plasma HDL which was higher in those in the a-tocopherol group 
(P<0.05). Concentrations of plasma total cholesterol (9% n=12; P<0.001) and 
apolipoprotein B (15% n=12; P<0.05) increased with a-tocopherol and vitamin C 
supplementation, respectively. The concentration of LDL in the plasma is not 
presented as it was not measured directly and an estimation using the Friedwald 
formula is not considered appropriate when plasma triglycerides are elevated. (530) 
Plasma concentrations of antioxidants during the study are presented in Table 
3.5. Plasma concentrations of a-tocopherol, vitamin C and lycopene were similar 
between the treatment groups at baseline and at the end of the placebo phase, but 
increased significantly after the supplement phase for the respective groups, 
suggesting both compliance with the treatment regimen and good bioavailability of 
the antioxidant supplements. Plasma concentrations of a-carotene and ~-carotene 
were not changed by the tomato juice supplementation ( data presented in appendix 
D). At baseline plasma lycopene, expressed per mol of plasma cholesterol, was 
significantly lower in the diabetic patients compared with younger non diabetic 
subjects measured in the same laboratory (patients 0.37 ± 0.24 mmol/mol n=52; 
control subjects 1.05 ± 0.41 n=18; P=0.001). This was also the case for a-tocopherol 
(patients 1.77 ± 0.35 mmol/mol n=52; control subjects 2.09 ± 0.50 mmol/mol n=l8; 












low amongst the patients at baseline and this remained similar during the study ( data 
presented in appendix E). 
Oxidation characteristics and the composition of the LDL are presented in 
Table 3.6. Lag time was significantly lengthened after supplementation with tomato 
juice (42% n=15; P<0.001) and a-tocopherol (54% n=12; P<0.001) but remained 
unchanged in those patients who received placebo and vitamin C supplements. 
Multiple linear regression analysis demonstrated in these patients, supplementing 
with tomato juice or a tocopherol increased the lag time by 31 (P=0.004) and 44 
(P=0.001) minutes, respectively, after adjusting for initial lag time (b=0.4 P=0.026). 
In contrast, supplementation with vitamin C (b= -2 P=0.838) or the initial levels of 
plasma a-tocopherol (b=-2 P=0.329), lycopene (b=-7 P=0.802) or cholesterol (b=6 
P=0.191) did not significantly influence the final lag time. Lag time remained stable 
during the placebo phase. The coefficient of variation between the two measures of 
lag time at each time point was 3.3% (n=57). At baseline the rate of conjugated 
diene formation during the propagation phase was 8.43 ± 2.3 nmol/µmol/minute and 
the maximal level was 1056 ± 134 nmol/µmol. The maximal and rate of conjugated 
diene formation were similar between the groups at baseline and levels were 
unaffected by the antioxidant treatments (data presented in appendix D). The levels 
of TBARS formed at 3 hours (17.92 ± 4.12 mmol MDAfmol cholesterol) and 
5 hours (18.11 ± 4.01 mmol MDAfmol cholesterol) were unaffected by the 
antioxidant or placebo supplementation regimens (data presented in appendix D). 
The chemical composition of the LDL was similar between the groups at baseline, 
with the exception of patients randomised to receive vitamin C who had a 
significantly higher percentage of phospholipid (P<0.05) and less triglyceride 
(P<0.05). The chemical composition of LDL did not change during the study, with 
the exception of a-tocopherol levels which were increased after supplementation 
with this antioxidant (111 % n=12 P<0.001). The peroxide content in the LDL 
remained unchanged with the antioxidant supplements. 
Indices of lipid oxidation in the plasma and erythrocyte TBARS are presented 
in Table 3.7. Levels were similar between the treatment groups at baseline and did 
not change significantly with the antioxidant regimens. At baseline FSB levels were 
significantly higher than levels measured previously in healthy subjects in the 
laboratory (8.8 ± 1.6 U/ml n=lO). 
Plasma levels of C-RP and cell adhesion molecules are reported in Table 3.8. 
At baseline the concentrations of C-RP, sVCAM-1, and sICAM-1 were not different 
between the groups, however there was a non significant trend for the patients 
randomised to receive a-tocopherol to have higher C-RP. Supplementation with a-
tocopherol reduced plasma C-RP by 51 % (P=0.009) while no effect was observed 
with tomato juice, vitamin C or placebo supplementation. C-reactive protein was 
stable during the placebo phase, as demonstrated by the strong correlation between 
baseline and the end of the placebo measures (r=0.998 P<0.001). Also plasma C-RP 
concentrations did not change in patients with baseline levels above 3 mg/1 who 
were not receiving a-tocopherol (baseline 6.3 ± 1.8 mg/I; end of placebo 5.0 ± 
2.0 mg/1; end of supplementation 5.4 ± 1.9 mg/I; n=23; P=0.340). Patients with 4 or 
more risk factors for CHD associated with syndrome X, including raised blood 
pressure (systolic blood pressure 2::160 or diastolic blood pressure 2::95 or anti-









high triglycerides (;?:1.5 mmol/1) had significantly higher baseline levels of C-RP 
compared with those with one or zero risk factors (syndrome X 4.5 ± 2.3 mg/1 
n=16; without syndrome X 1.7 ± 2.6 mg/1 n=12; P=0.007). Glucose, glycated 
hremoglobin, age and duration of diabetes were similar between patients with and 
without risk factors for syndrome X. 
Levels of cell adhesion molecules were not altered when concentrations of 
plasma a-tocopherol and lycopene were increased as a result of the supplementation 
regimens. Plasma sICAM-1 and sVCAM-1 levels displayed a strong correlation 
(r=0.576 P=0.001). 
3.4 Discussion 
Regular consumption of tomato juice increased the intrinsic resistance of LDL 
to oxidation in diabetic patients by 42%. The magnitude of this increase was 
comparable with a preliminary study in healthy subjects which used similar 
methodology(34) and several other non placebo-controlled studies which have 
reported tomato juice reduces LDL susceptibility to oxidation in people without 
diabetes.(33,35,36) Tomato juice contains a number of antioxidants which could 
potentially influence the susceptibility of LDL to oxidation. In particular, it is a rich 
source of the lipophilic antioxidant lycopene.(354) Enriching LDL in vitro with 
lycopene has been demonstrated to increase the intrinsic resistance of LDL to 
oxidation.C31) In the lipoprotein, lycopene may attenuate oxidative damage by 
reducing the availability of free radicals.(293) Lycopene may be oxidised in 
preference to the unsaturated fatty acids as a consequence of its similar structure, 
namely the allylic methylene group at the C-4 position(284,293,294) and high number 
of double bonds.(284,295) Furthermore, the resulting lycopene radical is unlikely to 
promote lipid peroxidation in vivo.(304) 
In the present study, plasma lycopene increased almost three fold following 
tomato juice consumption for several weeks and this increase was consistent with 
data in non diabetic subjects.(32,34-36) The good bioavailability of lycopene from the 
tomato juice used in this study was probably due to extensive heat treatment of the 
juice(316) which releases lycopene from the plant cell wall components.(288) 
Drinking the juice with meals would have further improved absorption of lycopene 
by co-ingestion with fat.(317) This increase in plasma lycopene would be expected to 
enrich LDL with lycopene, as in the circulation lycopene is associated primarily 
with lipoproteins. (345) 
Tomato juice contains a small amount of vitamin E(354) however plasma 
alpha-tocopherol levels were not increased after the tomato juice regimen. This 
finding indicates that increased alpha-tocopherol intake was not responsible for the 
reduced susceptibility of LDL to oxidation observed with tomato juice in the present 
study. However in isolated LDL, the antioxidant action of lycopene may be 
attenuated by lower alpha-tocopherol levels. Fuhrman and co-workers have 
suggested that lycopene is only effective in reducing LDL oxidation when high 













cholesterol). (31) In the present study, the intrinsic resistance of LDL to oxidation 
was improved in spite of apparently low levels of LDL alpha-tocopherol (levels at 
baseline 7 .26 ± 1.19 µmol/g cholesterol compared with at end of tomato juice 
supplementation 6.99 ± 1.19 µmol/g cholesterol). It is possible the antioxidant 
capacity of the lycopene may be dependent on its location within the LDL particle. 
When tomato products are fed to individuals, lycopene is incorporated into the 
chylomicron and the VLDL fractions, and during the following 48 hours 
concentrations rise in the other lipoprotein fractions.(327,330) Lycopene is 
predominantly transported by the LDL fraction where it is associated with the 
hydrophobic inner core components(245,338,339) and is therefore well-placed to 
protect the majority of the LDL lipids from oxidation. In contrast, enriching the 
LDL with lycopene, in vitro, may have incorporated it near the surface of the 
lipoprotein. (340) The present study findings do not support the hypothesis that high 
levels of alpha-tocopherol in the LDL are required to elicit the antioxidant action of 
lycopene. 
Tomatoes contain substantial levels of vitamin C and during processing tomato 
juice frequently has vitamin C added, further elevating these concentrations.(531) 
There was a non significant trend for vitamin C levels to increase during tomato 
juice supplementation in the present study. However, vitamin C alone did not appear 
to be responsible for the increased resistance to oxidation during supplementation 
with tomato juice, as the resistance of LDL was unchanged in patients who were 
randomised to receive high doses of vitamin C. However the trend toward increased 
plasma vitamin C levels may have enhanced the antioxidant effects of tomato juice 
in the present study as vitamin C may regenerate or spare alpha-tocopherol and 
carotenoids. (303) 
Vitamin C supplementation of people who are under oxidative stress, due to 
cigarette smoking, has been reported to have a modest effect on LDL resistance to 
oxidation (14%).(29) In this situation vitamin C may improve LDL resistance to 
copper induced oxidation by reducing the levels of lipid hydroperoxides in the 
LDL(29) and disrupting the copper metal-binding sites on apolipoprotein B(252) The 
diabetic patients in the present study are also under oxidative stress but vitamin C 
failed to reduce lipid hydroperoxide levels or alter the susceptibility of the LDL to 
oxidation. It is possible that the lower dose of vitamin C (500 mg/day) and the 
corresponding lower plasma vitamin C levels achieved during the supplementation 
period were insufficient to decrease LDL peroxides or alter LDL conformation, and 
increase the intrinsic resistance of LDL to oxidation. Also vitamin C 
supplementation may not normalise plasma ascorbate in diabetic patients, as 
demonstrated by Sinclair and co-workers. (532) 
Enriching LDL with alpha-tocopherol has been shown previously to improve 
the resistance of the LDL to oxidation in non diabetic volunteers. (23-27) However, 
pharmacological doses (~400 IU/day) of alpha-tocopherol for several weeks have 
been required to show significant improvements in lag time. The LDL isolated from 
diabetic patients has been reported to be depleted in alpha-tocopherol(493) and a 
proportion is likely to be small dense LDL which appears more difficult to enrich 
with alpha-tocopherol. (240) Thus it is unlikely non pharmaceutical doses of alpha-
tocopherol would influence LDL oxidation. In the present study, supplementation 











alpha-tocopherol levels and this resulted in a 54% extension of the LDL lag time. 
The magnitude of this improvement was only marginally shorter (15%) than a 
similar study in diabetic men supplemented for ten weeks with a higher dose of 
alpha-tocopherol (1600 IU/day).(494) 
Alpha-tocopherol reduced plasma C-RP levels by 51 % and this may indicate 
an improvement in systemic inflammatory status. At baseline, plasma levels C-RP 
were similar to the elevated levels previously reported in diabetic patients.(41) 
Inflammatory activity as a result of oxidative stress or atherosclerosis may 
contribute to high C-RP levels.(152,155) Most of the patients in the current study had 
multiple risk factors for CHD and those with several risk factors had higher levels of 
C-RP which is in agreement with data reported in diabetic patients with syndrome 
X.(41) Few patients reported infections but it cannot be excluded that undiagnosed 
and asymptomatic infections also contributed to the elevated C-RP levels.042,143) 
The mechanism underlying the reduction in C-RP with supplementation of alpha-
tocopherol in diabetic patients is uncertain. However, it appears to be specific to 
alpha-tocopherol, in as much as increased levels of the lycopene or vitamin C did 
not alter C-RP levels. Devaraj and Jialal reported supplementation with high doses 
of alpha-tocopherol in healthy subjects inhibited the release of IL-1 B from isolated 
monocytes.(28) The pro-inflammatory cytokines IL-lB and IL-6 increase the 
synthesis of C-RP by hepatic cells in vitro.(533) 
Baseline levels of plasma MDA, FSB and erythrocyte TBARS appeared to be 
elevated in the diabetic patients and this is consistent with increased oxidative stress. 
Levels of plasma MDA were comparable with the high levels recorded in people 
who smoke in a study which had used the same method of MDA estimation.(534) 
Erythrocyte TBARS levels were similar to concentrations documented in diabetic 
patients(489) and plasma FSB levels were markedly higher than levels in healthy 
subjects determined in Dr Sutherland's laboratory. While tomato juice and alpha-
tocopherol supplementation improved the resistance of isolated LDL to oxidation, 
these treatments did not change circulating levels of lipid oxidation products. The 
unchanged levels of plasma MDA during supplementation with high doses of alpha-
tocopherol was in contrast to a study by Mol and co-workers which reported a 
decrease in plasma TBARS in diabetic patients after four weeks supplementation 
with 600 IU/day of alpha-tocopheroI.(481) However variance in the levels of plasma 
glucose and alpha-tocopherol, and methods used to measure MDA may contribute to 
these dissimilar findings. In the present study, glycated haemoglobin and fasting 
plasma glucose were lower, and it is possible alpha-tocopherol may be less effective 
in decreasing circulating levels of lipid oxidation products under these conditions of 
lower gluco-oxidative stress. Determining the concentration of lipid oxidation 
products in the plasma is difficult and the possibility cannot be excluded that these 
determinations were not sufficiently specific or sensitive to detect a small decrease 
in lipid oxidation products during antioxidant supplementation. However in the 
present study, plasma MDA was determined using an HPLC method which had 
been designed to reduce the interference from molecules that are not products of 
lipid oxidation in the plasma099) and this method has previously identified oxidative 
stress in smokers and patients with peripheral vascular disease.(534) Also, the present 
findings appear consistent with a recent placebo-controlled alpha-tocopherol 
















highly specific index of lipid oxidation, were used to determine lipid oxidation 
products.(535) Erythrocytes are vulnerable to oxidative damage and provide an 
accessible cellular measure of peroxidation. The unchanged levels of erythrocyte 
TBARS in the diabetic patients in the present study suggest that although plasma 
antioxidant levels were increased following supplementation, membrane lipid 
oxidation and cellular oxidant stress were not inhibited. These results are in contrast 
to a similar study in non diabetic patients where erythrocyte TBARS were reduced 
during alpha-tocopherol supplementation.(536) It is possible that cells from diabetic 
patients are less responsive than normal cells to the effects of increased levels of 
alpha-tocopherol. 
At baseline, plasma levels of sICAM-1 were similar to the elevated levels 
previously reported in diabetic patients, ( 43) whereas levels of s VCAM-1 were not 
raised compared to data published previously in diabetic(44) and non diabetic 
subjects. (537) Lysophosphatidycholine, a product of oxidised LDL, can stimulate the 
expression of adhesion molecules on cultured cells<170,172,538) and studies have 
reported the expression of cell adhesion molecules is depressed when cultured cells 
are enriched with antioxidants, such as alpha-tocopherol or probucoI.(171,380) 
Circulating forms of ICAM-1 (163)and VCAM-1 (162) can be measured in the plasma 
and they appear to reflect the cellular expression of these molecules. Ceriello and co-
workers have previously reported a decrease in plasma sICAM-1 levels in patients 
with type 2 diabetes following the intravenous administration of the antioxidant 
glutathione.(515) However in the present study, the antioxidant regimens failed to 
reduce levels of sICAM-1 or sVCAM-1. It is possible the supplementation period 
may have been too short and the cellular concentration of antioxidants may not have 
been sufficiently elevated to reduce the cellular expression of adhesion molecules. 
Also plasma glucose levels remained elevated during the study which may have 
maintained elevated sICAM-1 levels, as glycremic control has previously been 
demonstrated to have a major influence on sICAM-1 levels in diabetic 
patients. (43,515) 
Supplementing diabetic patients with high doses of alpha-tocopherol and 
vitamin C in the present study had deleterious effects on plasma cholesterol and 
apolipoprotein B, respectively. After supplementation with high doses of alpha-
tocopherol the diabetic patients showed a significant increase in plasma cholesterol 
levels and a trend for apolipoprotein B to rise. This finding is not due to 
measurement variability. The measurement of plasma cholesterol conformed to strict 
quality control (CV 3%). Also, two measurements of plasma lipids and 
apolipoproteins were made at each time point. It is unlikely that there were changes 
in the usual diet and that these were responsible for the increase in plasma 
cholesterol levels. Patients were instructed to maintain their usual dietary habits 
during the study and plasma cholesterol levels did not change noticeably in the 
placebo group. Reaven and co-workers have previously reported a trend for 
increased plasma cholesterol levels, in patients with type 2 diabetes treated with 
vitamin E(494) and the magnitude of this trend was comparable with the increase in 
plasma cholesterol after vitamin E supplements in the current study. 
Supplementation with vitamin C increased plasma apolipoprotein B levels but not 
plasma cholesterol in the diabetic patients in the present study. Few studies have 
















diabetic patients. It has been clearly established that high plasma cholesterol 
concentrations are associated with an increased risk of CAD in diabetic patients and 
high plasma apolipoprotein B levels with normal cholesterol levels have also been 
associated with an increased risk of coronary atherosclerosis. (539) Thus this increase 
in apolipoprotein B with high dose vitamin E and vitamin C supplementation 
regimens in diabetic patients requires further investigation in a larger number of 
subjects and over a longer period of supplementation . 
The findings of the present study require some caution with interpretation as 
the number of patients in the treatment groups was relatively small and the treatment 
period was comparatively short. Nevertheless, the length of supplementation was 
sufficient to establish markedly increased levels of circulating antioxidants. The 
patients in this study were treated with a number of medications which have 
previously been shown to reduce the susceptibility of LDL to oxidation and plasma 
C-RP in non diabetic subjects. It is unlikely these regimens were responsible for the 
improvements in lag time and C-RP levels observed after alpha-tocopherol and 
tomato juice supplementation in the present study, as patient medication regimens 
remained stable throughout the study. 
In summary pharmacological doses of alpha-tocopherol increased the intrinsic 
resistance of LDL to oxidation and reduced chronic systemic inflammation, as 
indicated by a decrease in plasma C-RP. These changes may be associated with a 
reduced risk of CAD, according to several case-control studies.(156,216,266-268) 
Furthermore, similar doses of alpha-tocopherol have previously been associated with 
a reduction in non fatal MI in high risk patients in two randomised placebo-
controlled intervention trials. (17,20,21) However these benefits may be opposed by 
the potentially adverse effects the high doses of vitamin E appeared to have on 
plasma cholesterol levels in these diabetic patients. Further vitamin E intervention 
studies with a higher number of subjects for a longer duration are required to 
confirm these findings and the relationship between vitamin E and CVD in diabetic 
patients. The regular consumption of tomato juice by diabetic patients also improved 
the intrinsic resistance of LDL to oxidation and the magnitude of this change was 
almost equal to the value observed with high doses of vitamin E. High lycopene 
status appears to be associated with a low rate of CAD in case-control studies in non 
diabetic populations. (18, 19) Intervention trials are required to establish if the 
improved intrinsic resistance of LDL to oxidation confers an anti-atherogenic 



















Oxidation of heparin-treated LDL by 
peroxidases. A new model of LDL 
oxidation in the artery wall 
4.1 Introduction 
Oxidative modification of LDL that has become trapped in the arterial intima 
by interaction with glycosaminoglycan groups on proteoglycans is believed to play 
an important role in the development of atherosclerosis.(53,72,261) Proteoglycans and 
glycosaminoglycans can form reversible and irreversible complexes with LDL in 
vitro.04,262) There is evidence that these interactions also occur in the artery wall 
where they may lead to deposition of LDL in atherosclerotic lesions(8) and 
proteoglycan-LDL complexes have been isolated from human and rabbit arterial 
lesions.(261,540,541) Associations of LDL with proteoglycans and 
glycosaminoglycans appears to increase the susceptibility of LDL to oxidative 
modification and the opportunity for this modification to occur. (8) Isolated LDL 
that has complexed with proteoglycans and glycosaminoglycans is abnormally 
susceptible to oxidation by copper ions and by cultured ce1Is(8,l22) in a transition 
metal ion mediated process. These complexes promote lipid accumulation in 
cultured macrophages(540) which mimics foam cell formation. Human LDL that has 
been precipitated with proteoglycans or glycosaminoglycans in vitro and then 
resolubilised is thought to imitate LDL that has formed reversible associations with 
proteoglycans in the arterial intima.(261) This precipitated-resolubilised LDL has an 
altered structure04,263) and is bound and internalised more efficiently than native 
LDL by the apolipoprotein B/E receptor of cultured macrophages.(264) 
Myeloperoxidase (MPO), a h~me-containing enzyme which is present in 
inflammatory cells(91) and in arterial lesions,(86) may oxidise LDL in the artery 
wall. 0 02) High levels of 3-chlorotyrosine, a specific marker of MPO-catalysed 
oxidation, were measured in the LDL isolated from human atherosclerotic intima 
compared with levels in circulating LDL.(102) Also hypochlorous acid produced 
during MPO activity chlorinates proteins and lipids and modifies LDL to a form 
which is readily internalised by cultured macrophages.(95) The mechanism 
underlying peroxidase catalysed oxidation of LDL differs from LDL oxidation by 
transition metal ions. Peroxidases do not directly oxidise lipids (277) but radicals 
53 
derived from protein, alpha-tocopherol and tyrosine mediate oxidation. (11) 
Hydrogen peroxide generated by activated phagocytes accelerate peroxidase-
catalysed LDL oxidation. Horse radish peroxidase (HRP), an enzyme derived from 
plants, also oxidises isolated LDL via a protein radical(ll) and has been suggested as 
a model for transition metal ion independent oxidation of LDL. (88) 
The environment surrounding LDL in the micro-domains of the artery wall is 
believed to contain a variety of compounds which could modulate LDL 
oxidation.(246,247) Plasma proteins, other lipoproteins and water soluble antioxidants 
are present in the extracellular fluid(248) and have been demonstrated to inhibit 
transition metal ion oxidation of LDL in vitro. (125,249,252,256) Serum which is 
betalipoprotein deficient (BLPDS) has been proposed as a surrogate for the fluid 
surrounding LDL in the artery wall. (12) However, BLPDS appears to increase the 
oxidation of glycosaminoglycan LDL (HepLDL) when catalysed with the low 
molecular chelate of iron, hremin.(12) The aim of the present study was to determine 
the characteristics of peroxidase-catalysed oxidation of HepLDL including the effect 
of antioxidants, tyrosine and BLPDS. This model may approximate the situation in 
the arterial intima where LDL oxidation is believed to occur in vivo. 
4.2 Methodology 
4.2.1 Materials 
Chondoitin sulphate C, 1, 1,3,3-tetraethoxypropane, vitamin E ( d-a-
tocopherol), butylated hydroxytoluene (BHT), tyrosine, horse radish peroxidase 
(HRP) and myeloperoxidase (MPO) (from human leukocytes) were obtained from 
Sigma Chemical Company. Heparin (Multiparin, from porcine mucosa) was 
purchased from Fisions PTY Ltd. L-ascorbic acid was obtained from JT Baker, NJ 
and uric acid and polyethyleneglycol 20,000 from BDH. Ecocnopac PD-10 columns 
were purchased from Bio Rad. 
4.2.2 Preparation of lipoprotein fractions 
Lipoproteins were isolated from serum or EDT A plasma from 
normolipidaemic donors. Heparin LDL (HepLDL) was isolated by the following 
method.(12) Sodium citrate buffer (64 mmol/1, pH 5.12) containing heparin (50,000 
IU/1) was added to serum (0.5 ml) and incubated at 23°C for 10 minutes before 
centrifuging at 2800 x g for 15 minutes (23°C). The precipitate (HepLDL) was 
washed 3 times with hypotonic HEPES buffer (5 mmol/1 with sodium chloride 
20 mmol/1, calcium chloride 4.mmol/1 and magnesium chloride 2 mmol/1, pH 7.2) 
then redissolved in 4% sodium chloride in PBS. The redissolved HepLDL was used 
immediately. 
Native LDL (d 1.019-1.063 g/ml) was isolated by sequentially 
ultracentrifuging EDTA plasma adjusted to the appropriate densities for 20 hours 
and 24 hours respectively, at 40,000 rpm in a Beckman 50.3 Ti rotor at l0°C. The 














dialysed LDL was stored in the dark at 4 °C under argon and was used within 2 days. 
Native LDL was also isolated rapidly by ultracentrifugation of EDTA plasma on a 
single-step discontinuous gradient in a Beckman NVT 65 rotor.(217) The LDL 
isolated by this procedure was desalted into PBS by gel-filtration on Ecocnopac PD-
10 columns. The PBS was Chelex treated to remove any metal ions. Chondroitin 
sulphate treated LDL (CsLDL) was prepared by adding an aliquot (200 µl) of 
chondroitin sulphate C solution (13 mg/ml in PBS) to native LDL (2.6 mg protein in 
3 ml PBS) and adjusting the pH to 4.6.(12) The precipitate was washed with PBS and 
redissolved in 4% sodium chloride in PBS. An insoluble complex between LDL and 
dextran sulphate (DexLDL) was prepared by adding 0.12 ml of dextran 
sulphate/magnesium chloride reagent(524) to 0.5 ml of native LDL solution (2-4 
mmol/1 cholesterol) followed by 3 ml of hypotonic HEPES buffer. The precipitate 
was sedimented, washed and redissolved in 4% sodium chloride in PBS as described 
for the preparation of HepLDL. Native LDL (1 volume) was also precipitated by 
adding 2 volumes of 9.5% polyethyleneglycol (MW 20, 000) solution in phosphate 
buffer pH 6.5, resulting in PegLDL.(542) Aggregated native LDL was prepared 
essentially according to the method of Khoo and co-workers.(543) Isolated LDL was 
passed through a Ecocnopac PD-10 gel-filtration column equilibrated with PBS 
containing EDTA (0.01 %) and the resulting solution was vortexed for 1 minute. 
The betalipoprotein deficient serum (BLPDS)fraction was prepared by the 
addition of dextran sulphate/magnesium chloride to serum.(524) The apolipoprotein-
B containing lipoproteins were pelleted by centrifugation in a Beckman microfuge 
for 5 minutes and BLPDS was isolated in the supernatant. Gel-filtered BLPDS was 
prepared by loading 1 ml of BLPDS onto a Ecocnopac PD-10 gel-filtration column 
equilibrated with PBS. A volume of PBS (2 ml) was added to the column and the 
ensuing eluate was discarded. The gel-filtered BLPDS was eluted with 1 ml of PBS. 
4.2.3 Oxidation of LDL 
Formation of conjugated dienes or TBARS were used to monitor oxidation of 
LDL which had been rapidly isolated and desalted within the preceding 60 minutes. 
When conjugated dienes were measured, isolated LDL (50-100 µl, 0.1 µmol 




(10 µl of 12.9 µmol/ml in PBS)and added to 1.8 ml 
PBS and distilled water (0.20-0.25 ml) to maintain approximate isotonicity in the 
incubation medium. An aliquot of HRP (10 µl of 119 U/ml in PBS) or MPO (10 µl 
of 250 U/ml in PBS) was added with rapid mixing and the absorbance at 234 nm was 
monitored during incubation of the mixture at room temperature (23°C). The final 
volume of the incubation mixture was 2.12 ml. Tonicity of the incubation medium 
and use of Chelex-treated PBS or untreated PBS did not appreciably influence 
oxidation rates. Maximal absorbance was determined by spectrophotometer 
(Ultrospec 2000 UV Visible Spectrophotometer, Pharmacia Biotech) at 'A 234 nm 
and time taken to attain half-maximal absorbance (tv,m.J were determined from the 
plot of absorbance values against time. 
When TBARS were measured, the LDL (100-150 µl, 0.2 µmol cholesterol), the 




(10 µl of 12.9 µmol/ml in PBS), and HRP (10 µl of 
119 U/ml in PBS) or MPO (10 µl of 250 U/ml in PBS) were added to PBS (1 ml) 













minutes. At the end of this period, BHT (10 µl of 4 mmol/1 in methanol) and EDTA 
(50 µI of 4 mmol/1) were added and TBARS were measured essentially by the 
method of Beuge and Aust. (197) Thiobarbituric acid solution (2 ml) containing 
0.375% thiobarbituric acid in 15% trichloracetic acid and 0.25 mol/1 hydrochloric 
acid was added to the incubation mixture and to the standards containing 1,1,3,3-
tetraethoxypropane (1.84-4.60 nmol). Tubes were heated on a boiling water bath for 
30 minutes and after cooling were centrifuged at 2800 x g for 30 minutes. The 
optical density of the clear supernatant was determined by a spectrophotometer 
(Ultrospec 2000 UV Visible Spectrophotometer, Pharmacia Biotech) at A 532 nm 
against the blank and amount of TBARS formed was calculated using standards. 
Rates of LDL oxidation were expressed as nmol TBARS/ µmol LDL cholesterol/ 30 
minutes. 
4.2.4 Analytical methods 
Commercial enzymatic kits and calibrators (Boehringer Mannheim) were used 
to determine concentrations cholesterol. Serum paraoxonase activity was measured 
by monitoring the rate of phenylacetate hydrolysis at 270 nm following the addition 
of diluted serum. (544,545) A fluorimetric method was used to measure TBARS in 
unoxidised HepLD L. (546) 
4.2.5 Statistical analysis 
The means of variables were compared with two-tailed t-tests, with P ~ 0.05 
considered statistically significant. Analysis of variances was used to compare the 
effects of several concentrations of hydrogen peroxide on tv.max and maximal 
absorbance at 234 nm, and varying levels of BLPDS on TBARS formation during 
HepLDL oxidation. The statistical analysis was carried out using SPSS release 6.1 
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Oxidation of HepLDL and native LDL by HRP and H20 2 
30 
30 
A Change in optical density at 234 nm during the oxidation of HepLDL [ open circle] or native LDL 
[open triangle] (0.47 µmol cholesterol/ml) by HRP (0.56 U/ml) and H20 2 (58 µmol/1) incubated in 
PBS at 23°C. HepLDL incubated in PBS without the oxidants [circle]. The figure represents a typical 
experiment from over 6 individual experiments with HepLDL and 5 experiments with native LDL. B 
Time-course of TBARS formation during the oxidation of HepLDL [ open circle] (0.14 µmoll 
cholesterol/ml) by HRP (0.85 U/ml) and H20 2 (87 µmol/1) incubated in PBS at 23°C. The figure 
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Figure 4.2 Oxidation of HepLDL and native LDL by MPO and H20 2 
Change in optical density at 234 nm during the oxidation of HepLDL [open circle] or native LDL 
[circle] (0.47 µmol cholesterol/ml) by MPO (0.09 U/ml) and H20 2 (58 µmol/1) incubated in PBS at 
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Figure 4.3 Effect of ascorbate and vitamin Eon the oxidation of HepLDL by HRP and 
H202 
A Change in optical density at 234 nm during oxidation of HepLDL (0.47 µmol cholesterol/ml) by 
HRP (0.56 U/ml) and H20 2 (58 µmol/1) incubated in PBS at 23°C with [circle] and without ascorbate 
[open circle] (79 µmol/1). Also, ascorbate (79 µmol/1) was incubated with the oxidants [open square]. 
The figure represents a typical experiment from 3 independent experiments. B Vitamin E solution 
in ethanol (27.2 mmol/1) was added to serum (10 µl and 272 nmol vitamin E/ml serum) and the 
mixture was incubated at 37°C for 1.5 hours. A control [open circle] incubation of serum was added 
to ethanol (10 µ1/ml serum). HepLDL was isolated from serum [circle] and 0.47 µmol HepLDL 
cholesterol/ml was oxidised with HRP (0.56 U/ml) and H20 2 (58 µmol/1). The mean vitamin E 
content of the control HepLDL was 1.3 ± 1.0 nmol/µmol cholesterol and of vitamin E enriched 



























Figure 4.4 Effect of added tyrosine on the oxidation of HepLDL by 
HRP and H202 
Change in optical density at 234 nm during the oxidation ofHepLDL (0.47 µmol/1 cholesterol/ml) by 
HRP (0.56 U/ml) and H20 2 (58 µmol/1) incubated in PBS at 23°C with tyrosine (48 µmol/1) [circle] 
or without tyrosine [open circle]. The stock solution (20.44 mmol/1) of tyrosine was prepared by 
dissolving tyrosine in dilute hydrochloric acid. The addition of 5 µl of tyrosine solution to the PBS 
did not appreciably alter the pH of the incubation medium (pH 7.39). The figure represents a typical 
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Figure 4.5 Effect of BLPDS on oxidation of HepLDL by HRP or 
MPO and H202 
16 
16 
A Formation of TEARS after 30 minutes oxidation of HepLDL (0.14 µmol cholesterol/ml) with 
BLPDS (1.9%, 7.5%, 11.2%, 14.9% by volume) by HRP (0.85 U/ml) and H20 2 (58 µmol/1) incubated 
in PBS at 23°C. Similar incubations but without HepLDL were also performed and TEARS were 
subtracted from the levels measured when HepLDL was also present. Values are averages of 3 
separate experiments and the bars represent the range. B A similar experiment in which MPO 
(0.14 U/ml) replaced HRP is displayed. Values are averages of 2 separate experiments and the bars 











TABLE 4.1 Effect of serum components on TBARS formation in 
HepLDL oxidised by HRP/H202 
Additions 
BLPDS (14.9% by volume) 
Dialysed BLPDS (14.9 % by volume) 
Gel-filtered BLPDS (14.9% by volume) 
+ Mg2+ (54 mmol/1) 
+ ascorbate (84 µmol/1) 
+ tyrosine (48 µmmol/1) 
+ cysteine hydrochloride (134 µmol/1) 




88 ± 15 
100 ± 1 
101 ± 8 
122 ± 23 
98 ±2 


















Conjugated diene formation when native LDL and glycosaminoglycan LDL 
stimulated with HRP/H20 2 is presented in Figure 4.1A. Conjugated diene formation 
increased rapidly with no lag-time during HRP catalysed oxidation of HepLDL 
while there was little change with native LDL. The mean tv.max was 3 ± 1 minutes 
(n=5) for the oxidation of HepLDL and values for CsLDL were within the range of 
those observed in HepLDL. Similar results were obtained when native LDL that had 
been isolated by ultracentrifugation of plasma, precipitated with heparin or 
chondroitin sulphate and then resolubilised, was oxidised by HRP. There was no 
change in absorbance at A 234 nm when HepLDL was incubated alone or with H20 2 
in the absence of HRP. The formation of TBARS paralleled that of conjugated 
dienes during HRP oxidation of HepLDL, this is displayed in Figure 4.1B. 
Thiobarbituric acid reacting substances were virtually undetectable ( 10 -
30 µmol/mol cholesterol) in freshly isolated HepLDL. Redissolving the HepLDL 
precipitate in 4% sodium chloride/PBS was not responsible for the increased 
susceptibility of HepLDL to oxidation. When an aliquot of a suspension of HepLDL 
precipitate in hypotonic HEPES buffer was added to PBS (in which it was 
dissolved) and oxidised with HRP/ H
2
0 2 the rate of TBARS formation 
(26.5 ± 5.7 mmol/mol cholesterol/30 minutes, n=3 experiments) was not 
significantly different compared with the corresponding rate with HepLDL that had 
been redissolved in 4% sodium chloride/PBS. Addition of EDTA (0.14 mmol/1) did 
not reduce the formation of TBARS during oxidation of HepLDL by HRP/ H20 2 • 
When a suspension of precipitated native LDL in polyethyleneglycol solution 




(maximum final polyethyleneglycol concentration, 
0.17 mmol/1) absorbance at 234 nm increased slowly to a mean value of 
0.029 ± 0.013 mmol/mol cholesterol (n=3) at 30 minutes which was significantly 
(P=0.0004) lower than the corresponding value for the oxidation of HepLDL (0.236 
± 0.029 mmol/mol cholesterol/ 30 minutes with tv.max 5.9 ± 0.6 minutes, n=3) in the 
presence of polyethyleneglycol (0.17 mmol/1). The precipitated LDL suspended in 
polyethyleneglycol solution redissolved to give virtually zero absorbance at 680 nm 
(a measure of turbidity) when the suspension was added to PBS prior to addition of 
the oxidants. Aggregated LDL did not dissolve in 4% sodium chloride/PBS and a 
suspension of the lipoprotein in PBS was not oxidised to TBARS by HRP/H
2
0 2• 





was rapid with no lag-phase compared with the corresponding oxidation 
of native LDL which had a lag-time of greater than 150 minutes, displayed in 
Figure 4.2. The tv.rnax for the formation of dienes from HepLDL was approximately 
50 minutes. 
Figure 4.3 shows the effect of antioxidants, ascorbic acid and vitamin E, on 




• In the presence of ascorbate, conjugated 
diene formation increased within the first two minutes and then declined toward zero 
during the 30 minute incubation period. Optical density at 'A, 234 nm also increased 
















inhibited, by 98% in each of the two separate experiments, when HepLDL was 
oxidised with HRP/H20 2 in the presence of 79 µmol/1 ascorbate. The rate of diene 
formation during oxidation of vitamin E enriched HepLDL (isolated from serum 
enriched with vitamin E and contained increased levels of vitamin E) was similar to 
the rate in control HepLDL (isolated from serum incubated with ethanol). In 
separate experiments (n=3) with materials from different subjects, additional of 
vitamin E in ethanol at concentrations of 1 µmol/1, 2 µmol/1 and 3 µmol/1 and a final 
ethanol concentration of 0.9% did not significantly affect tv.max (control: 
2.7 ± 0.3 minutes; 1 µmol/1 vitamin E: 3.0 ± 1.3; 2 µmol/1 vitamin E: 3.3 ± 1.2 
minutes; 3 µmol/1 vitamin E: 3.0 ± 1.0 minutes, ANOV A P=0.88) and the ratio 
maximum absorbance in the presence of vitamin E/ control maximum absorbance in 
the absence of vitamin E and with added ethanol (ANOV A P=0.29). Added BHT 
(18.9 µmol/1) significantly (P<0.001) decreased the maximum amount of conjugated 
dienes formed (-75 ± 13%, n=3) and the production of TBARS to 2% of control 




• Tyrosine (48 µmol/1) 
inhibited the early rapid formation of conjugated dienes during oxidation of 
HepLDL, presented in Figure 4.4. After 30 minutes, amounts of dienes formed were 
similar in the presence or absence of tyrosine. 
Figure 4.5 plots the effect of increasing concentrations of BLPDS on the 
formation of TBARS during oxidation of HepLDL with HRP and MPO. Oxidation 
was followed by measuring TBARS formation because conjugated dienes cannot be 
readily measured in the presence of BLPDS which absorbs strongly at 'A, 234 nm. 
Added BLPDS significantly inhibited TBARS formation (ANOVA P<0.0001) 
particularly at concentrations between 7.5 - 14.9%. The rate of TBARS formation 
increased (0.1- 1.2 nmol/30 minutes) with increasing concentrations of BLPDS 
alone, and quantities of TBARS produced were markedly smaller than levels when 
HepLDL was also present. Levels of TBARS derived from BLPDS alone were 
subtracted from values obtained during oxidation of HepLDL in the presence of 
BLPDS. Oxidation of HepLDL by MPO/H20 2 was also inhibited by increasing 
concentrations of BLPDS. This inhibition was less marked compared with 
corresponding inhibition of HRP catalysed oxidation of HepLDL. 
The effect of BLPDS (14.9% by volume) that had been dialysed or gel-filtered 
to remove small water soluble molecules and the addition of magnesium ions, 
ascorbate, tyrosine and cysteine hydrochloride to gel-filtered BLPDS on the 
formation of TBARS during oxidation of HepLDL by HRP/H20 2 is summarised in 
Table 4.1. Both dialysed and gel-filtered BLPDS failed to inhibit this oxidation 
significantly. Gel-filtered BLPDS with added magnesium ions (equivalent to the 
level in BLPDS) and physiological levels of ascorbate, tyrosine and cysteine 
hydrochloride did not inhibit TBARS formation. Added urate (19.2 - 76.9 µmol/1) 





• The inhibitory effect was still present in BLPDS that was 
prepared from serum that had been heated for 1 hour at 58°C and had only 3% of its 
initial activity of paraoxonase, an enzyme which metabolises oxidised lipids 
(control: 23.5 ± 0.7 nmol/ µmol/ 30 minutes; heated BLPDS: 2.1 ± 1.9 nmol/ µmoll 


















Low density lipoproteins which have been resolubilised from complexes with 
glycosaminoglycans are more susceptible than native LDL to peroxidase-catalysed 
oxidation and were only partially inhibited by BLPDS when MPO was the catalyst. 
This enhanced susceptibility to oxidation may contribute to increased levels of 
myeloperoxidase-modified LDL and oxidised LDL that are present in atherosclerotic 
arteries. (74,102) 
In the presence of H
2
0/HRP or MPO rapidly oxidised HepLDL compared 
with native LDL. Following HRP catalysed oxidation of HepLDL by monitoring the 
lipid oxidation products conjugated dienes and TBARS gave similar profiles. The 




catalysed HepLDL oxidation displayed appropriate 





Furthermore, oxidation occurred at levels of H20 2 which may occur in vivo. 
The increased susceptibility of HepLDL (and other glycosaminoglycan treated 
LDL) to peroxidase oxidation appeared to be due to changes in LDL as a result of 
the interaction with glycosaminoglycan and not as a result of precipitation and 
resolubilisation of LDL. Precipitation with polyethyleneglycol which sterically 
excludes LDL from solution(547) and does not form a complex with the lipoprotein, 
did not increase the oxidisability of the resolubilised LDL by HRP. Levels of lipid 
oxidation products were low in freshly isolated HepLDL suggesting that the 
isolation procedure did not oxidatively stress HepLDL and thereby increase its 
susceptibility to peroxidase catalysed oxidation. When LDL is precipitated with 
heparin, apolipoprotein B-containing remnant lipoproteins such as intermediate 
density lipoproteins are also precipitated. However these remnants were not uniquely 
responsible for the rapid oxidation of HepLDL as native LDL which had been 
precipitated with heparin also displayed rapid oxidation. 
Changes in lipoprotein structure caused by the interaction of LDL with 
glycosaminoglycans may underlie the rapid rate of peroxidase stimulated lipid 
peroxidation in HepLDL compared with native LDL. These structural changes may 
increase the efficiency of peroxidase induced formation of radicals from 
apolipoprotein B and alpha-tocopherol which may mediate oxidation of LDL lipids 
by MPO and HRP. Also, the altered molecular structure in HepLDL may increase 
the proximity of the radicals to lipids. Camejo and co-workers have reported that the 
interaction with arterial proteoglycans and glycosaminoglycans in vitro alters the 
structure of both lipid and protein components of LDL06,263) and this could be as a 
result of disruption of the molecular organisation of the cholesterol ester core(263) 
and apolipoprotein B moiety.(14,261,548) Thus, it is possible that altered protein 
conformation may increase the accessibility of sites on apolipoprotein B to 
peroxidase catalysed radical formation and may place apolipoprotein B radicals in a 
better position to attack the lipid substrate in HepLDL. The increased access of the 
peroxidase enzymes to apolipoprotein B in glycosaminoglycan treated LDL is 
consistent with previous reports that have shown that the protein in LDL which has 
interacted with proteoglycans has increased susceptibility to fragmentation.06,548) It 
has also been suggested that the physical state of lipids and their proximity to 
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radicals generated in the lipoprotein may be important in the oxidation by 
peroxidases. (277) 
Glycosaminoglycans induced changes in lipoprotein structure that may also 
alter the effect of alpha-tocopherol on LDL oxidation by HRP. Santanam and 
co-workers have reported that addition of small amounts of alpha-tocopherol 
accelerates peroxidase oxidation in native LDL apparently by increasing numbers of 
alpha-tocopherol radicals.(277) At higher levels of alpha-tocopherol, the oxidation is 
inhibited suggesting that sufficient free alpha-tocopherol may remain to inhibit 





LDL that has interacted with heparin glycosaminoglycan is unaffected not only by 
additions of small quantities of alpha-tocopherol to the incubation but also by 
massive prior enrichment of HepLDL with alpha-tocopherol. It is possible that 
molecular disorganisation(263) may allow HRP increased access to alpha-tocopherol 
in the cholesterol ester-rich hydrophobic core of HepLDL resulting in faster 
production of alpha-tocopherol radicals and decreased free alpha-tocopherol. The 
HRP catalysed lipid oxidation in HepLDL is probably near or at maximal rate and 
may therefore be unaffected by extra alpha-tocopherol radicals generated from 
added alpha-tocopherol. Lipid oxidation in HepLDL was markedly inhibited by 
BHT, a lipophilic antioxidant whose radicals are sterically hindered and may be 
inaccessible for propagation of the radical chain reaction. (277) Thus, increased 
generation of alpha-tocopherol radicals that are not sterically hindered and can 
accelerate lipid oxidation(277) may contribute to the inefficiency of alpha-tocopherol 
as an antioxidant in the HepLDL and HRP/H20 2 system. It remains to be determined 
whether rapid oxidation reduces free alpha-tocopherol to levels that no longer inhibit 
lipid oxidation in alpha-tocopherol enriched HepLDL. 
Ascorbate inhibited HepLDL oxidation by HRP, possibly by decreasing levels 
of apolipoprotein B and alpha-tocopherol radicals. The protein component of LDL is 
largely at the surface of the LDL and therefore readily accessible to a water soluble 
antioxidant. Horse-radish peroxidase may oxidise ascorbate to products which react 
with LDL protein and decrease the formation of apolipoprotein B radicals. This 
proposed mechanism is essentially analogous to that which governs the inhibition of 
copper ion oxidation of LDL by ascorbate. Retsky and co-workers have reported that 
during copper ion oxidation of LDL in the presence of ascorbate there is oxidation 
of ascorbate to dehydroascorbate (and other products) which may react with LDL 
protein and inhibit the subsequent copper ion catalysed lipid oxidation. (252) In the 
present study, ascorbate appeared to have been oxidised before it appreciably 
inhibited the oxidation of HepLDL. There was a large and rapid increase in 
absorbance at 'A, 234 nm when ascorbate and oxidants were incubated in PBS 
suggesting that ascorbate had been modified. The momentary increase in absorbance 
at 'A, 234 nm when HRP and H
2
0 2 were added to a solution of HepLDL in the 
presence of ascorbate may be due mainly or solely to the formation of oxidation 
products of ascorbic acid that absorb at this wavelength and not to increased 
conjugated diene formation. The gradual decline of this early peak in absorbance at 
'A, 234 nm may reflect a reaction between the ascorbate oxidation products and 
HepLDL. These findings suggests that there may be differences in the antioxidant 









reduced form of ascorbate can convert alpha-tocopherol radicals to free alpha-
tocopherol in LDL.(278) However, it is uncertain whether this regenerating activity 





Free tyrosine also inhibited the oxidation of HepLDL by HRP but only during 
the early stages of the incubation. Tyrosine may have initially competed with 
HepLDL for oxidation until eventually levels of the amino acid were decreased and 
no longer competed effectively for oxidation. Santanam and co-workers reported the 
oxidation of native LDL by myeloperoxidase was inhibited by high levels of added 
tyrosine. (277) The requirement of free tyrosine for the oxidation of native LDL by 
MPO (89) may only be essential when the alpha-tocopherol content of the lipoprotein 
is low. (277) In the present study, MPO readily oxidised HepLDL in the absence of 
free tyrosine. Freshly isolated HepLDL is not depleted of alpha-tocopheroI02) which 
may mediate MPO catalysed lipid oxidation. Also, the altered lipoprotein structure 
may allow the oxidation of HepLDL by MPO in the absence of tyrosine. 
Added BLPDS decreased the oxidation of HepLDL catalysed by HRP but 
even at the highest concentration only partially inhibited the corresponding oxidation 
catalysed by myeloperoxidase. The inhibitor(s) in BLPDS was a small, water soluble 
molecule which did not appear to be ascorbate, urate, tyrosine or reduced thiols. The 
mechanism underlying the greater sensitivity of HRP oxidation to inhibition by 
BLPDS is uncertain but may relate to the position of the catalytic hreme unit in 
HRP. In HRP the hreme unit is relatively exposed whereas in myeloperoxidase it is 
buried deep in a hydrophobic cleft(549) and may be less accessible to components of 
BLPDS. The finding that BLPDS only partially inhibited the oxidation of HepLDL 
by myeloperoxidase appears to be consistent with evidence that myeloperoxidase 
oxidises LDL in the artery wall002) where components of extracellular fluid can 
modulate the process. Levels of BLPDS used in the present study were irt the range 
which corresponds with the concentration of many of the compounds in extracellular 
fluid.(550) 
In conclusion, the present data suggest that LDL which has formed complexes 
with glycosaminoglycans is abnormally susceptible to oxidation by peroxidases 
including a physiological oxidant MPO. These experiments support the hypothesis 
that LDL which becomes trapped in the artery wall by interaction with 
proteoglycans may be susceptible to oxidation by MPO. Also peroxidase oxidation 
of LDL may be favoured at low levels of water-soluble antioxidants. Proteoglycans 
and glycosaminoglycans are negatively charged and may attract MPO which has a 
basic pK. and will be positively charged at physiological pH. An interaction of this 
type could bring the enzyme and LDL into close proximity and potentate lipoprotein 
modification. Oxidation of LDL-proteoglycan complexes by MPO may increase 











Over recent years there has been considerable interest in the hypothesis that 
supplementation with antioxidants may reduce the risk of CHD. This interest has 
been generated largely by evidence that the oxidation of LDL is an important step in 
atherogenesis. Also, recently published research has indicated that other steps in 
lesion formation, including the expression of pro-inflammatory cytokines and cell 
adhesion molecules, may be mediated by oxidant sensitive mechanisms. One of the 
studies in this thesis has compared the effect of supplementation with a tomato juice, 
which is rich in the carotenoid lycopene, and high doses of vitamin E or vitamin C 
on LDL oxidation and markers of inflammation in patient with type 2 diabetes. 
These patients have a high risk of CAD and may benefit from antioxidant therapy as 
they are often under increased oxidative stress. The supplementation regimens with 
tomato juice, alpha-tocopherol and vitamin C each resulted in plasma concentrations 
of lycopene, alpha-tocopherol and vitamin C increasing over two fold. Lycopene and 
alpha-tocopherol are primarily associated with lipoproteins in the plasma, thus this 
enrichment would significantly enhance the intrinsic antioxidant protection of LDL. 
The resistance of isolated LDL to copper ion stimulated oxidation was increased by 
42% after the patients consumed tomato juice for several weeks, and this was 
comparable to the 54% found after the alpha-tocopherol regimen. An extension in 
resistance to oxidation may conceivably reflect a lower risk of atherosclerosis, 
however, the relationship between lag time of isolated LDL to copper ion stimulated 
oxidation and atherosclerosis has not yet been established with absolute certainty. 
Alpha-tocopherol supplementation also decreased plasma C-RP levels, suggesting a 
reduction in systemic inflammation. On the basis of recent epidemiological studies 
this change could be associated with a reduced risk of MI. Expression of cell 
adhesion molecules in diabetic patients does not appear to be affected by high 
intakes of dietary antioxidants with differing structures and modes of action. 
Supplementation with high doses of vitamin E and vitamin C increased plasma 
cholesterol and apolipoprotein B, respectively, and this change would be expected to 
increase the risk of CAD, thus the effects of high dose supplementation with 
vitamins E and C requires careful evaluation of the possible risks and benefits in 
diabetic patients. Overall, this research has identified changes with potential 
relevance to CHD in diabetic patients during supplementation with dietary 
antioxidants. In the future, studies with larger numbers of patients and of a longer 
duration are required to confirm the effects of vitamin E supplementation on plasma 
lipids and markers of systemic inflammation. 
Copper ion oxidation of isolated LDL may not reflect the complexity of LDL 
oxidation in the artery wall. Interactions of LDL with proteoglycans and 








factors which may have an important influence on LDL oxidation in the arterial 
intima. A second study established a model of LDL oxidation which incorporated 
several of these elements. Low density lipoproteins which have complexed with 
glycosaminoglycans were rapidly oxidised by peroxidases, including MPO and 
HRP. This rapid oxidation was inhibited by vitamin C and small water soluble 
compounds in the human serum, but not by added vitamin E. This model predicts 
that LDL which becomes trapped in the artery wall by interactions with 
proteoglycans may be susceptible to oxidation by MPO particularly when levels of 
water soluble antioxidants are low. These findings may be relevant to oxidation of 
LDL in the micro-domains of the artery wall which become depleted of 
antioxidants. Finally, the model may provide new insights on the effect of 
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OBJECTIVE - To compare the effects of dietary supplementation with tomato juice, 
vitamin E and vitamin Con susceptibility of low density lipoprotein (LDL) to oxidation 
and circulating levels of C-reactive protein (C-RP) and cell adhesion molecules in 
patients with type 2 diabetes. 
RESEARCH DESIGN AND METHODS - Fifty-seven patients with well-
controlled type 2 diabetes and aged< 75 years were treated with placebo for 4 weeks 
and then randomised to receive either tomato juice (500 ml/day), vitamin E (800 
IU/day), vitamin C (500 mg/day) or continued placebo treatment for 4 weeks. 
Susceptibility of LDL to oxidation (lag time) and plasma concentrations of C-RP, 
vascular cell adhesion molecule-I (VCAM-I) and intercellular adhesion molecule-I 
(I CAM-I) were measured at the beginning of the study, after the placebo phase and at 
the end of the study. 
RESULTS- Plasma lycopene levels increased nearly 3- fold (P=O.OOI) and the lag-
time in isolated LDL oxidation by copper ions increased by 42% (P=O.OOI) in patients 
during supplementation with tomato juice. The magnitude of this increase in lag time 
was comparable with the corresponding increase during supplementation with vitamin 
E (54%). Plasma C-RP levels decreased significantly (-49%, P=0.004) in patients 
who received vitamin E. Circulating levels of cell adhesion molecules and plasma 
glucose did not change significantly during the study. 
CONCLUSIONS - This study indicates that drinking commercial tomato juice 
increases plasma lycopene levels and the intrinsic resistance of LDL to oxidation almost 
as effectively as supplementation with a high dose of vitamin E in patients with 
diabetes. Supplementation with vitamin E also decreases plasma C-RP levels which 
, 
may indicate reduced systemic inflammatory activity. These findings may be relevant 










Patients with type 2 diabetes are at increased risk of developing coronary heart disease 
(CHD) compared with the general population (1). Increased oxidative stress (2) and 
enhanced oxidation of low density lipoproteins (LDL) (3) are believed to contribute to 
this excess risk of arterial disease (1). In vitro, high glucose levels increase LDL 
oxidation (4) and glycated LDL.is abnormally susceptible to oxidative modification (5). 
Also, levels of small dense LDL are increased in diabetic subjects (6) and these particles 
are more readily oxidised than larger, more buoyant LDL (7). Oxidation of low density 
lipoprotein (LDL) that becomes trapped in the artery wall is widely regarded as an 
important step in the development of atherosclerosis (8,9). There is evidence that 
mildly oxidised LDL enhances the expression of proinflammatory cytokines, 
chemoattractants and cellular adhesion molecules (9) by endothelial cells. These 
molecules promote adhesion of monocytes to the vascular endothelium followed by 
transmigration of adhered cells into the intima where they are retained and transformed 
into macrophages (8,9). Cultured macrophages avidly internalise oxidised LDL via 
scavenger receptors to form lipid-filled cells (8,9). A similar process may occur in the 
artery wall to generate foam cells that are seen early in the development of the 
atherosclerotic lesion. In diabetic patients, circulating levels of proinflammatory 
cytokines (10), C-reactive protein (C-RP) (10) and soluble vasular cell adhesion 
molecule-I (VCAM-1) and soluble intercellular adhesion molecule-l(ICAM-1) (11,12), 
are elevated suggesting stimulation of proatherogenic inflammatory activity. Plasma C-
RP is a sensitive marker of systemic inflammation and chronically high levels predict 
increased risk of future coronary events (13-15). 
There is epidemiologic and clinical evidence that high intake or levels of vitamin E, 
lycopene and vitamin C may be associated with decreased risk of CHD (17-18). 
Laboratory studies suggest that these compounds may potentially attenuate a number of 
the steps in the postulated pathway of atherosclerotic lesion formation. 
Supplementation with high doses of vitamin E markedly reduces susceptibility of 
isolated LDL to oxidation and inhibits secretion of proinflammatory cytokines (19). 
Enriching cultured endothelial cells (20, 21) or LDL (20) with vitamin E decreases 
expression ofintercellular adhesion molecule-I (ICAM-1) and vascular cell adhesion 
molecule-I (VCAM-1) induced by native or oxidised LDL. Lycopene, a major 
carotenoid in human plasma, also inhibits the oxidative modification of isolated LDL 
(22). Tomato products in the diet are the main source of plasma lycopene and 
supplementation with tomato juice increases plasma lycopene levels in healthy subjects 
(23). Vitamin C in the aqueous milieau can protect plasma lipids and LDL from 
oxidative damage (24). Also, supplementation with vitamin C normalises low plasma 
vitamin C levels and enhanced monocyte adhesion in smokers (25). 
3 
In diabetic patients, antioxidant protection may be inadequate and levels of some 
antioxidants including vitamin C and lycopene (26) are frequently low. 
Supplementation with vitamin E increases isolated LDL resistance to oxidation in 
patients with type 2 diabetes (27). However, information regarding the effects of food 
products such as tomato juice rather than supplements on susceptibility of LDL to 
oxidation and circulating levels of antioxidants and inflammatory products in patients 
with type 2 diabetes is sparse. The present study was therefore designed to compare 
the effects of supplementation with tomato juice, vitamin E and vitamin Con these 
factors in patients with type 2 diabetes in a randomised, placebo-controlled trial. 
RESEARCH DESIGN AND METHODS 
Patients 
Patients with type 2 diabetes under the age of 75 years and with HbA le < 10% and 
fasting plasma glucose< 1 lmmol/1 were recruited from the Diabetes Clinic, Dunedin 
Hospital, from local general practitioners and by advertisement in the newspaper. 
Exclusion criteria included, presence of hepatic or renal disease, cigarette smoking, use 
of dietary antioxidant supplements and treatment with insulin, lipid-lowering drugs or 
hormone therapy during the preceeding 6 months. 
At recruitment, a medical history was obtained from the patients. Past smoking habits 
and medication use were recorded. Blood pressure and body mass index (BMI) were 
measured. Patients were instructed not to change their usual dietary habits for the 
duration of the study and to take the experimental dietary supplements with meals. A 
checklist was used to estimate the frequency of tomato product consumption during the 
study. Patients were also instructed to return any unused supplements and compliance 
with study protocol was assessed during the study by counting returned supplements. 
Study design and protocol 
The study was a randomised, placebo-controlled parallel trial. Randomisation was 
carried out independently using a computer generated scheme (Excel, Microsoft Office 
for Windows 95). A total of 57 patients were randomised to receive either: (a) 800 
IU/day vitamin E (d-a -tocopherol from a natural source, Red Seal); 500 mg/day 
vitamin C (Redoxin, Roche); 250 ml tomato juice which did not contain added sugar 
(Campbells Foodstuffs, Australia) twice daily; or a placebo gelatine capsule containing 
pharmaceutical starch. During the initial 4 weeks of the study, all patients received the 
placebo capsule and then proceeded to their assigned supplement for the following 4 
weeks. Blood samples, blood pressure and BMI were taken on two occasions and 3 
days apart, at baseline, end of placebo and end of intervention. The mean of values 








the study. The study was approved by the Ethics Committee of the Southern Regional 
Heal th Authority. 
Patients reported to the study centre in the early morning after an overnight fast. 
Venous blood was collected into tubes containing disodium EDTA, sodium fluoride or 
heparin. Blood was kept on ice for a maximum of 2 hours before plasma was 
separated by low-speed centrifugation at 4°C. Metaphosphoric acid (900µ1, 5% 
solution) was added to an aliquot of plasma (100µ1) to be assayed for vitamin C and 
these aliquots and others were stored at -80°C. A sample of EDTA plasma to be used 
for the isolation of LDL was flushed with argon and was stored at 4°C in the dark for a 
maximum of 24 hours. 
Separation and oxidation of LDL 
Native LDL was rapidly separated by ultracentrifuging EDT A plasma for 2 hours at 
60,000 rpm on a single-step discontinuous gradient in a Beckman NVT 65 rotor (28). 
The LDL isolated by this procedure did not contain appreciable levels of albumin (29). 
The LDL was desalted into phosphate buffered saline (PBS) by gel-filtration in 
Econopac PD-10 columns (28). The PBS was Chelex treated to remove any transition 
metal ions. 
Oxidation of LDL was performed essentially as described by Puhl and coworkers (30). 
LDL (0.39 µmol cholesterol) was added to 2ml PBS in a quartz cuvette at ambient 
temperature in an air conditioned room that was maintained at constant temperature. 
The oxidation was initiated by the addition of copper ions (1.6 µmol/1) and was 
followed by monitoring the formation of conjugated dienes at 234 nm. The temperature 
in the cuvette was constant within one degree of 27°C. The interassay coefficient of 
variation for the lag-time in LDL oxidation was 5% . 
Analytical methods 
Cholesterol and triglycerides in plasma and lipoprotein fractions were measured using 
commercial enzymatic kits and calibrator (Boehringer Mannheim). High density 
lipoprotein cholesterol was measured in the supernatant after precipitation of 
apolipoprotein B (apoB)-containing lipoproteins with dextran/magnesium chloride (31). 
Plasma apoAl and B were measured by immunoturbidimetry (32). Plasma glucose 
was measured enzymatically using a commercial kit (Boehringer Mannheim). HbA1c 
was measured using a commrecial kit (Pierce, Glycotest 2). Concentrations of VCAM-
1 and ICAM-1 were measured in duplicate by ELISA (R&D Systems) in one of the two 
plasma samples obtained at each time-point in the study. The coefficient of variation 
















was measured in duplicate by a commercial ELISA assay (Hemagen) with a coefficient 
of variation of 8% and sensitivity of 0.2 mg/1. In the plasma VCAM-1, ICAM-1 and 
C-RP assays, all samples from a patient were measured in the same run. High pressure 
liquid chromatography (HPLC) was used measure to plasma a-tocopherol and 
lycopene levels (33) and LDL a-tocopherol content (34). Plasma vitamin C was 
measured by fluorimetry (35). 
Statistical analysis 
The study was able to detect a change in lag-time in LDL oxidation of 10 minutes at a 
power of 90% and P=0.05. Variables were log-transformed before statistical analysis. 
The multivariate analysis of variances (MANOVA) procedure in SPSS with repeated 
measures and with covariate correction for baseline values was used to test for 
differences in the response of variables to the various dietary supplementation regimen. 
When a significant difference was detected among the treatment groups, unadjusted 
paired t-tests were used to test for within-group changes during the active treatment 
phase of the study. Mean (95% confidence interval) was also calculated for changes 
during active treatment. Two-sided tests of significance were used and a P value <0.05 
was considered as statistically significant. Unless otherwise stated all data are 
expressed as mean±SD. 
RESULTS 
Five patients withdrew during the study due to difficulties in donating a blood sample 
(n=2), alterations in medications (n=2) or problems with consuming the tomato juice 
(n=l). The baseline characteristics of the patients are detailed in Table 1. The majority 
of participants (86%) had diagnosed diabetes for less than 6 years. A third of the study 
group controlled their diabetes by diet alone and the remainder were receiving treatment 
with oral antihyperglycemic drugs. A majority of patients had multiple risk factors for 
CHD and many had clinical evidence of cardiovascular disease. Several patients were 
receiving treatment with ACE inhibitor drugs which are known to reduce the 
susceptibility of isolated LDL to oxidation (36). However, treatment with ACE 
inhibitor drugs remained unchanged during the study. There were no significant 
changes in BMI during the study. 
Plasma antioxidants 
Plasma concentrations of antioxidants in the patients during the study are shown in 
Table 2. Levels of a -tocopherol, vitamin C and lycopene were similar between 
treatment groups at baseline and at the end of the placebo phase of the study and 
increased significantly in the appropriate treatment group indicating both compliance 







supplements. The frequency checklist of tomato products in the diet showed that at 
baseline, 82% of patients consumed raw tomatoes, 37% baked beans, 8% pizza, 13% 
canned tomatoes, 5% tomato soup, 67% tomato sauce and 21 % spagetti/sauce at least 
once during a 4 day period and these proportions were similar at the end of the study 
(excluding tomato juice supplement). 
LDL oxidation 
Oxidation characteristics and a-tocopherol content of LDL from the participants is 
shown in Table 3. The lag-time in conjugated diene formation increased significantly in 
patients treated with tomato juice [30 (95%CI: 17,43) min] and vitamin E [40 (95%CI: 
24, 57) min] and remained unchanged in those who received placebo [-6 (95%CI: -24, 
12) min] and vitamin C [4 (95%CI: -11, 18) min]. The coefficient of variation between 
the two measures of the lag-time at baseline was 3.3% (n=57). The LDL content of a-
tocopherol increased significantly only in the group which was supplemented with this 
antioxidant. Rate of oxidation during the propagation phase and maximum 
concentration of conjugated dienes formed did not change significantly during the 
study. The chemical composition (protein and lipids) of LDL also did not change 
significantly in patients during the study (data not shown). 
C-RP and cell adhesion molecules 
Plasma concentrations of C-RP and adhesion molecules in the patients during the study 
are shown in Table 4. Plasma C-RP levels decreased significantly (P=0.001) in 
patients supplemented with vitamin E [-3.5 (95%CI: -1.3, -5.7) mg/I] and did not vary 
significantly in those treated with vitamin C [-0.1 (95%CI: -2.2, 2.0) mg/1], tomato 
juice [0.6 (95%CI: -0.6,1.8) mg/I] and placebo [0.8 (95%CI: -0.2, 1.8) mg/I]. At 
baseline, plasma C-RP tended to be higher in patients who were treated with vitamin E. 
Two patients had infections ( colds) during the study. Concentrations of circulating 
adhesion molecules were similar between the treatment groups at baseline and did not 
change significantly during the study (Table 4). 
Plasma lipids and glucose 
Plasma lipids, lipoproteins, apolipoproteins and fasting glucose concentrations were 
similar between the treatment groups at baseline, excepting plasma triglyceride levels 
were lower in patients who were randomised to receive the vitamin C supplement 
(Table 5). Plasma total cholesterol concentration increased significantly [0.50 mmol/1 
(95% CI: 0.19, 0.81) mmol/1] in patients treated with vitamin E and did not change 
significantly in those treated with tomato juice [-0.10 (95%CI: -0.45,0.25) mmol/1], 
vitamin C [0.04 (95%CI: -0.17, 0.25) mmol/1] and placebo [0.03 (95%CI: -0.25, 
0.30) mmol/1]. Plasma apoB concentration increased significantly in patients receiving 
7 
vitamin C [0.14 (95%CI: 0.004 ,0.28) g/1] and did not change significantly in the 
placebo group [0.03 (95%CI: -0.10, 0.16) g/1]. Fasting glucose did not change 
significantly during the study. 
CONCLUSIONS 
These data indicate that regular supplementation with tomato juice increases plasma 
lycopene levels nearly 3-fold and the intrinsic resistance of LDL to oxidation by 
approximately 42% in diabetic patients. The magnitude of these changes were similar 
to those reported previously in healthy subjects during supplementation with tomato 
juice in a preliminary study (37). Furthermore, the magnitude of the present increase in 
LDL resistance to oxidation during tomato juice supplementation was comparable with 
the corresponding increase during supplementation with vitamin E. In addition, 
treatment with vitamin E markedly decreased plasma levels of C-RP that is a risk factor 
for myocardial infarction (13-15). 
The increase in LDL resistance to oxidation during dietary supplementation with tomato 
juice is presumably due to increased LDL content of lycopene. Carotenoids are 
transported by lipoproteins, and substantially by LDL, in the blood (38). Thus, the 3-
fold increase in plasma lycopene in the present study undoubtedly included an increase 
in LDL lycopene levels. Fuhrman and coworkers have reported that enrichment of 
LDL with lycopene in vitro increases its resistance to copper ion oxidation (22). 
Vitamin C is usually added to commercial tomato juice but this antioxidant alone is not 
responsible for the increased resistance to oxidation of LDL isolated during 
supplementation with tomato juice in our data. The susceptibility of LDL to oxidation 
was unchanged in patients who were randomised to receive a high dose of vitamin C. 
Also, LDL content of a-tocopherol , a major antioxidant in lipoproteins, did not change 
appreciably in patients randomised to receive tomato juice. It is unlikely that ACE 
inhibitor therapy was responsible for the increase in LDL resistance to oxidation in 
these patients. Numbers of patients receiving ACE inhibitor drugs (that are reported as 
inhibiting LDL oxidation (36)) were comparable in the groups of patients treated with 
tomato juice and placebo while LDL susceptibility to oxidation was clearly decreased in 
those receiving tomatojuice but not in those receiving placebo. Furthermore, treatment 
with ACE inhibitor drugs remained unchanged during the study. 
Plasma C-RP levels in the current patients with type 2 diabetes were comparable with 
elevated levels reported previously (39). The mechanism(s) responsible for these 
elevated C-RP levels is unclear. It is possible that obesity, oxidative stress, 
atherosclerotic disease and enhanced release of proinflammatory cytokines induced by 
























patients with type 2 diabetes (10, 4D). In the present study, few of the patients reported 
infections but we cannot exclude the possibility that undiagnosed and asymptomatic 
infections also contributed to their elevated C-RP levels. 
The decrease in plasma C-RP in patients with type 2 diabetes during supplementation 
with vitamin E in this study may indicate an improvement in systemic inflammatory 
status. It is possible that vitamin E decreases the secretion of proinflammatory 
cytokines which promote the synthesis of C-RP in the liver. Devaraj and Jialal (19) 
have reported that dietary supplementation of healthy subjects with a high dose of 
vitamin E inhibits the release of IL-lB from isolated monocytes. The proinflammatory 
cytokine IL- lB stimulates the expression of IL-6 which in tum increases the synthesis 
of C-RP (15, 41). The decrease in IL-lB secretion induced by vitamin E appears to be 
independent of its antioxidant properties and relies on a decrease in 5-lipoxygenase 
activity (42). Our data suggest that plasma C-RP levels may also be unaffected by 
increased antioxidant protection and greater intrinsic resistance of LDL to oxidation in 
patients with type 2 diabetes. In patients supplemented with vitamin C and tomato 
juice, levels of ascorbate and lycopene were increased respectively and in those treated 
with tomato juice LDL resistance to copper ion oxidation was also increased but plasma 
C-RP remained unchanged. 
The expression of cell adhesion molecules is also stimulated by proinflammatory 
cytokines (15) and by oxidised LDL in vitro in a process which can be inhibited by 
addition of antioxidants (20, 21). However, our data suggest that supplementation 
with natural antioxidants and increased intrinsic resistance of LDL to oxidation may not 
inhibit enhanced expression of VCAM-1 and ICAM-1 in patients with type 2 diabetes. 
This finding appears to be in keeping with a recent study which has reported a neutral 
effect of treatment with smaller amounts of vitamin E (75 mg/day) and vitamin C (150 
mg/day) on plasma levels of VCAM-1 in male smokers (43). Hyperglycemia (11) and 
increased levels of advanced glycation end.::products (44) may have continued to 
enhance the expression of cell adhesion molecules in patients during the present study. 
The increases in plasma total cholesterol and apoB levels in patients receiving vitamin E 
and vitamin C respectively must be interpreted with caution. These increases may not 
be clearly different from the corresponding changes in the placebo group as the 95% 
confidence intervals for the changes overlapped appreciably. Few if any, published 
placebo-controlled studies have reported an increase in plasma cholesterol in humans 
during vitamin E supplementation. However, a trend toward an increase in plasma 
























the effect of supplementation with vitamins Eon plasma cholesterol in a larger number 
of patients with type 2 diabetes are warranted. 
This study has limitations that must be considered. Numbers of patients in the 
treatment groups were relatively small. Thus, care should be taken in extrapolating the 
present findings to other populations. Also, the treatment period was comparatively 
short. On the other hand, the length of the supplementation period was sufficient to 
establish markedly increased levels of circulating antioxidants. Patients were taking a 
number of medications to control diabetes and hypertension or reduce risk of a 
cardiovascular event. However, these treatments are characteristic of patients with type 
2 diabetes and remained unchanged during the study. 
In conclusion, this study indicates that regular consumption of tomato juice markedly 
increases plasma lycopene levels and increases the resistance of isolated LDL to 
oxidation almost as effectively as a high dose of vitamin E in patients with type 2 
diabetes. However, vitamin E supplementation also decreases plasma C-RP indicating 
lower systemic inflammatory activity. These changes are consistent with a lower risk 
of CHD according to epidemiological studies (13,17,45). Our findings may have 
application in the development of strategies aimed at reducing the risk of CHD in 
patients with type 2 diabetes. 
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Table 1 - Baseline characteristics of patient groups. 
VitaminE Vitamin C Tomato juice Placebo 
n=12 n=12 n=15 n=l3 
Age (years) 56±14 56±9 63±8 60±6 
Gender (M/F) 6/6 6/6 10/5 10/3 
Duration of 
diabetes (years) 5.8±7.6 1.9±1.3 4.9±5.5 3.2±2.4 
BMI (kg/m2) 31.5±7.4 30.7±6.3 30.9±7.0 31.8±4.1 
HbA1c (%) 6.7±0.9 6.7±1.0 6.0±0.7 6.6±1.7 
Plasma glucose 
(mmol/1) 8.4±2.1 8.7±1.5 8.2±1.3 9.1±2.4 
Systolic BP 
>90 mmHg (n) 6 2 4 6 
IHD (n) 8 5 10 8 
Diet only (n) 4 5 6 4 
OHAs (n) 8 7 9 9 
Biguanides (n) 2 0 4 2 
Sulphonylureas (n) 8 7 7 7 
ACE inhibitors (n) 1 2 9 7 
B-blockers (n) 2 2 3 1 
Ca antagonists (n) 3 1 4 2 
Aspirin (n) 1 3 5 3 
Values are mean±SD and numbers of patients in categories . 
Abbreviations: M, male; F, female; BMI, body mass index; HbA1c, glycated 
hemoglobin; BP, blood pressure; IHD, clinical ischemic heart disease; OHAs, oral 
hypoglycemic agents. 
16 
Table 2-Plasma antioxidants at baseline (B), end of placebo (PL) and end of 
su:eplementation (S). 
VitaminE Vitamin C Tomato juice Placebo p* 
n=12 n=12 n=15 n=l3 
a-tocopherol (µmol/1) 
B 24.4±8.6 22.7±4.1 26.1±4.9 23.9±5.3 
PL 24.3±8.8t 22.2±5.0 25.5±4.5 25.4±5.8 
s 56.7±23.7t 22.6±4.8 26.7±6.0 24.4±6.5 0.001 
;r Lycopene (µmol/1) 
+ B 0.35±0.24 0.41±0.27 0.39±0.23 0.31±0.26 
>. PL 0.31±0.19 0.41±0.27 0.39±0.26t 0.33±0.28 
s 0.41±0.23 0.44±0.32 1.08±0.39t 0.28±0.21 0.001 
., Vitamin C (µmol/1) 
•l B 39.6±19.5 40.7±15.4 38.9±25.5 25.0±15.6 
PL 42.7±18.0 37.7±12.4t 43.8±28.6 27.3±15.4 
s 40.0±13.7 64.7±14.3t 56.0±23.4 29.7±21.1 0.089 
·;-
t>- Values are mean±SD. 
* Repeated measures ANOVA with baseline values as a covariate. 












Table 3 - Low density lipoprotein lag time, rate and concentration of conjugated dienes 
formed during copper ion oxidation and content of a-tocopherol at baseline (B), end of 
placebo (PL) and end of supplementation (S). 
Vitanun E Vitamin C Tomato juice Placebo p* 
n=12 n=12 n=15 n=13 
Lag time (minutes) 
B 74±16 56±19 69±18 81±21 
PL 74±16t 63±15 71±24t 86±23 
7 
s 114±26t 67±18 101±27t 80±23 0.001 
; Rate (nmol/µmol LDL cholesterol/min) 
_, B 1.10±0.34 1.09±0.38 1.13±0.32 1.15±0.39 
PL 1.13±0.34 1.09±0.39 1.12±0.32 1.15±0.40 
" s 1.12±0.34 1.10±0.39 1.12±0.32 1.14±0.38 0.693 
i Concentration (nmol/µmol LDL cholesterol) 
B 139±26 137±12 146±17 142±15 
PL 127±16 132±29 144±17 147±15 
7 
s 138±22 137±22 149±16 147±19 0.501 
t;--
a-tocopherol (µmol/mmol cholesterol) 
B 2.7±0.9 2.5±0.6 2.9±0.5 2.4±0.6 
PL 2.7±0.8t 2.5±0.7 2.7±0.5 2.5±0.6 
s 5.6±I.5t 2.4±0.8 2.7±0.5 2.4±0.4 0.001 
~ 
,._, Values are mean±SD. 
T * Repeated measures ANOV A with baseline values as a cov~ate. 







Table 4-Plasma concentrations of C-reactive protein and soluble adhesion molecules 
at baseline (B), end of placebo (PL) and end of supplementation (S). 
VitaminE Vitamin C Tomato juice Placebo p* 
n=12 n=12 n=15 n=13 
C-RP (mg/1) 
~ B 4.5±3.8 2.9±3.3 3.8±2.2 3.1±2.6 
PL 5.6±3.1 t 3.0±3.3 3.5±2.2 2.9±1.9 
s 2.9±3.6t 3.1±2.9 4.1±2.1 3.1±2.5 0.004 
ICAM-1 (ng/ml) 
). B 257±85 256±59 244±70 297±131 
PL 276±66 244±55 246±60 289±112 
s 272±55 243±62 240±49 287±112 0.893 
_, VCAM-1 (ng/ml) 
-) B 533±148 582±353 619±179 626±232 
PL 526±139 584±370 632±189 635±244 
s 534±153 585±354 632±160 640±256 0.997 
? Values are mean ±SD. 
Abbreviations: C-RP, C-reactive protein; ICAM-1, intercellular adhesion molecule-I; 
VCAM-1, vascular cell adhesion molecule-I. 
* Repeated measures ANOVA with baseline values as a covariate. 







Table 5- Plasma lipids, lipoproteins, apolipoproteins and glucose concentrations at 
baseline (B), end of placebo (PL), and end of supplementation (S). 
VitaminE Vitamin C Tomato juice Placebo p* 
n=12 n=12 n=15 n=13 
·i TC (mmol/1) 
:, B 5.65±1.16 5.96±0.97 5.87±1.02 6.48±1.14 
PL 5.57±1.30t 5.92±0.94 5.82±0.93 6.49±1.19 
s 6.07±1.50t 5.97±0.86 5.73±0.97 6.52±1.09 0.022 
-r HDL-C (mmol/1) 
cl B 1.14±1.21 1.10±1.25 1.01±1.29 0.93±1.17 
PL 1.14±1.21 1.12±1.26 0.99±1.30 0.95±1.18 
s 1.18±1.25 1.13±1.22 1.03±1.33 0.96±1.22 0.693 
·., TG (mmol/1) 
-1 B 1.86±1.68 1.75±1.64 2.38±1.36 2.70±1.60 I 
PL 1.77±1.68 1.76±1.64 2.50±1.28 2.70±1.58 
s 2.00±1.72 1.91±1.65 2.35±1.48 2.56±1.57 0.070 
i ApoA-1 (g/1) 
?" B 1.23±1.17 1.17±1.21 1.16±1.25 1.11±1.16 
PL 1.25±1.12 1.22±1.25 1.23±1.30 1.10±1.10 
s 1.35±1.17 1.25±1.23 1.18±1.25 1.12±1.21 0.316 
ApoB (g/1) 
'.>.. B 0.89±1.48 0.84±1.24 0.92±1.29 1.09±1.28 
"' PL 0.88±1.45 0.90±1.28t 0.98±1.25 1.16±1.18 
r s 0.97±1.50 1.04±1.20t 0.90±1.21 ,1.16±1.30 0.027 
Fasting glucose (mmol/1) 
/> B 8.4±2.1 8.7±1.5 8.2±1.3 9.1±2.4 
.. PL 8.9::!;l.6 · 8.4±2.3 8.1±1.2 9.3±2.8 
,- s 9.1±1.7 8.8±2.3 8.3±1.3 9.3±2.8 0.699 
;I Values are mean±SD 
.,. Abbreviations: TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; 
,- TG, triglycerides; apoA-1 apolipoprotein A-1, apoB, apolipoprotein B. 
* Repeated measures ANOVA with baseline values as a covariate. 


















Upritchard JE, Sutherland WHF. Oxidation of heparin-treated low 















/pscript6:/sco4/jobs2/ELSEVIER/ath/week.14/Path6820.001 Fri Apr 30 08:00:21 1999 Page 1 
ATHEROSCLEROSIS 
ELSEVI~R Atherosclerosis 000 (1999) 1-9 
Oxidation of heparin-treated lovv density lipoprotein by peroxidases 
Jane E. Upritchard a, Wayne H.F. Sutherland b,* 
1 
a Department of Human Nutrition, University of Otago Medical School, Dunedin, New Zealand 
b Departi;nent of Medicine, Dunedin School of Medicine, University of Otago Medical School, P.O. Box 913, Dunedin, New Zealand 
Received 24 July 1998; received in revised form 18 January 1999; accepted 8 March 1999 
Abstract 
Low density lipoproteins (LDL) can bind to glycosaminoglycans and proteoglycans rich in heparin and chondroitin sulphate 
in the arterial intima and may become a target for atherogenic modification by myeloperoxidase activity. We have examined the 
susceptibility of resolubilized LDL, that has been precipitated from serum with heparin (HepLDL), to peroxidase-H20 2-catalysed 
oxidation and the effects of antioxidants and components of human serum on the oxidation. HepLDL was oxidised rapidly by 
horse radish peroxidase (HRP) and H 20 2 (mean t112 max for conjugated diene formation, 3 min) while there was little oxidation 
of native LDL or native LDL precipitated with polyethyleneglycol and resolubilised during the 30 min incubation period. The 
formation o1f thiobarbituric acid reacting substances (TBARS) essentially paralleled that of conjugated dienes during oxidation of 
HepLDL. HepLDL was also more rapidly oxidised than native LDL by myeloperoxidase-H20 2• Oxidation of HepLDL by 
peroxidases 'did not require free tyrosine, was almost totally inhibited by butylated hydroxytoluene (BHT) and ascorbate, and was 
unaffected by vitamin E and urate. Increasing concentrations (0-14.9%) of ~-lipoprotein deficient serum (BLPDS) significantly 
(P < 0.0001) inhibited the formation of TEARS during HepLDL oxidation catalysed by HRP and partially inhibited the 
correspondipg myeloperoxidase-catalysed oxidation. This inhibitory activity was removed by dialysis and gel-filtration of BLPDS 
and was not restored by addition of magnesium ions used in the isolation of BLPDS1 or physiological levels of ascorbate, tyrosine 
and reduce(\ thiols (cysteine) to gel-filtered BLPDS. The results indicate that LDL from complexes with glycosaminoglycans are 
highly susceptible to oxidation by peroxidases, particularly at low levels of water soluble antioxidants, and that vulnerability of 
these LDL to myeloperoxidase oxidation remains in the presence of serum components that should exist in the arterial intima. 
These findings may be relevant to the oxidative modification of LDL that becomes trapped by binding to arterial proteoglycans 
and to the formation of myeloperoxidase-modified LDL in the artery wall. © 1999 Elsevier Science· Ireland Ltd. All rights 
reserved. 
Keywords: Peroxidases; Low density lipoproteins; Heparin; Glycosaminoglycans; Antioxidants; Serum inhibitors 
1. Introduction 
Oxidative modification of low density lipoproteins 
(LDL) that have become trapped in the arterial intima 
by interaction with glycosaminoglycan groups on pro-
teoglycans is believed to have an important role in the 
development of atherosclerosis [1-3]. Proteoglycans 
and glycosaminoglycans can form reversible and irre-
versible complexes with LDL in vitro [4,5]. There is 
evidence that these interactions also occur in the artery 
* Corresponding author. 
wall where they may lead to deposition of LDL in 
atherosclerotic lesions [6]. Proteoglycan-LDL com-
plexes in different states of aggregation have been 
isolated from human and rabbit arterial lesions [3,7,8]. 
These complexes promote lipid accumulation ih cul-
tured macrophages [8] which mimics foam cell forma-
tion; an early stage of atherogenesis. Human LDL that 
has been precipitated with proteoglycans or gly-
cosaminoglycans in vitro and then resolubilised is 
thought to imitate LDL that has formed reversible 
associations with proteoglycans in the arterial intima 
[3]. This precipitated-resolubilised LDL has an altered 
0021-9150/99/$ - see front matter © 1999 Elsevier Science Ireland Ltd. All rights reserved. 
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structure [9-11] and is bound and internalised more 
efficiently than native LDL by the apo B, E receptor of 
cultured macrophages [12]. 
Oxidation of LDL produces a number of biologically 
active molecules and modifies apo B. As a result, the 
lipoprotein no longer binds to the apo B, E receptor 
and is avidly taken up by macrophages via the scav-
enger receptor resulting in foam cell formation [2]. 
Oxidatively modified LDL has been isolated from hu-
man atherosclerotic lesions [13]. It has been postulated 
that reversible associations of LDL with proteoglycans 
and glycosaminoglycans increase both the susceptibility 
of LDL to oxidative modification and the opportunity 
for this modification to occur [6]. Isolated LDL that 
has complexed with proteoglycans and glycosaminogly-
cans is abnormally susceptible to oxidation by copper 
ions and by cultured cells [5,14] in a transition metal 
ion mediated process. However, proteins in the extra-
cellular fluid of the artery wall probably bind any free 
transition metal ions and prevent them from catalysing 
LDL oxidation [15,16]. In contrast, activity of oxidants 
which do not depend on free transition metal ions 
should be unaffected by protein binding of these ions. 
An earlier study from our laboratory [17] indicated that 
hernin-catalysed oxidation of LDL which has been iso-
lated by precipitation with heparin glycosaminoglycan 
(HepLDL) is stimulated by low concentrations of ~-
lipoprotein deficient serum (BLPDS) and human serum 
albumin comparable to concentrations in the human 
arterial intima-media. Serum BLPDS contains most of 
the compounds that are found in extracellular fluid. 
Other oxidants, which may have an important role in 
LDL oxidation in vivo [2], have not been tested in this 
model. 
There is recent evidence [18] that myeloperoxidase, a 
heme-containing enzyme which is present in inflamma-
tory cells [19] and in arterial lesions [20], oxidises LDL 
in the artery wall. High levels of 3-chlorotyrosine, 
which is a specific marker of myeloperoxidase-catalysed 
oxidation, were measured in LDL isolated from human 
atherosclerotic intima compared with levels in circulat-
ing LDL [18]. Hypochlorous acid produced during 
myeloperoxidase activity chlorinates proteins and 
lipids, and modifies LDL to a form which is readily 
internalised by cultured macrophages [21]. Hydrogen 
peroxide accelerates peroxidase-catalysed LDL oxida-
tion ~nd can be generated by activated phagocytes. The 
mechanism underlying peroxidase-catalysed oxidation 
of LDL differs notably from that which governs LDL 
oxidation by transition metal ions. In contrast to transi-
tion metal ions, peroxidases do not directly oxidise 
lipids in LDL [22]. Radicals derived from protein, 
vitamin E and tyrosine appear to mediate oxidation of 
LDL by peroxidases [23]. Horse radish peroxidase 
(HRP), an enzyme derived from plants, also oxidises 
isolated LDL via a protein radical [23] and has been 
suggested as a model for transition metal ion indepen-
dent oxidation of LDL in vivo (24]. The aim of the 
present study was to determine the characteristics of 
peroxidase-catalysed oxidation of HepLDL including 
the effect of antioxidants, tyrosine and BLPDS. This 
model system may approximate the situation in the 
arterial intima. 
2. Materials and methods 
2.1. kfaterials 
Chondroitin sulphate C, 1,1,3,3-tetraethoxypropane, 
vitamin E, butylated hydroxytoluene (BHT), tyrosine, 
HRP and myeloperoxidase from human leukocytes 
were obtained from Sigma (St. Louis, MO). Heparin 
(Multiparin, from porcine mucosa) was purchased from 
Fisions. L-Ascorbic acid was obtained from JT Baker 
(NJ) and uric acid and polyethyleneglycol 20 000 from 
BDH (UK). 
2.2. Preparation of lipoprotein fractions 
Lipoproteins were isolated from serum or EDT A 
plasma from normolipidemic donors. HepLDL was 
isolated as was described previously [17]. Briefly, 
sodium citrate buffer (64 mmol/1, pH 5.12) containing 
heparin (50 000 I.U./1) was added to serum (0.5 ml). 
The tubes were left at room temperature for 10 min 
then centrifuged· at 2800 x g for 15 min at room tem-
perature. The precipitate (HepLDL) was washed three 
times with hypotonic Hepes buffer (5 mmol/1 with 
sodium chloride 20 mmol/1, calcium chloride 4 mmol/1 
and magnesium chloride 2 mmol/1, pH 7.2) then redis-
solved in 4% sodium chloride in phosphate buffered 
saline (PBS). The redissolved HepLDL was used imme-
diately. Native LDL (d 1.019-1.063 g/ml) was isolated 
by sequentially ultracentrifuging EDTA plasma at l0°C 
[25] or on a single-step discontinuous gradient in a 
Beckman NVT 65 rotor [26]. The LDL isolated was 
desalted either by dialysis (twice against PBS (2 1) in the . 
dark at 4°C) or by gel-filtration on Ecocnopac PD-10 
columns equilibrated with PBS. The PBS was Chelex 
treated to remove any metal ions. Chondroitin sulphate 
treated LDL (CsLDL) was prepared as described previ-
ously [17]. Native LDL (1 volume) was also precipi-
tated by adding 2 volumes of 9 .5% polyethyleneglycol 
(mo!. wt. 20 000) solution in phosphate buffer pH 6.5 
(27]. Aggregated native LDL was prepared essentially 
according to the method of Khoo et al. [28]. The 
BLPDS fraction was prepared by the addition of dex-
tran sulphate-magnesium chloride to serum [29]. The 
apo B-containing lipoproteins were pelleted by centrifu-
gation in a Beckman microfuge for 5 min and BLPDS 
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was prepared by loading 1 ml BLPDS onto a PD-10 
gel-filtration column equilibrated with PBS. A volume 
of PBS (2 ml) was added to the column and the ensuing 
eluate was discarded. The gel-filtered BLPDS was 
eluted with 1 ml PBS. 
2.3. Oxidation of LDL 
Formation of conjugated dienes or thiobarbituric 
acid reacting substances (TBARS) was used to monitor 
oxidation of lipoproteins. When conjugated dienes were 
measured, the LDL species (50-100 µl, 0.1 µmol 
cholesterol) and H20 2 (10 µ1 of 12.9 µmol/ml in PBS) 
were added to 1.8 ml PBS and distilled water (0.20-
0.25 ml) to maintain approximate isotonicity in the 
incubation medium. An aliquot of HRP (10 µ1 of 119 
U/ml in PBS) or MPO (10 µl of 250 U/ml in PBS) was 
added with rapid mixing and the absorbance at 234 nm 
was monitored during incubation of the mixture at 
room temperature (23°C). The final volume of the 
incubation mixture was 2.12 ml. Tonicity of the incuba-
tion medium and use of Chelex-treated PBS or un-
treated PBS did not appreciably influence the oxidation 
rates. Maximal absorbance at 234 nm and time taken to 
attain half-maximal absorbance (t112 max) were deter-
mined from the plot of absorbance values against time. 
When TBARS were measured, the LDL species 
(100-150 µ1, 0.2 µmol cholesterol), the serum fraction 
(0-200 µ1), H20 2 (10 µ1 of 12.9 µmol/ml in PBS), and 
HRP (10 µ1 of 119 U/ml in PBS) or myeloperoxidase 
(10 µ1 of 250 U/ml in PBS) were added to PBS (1 ml) 
and the final volume was adjusted to 1.4 ml. The 
mixture was incubated at room temperature (23°C) for 
30 min. At the end of this period, BHT (10 µ1 of 4 
mmol/1 in methanol) and EDTA (50 µl of 4 mmol/1) 
were added and TBARS were measured essentially by 
the method of Beuge and Aust [30]. Rates of LDL 
oxidation were expressed as nmol TBARS/µmol LDL 
cholesterol/30 min. 
2.4. Analytical methods 
Cholesterol was measured using a commercial kit 
and standards from Boehringer Mannheim (Germany). 
Serum paraoxonase activity was measured by monitor-
ing the rate of phenylacetate hydrolysis at 270 nm 
following the addition of diluted serum [31 J. A fluori-
metric method [32] was used to measure TEARS in 
unoxidized HepLDL. 
2.5. Statistical analysis 
Student's t-test was used to compare mean values. 
Analysis of variance (ANOV A) was used to compare 
the effects of several concentrations of H20 2 on t112 max 
and maximal absorbance at 234 nm and varying levels 
of BLPDS on TBARS formation during HepLDL oxi-
dation. A two-sided test of significance was used and 
P < 0.05 was considered statistically significant. Results 
are mean± S.D. unless stated otherwise. 
3. Results 
Fig. IA shows the oxidation of native LDL and LDL 
that had interacted with glycosaminoglycans. Conju-
gated diene formation increased rapidly with no lag-
0.3 
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Fig. 1. (A) Oxidation of HepLDL and native LDL with HRP and 
H20 2. The LDL species (0.047 µmo! cholesterol/ml), HRP (0.56 
U/ml) and H20 2 (58 µmol/1) in PBS were incubated at room temper-
ature (23°C) and optical density at 234 nm was monitored. The figure 
represents a typical experiment from over six individual experiments 
with HepLDL and five experiments with native LDL. (B) Time-
course of TBA RS formation during oxidation of HepLDL with HRP 
and H20 2. HepLDL (0.14 µmo! cholesterol/ml), HRP (0.85 U/ml) 
and H20 2 (87 µmol/1) in PBS were incubated at room temperature 
(23°C). TBARS were measured in the incubation medium at intervals 
up to 30 min. Values are averages of two experiments and the bars 
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time during HRP-catalysed oxidation of H~pLDL, 
while there was little change with native LDL. The 
mean t112 max was 3 ± 1 min (n = 5) for the oxid~tion of 
HepLDL and values for CsLDL were within thr range 
of those observed for HepLDL. Similar results were 
obtained when native LDL that had been isolated by 
ultracentrifugation of plasma, precipitated with J:ieparin 
or chondroitin sulphate and then resolubilised was oxi-
dised by HRP. There was no change in absorb.ance at 
234 nm when HepLDL was incubated alone or with 
H20 2 in the absence of HRP. The formation of TBARS 
paralleled that of conjugated dienes during HRP oxida-
tion of HepLDL (Fig. lB). TBARS were virtually 
undetectable (10-30 pmoljµmol cholesterol) in freshly 
isolated HepLDL. Redissolving the HepLDL precipi-
tate in 4% sodium chloride-PBS was not responsible 
for the increased susceptibility of HepLDL to oxida-
tion. When an aliquot of a suspension of HrpLDL 
precipitate in hypotonic Hepes buffer was added to 
PBS (in which it dissolved) and oxidised with, HRP-
H202 the rate of TBARS formation (26.5 ± 5.7 nmol/ 
µmol cholesterol/30 min, n = 3 experiments) was not 
significantly different compared with the corresf1onding 
rate with HepLDL that had been redissolved; in 4% 
sodium chloride-PBS. Addition of EDTA (0.14 mmol/ 
1) did not reduce the formation of TBARS during 
oxidation of HepLDL by HRP-H20 2. . 
When a suspension of precipitated native LDL in 
polyethyleneglycol solution was treated with . HRP-
H202 (maximum final polyethyleneglycol concentra-
tion, 0.17 mmol/1) absorbance at 234 nm increased 
slowly to a mean value of 0.029 ± 0.013 (n = 3) at 30 
min which was significantly (P = 0.0004) lower than the 
corresponding value for the oxidation of HepLDL 
(0.236 ± 0.029 with t 112 max 5.9 ± 0.6 min, n = 3) in the 
presence of polyethyleneglycol (0.17 mmol/1). T,he pre-
cipitated LDL suspended in polyethyleneglycol solution 
redissolved to give virtually zero absorbance at 680 nm 
(a measure of turbidity) wllen the suspension was added 
to PBS prior to addition of the oxidants. Aggregated 
LDL did not dissolve in 4% sodium chloride-Pt13S and 
a suspension of the lipoprotein in PBS was not oxidised 
to TBARS by HRP-H20 2. 
The formation of conjugated dienes during incuba-
tion of HepLDL with myeloperoxidase-Hi02 was 
rapid, with no lag-phase compared with the corre-
sponding oxidation of native LDL, which had a lag-
time of greater than 150 min (Fig. 2). The t112 max for 
the formation of dienes from HepLDL was approxi-
mately 50 min. 
The rate of HepLDL oxidation (t112 max absorbance at 
234 nm and maximal absorbance) did not change sig-
nificantly (ANOVA P > 0.60) at H20 2 concentrations 
between 6 and 60 µmol/1 (HRP concentration, 0.56 
U/ml) or at HRP concentrations between 0.125 and 
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Fig. 2. Oxidation of HepLDL with myeloperoxidase. HepLDL or 
native LDL (0.047 µmo! cholesterol/ml), myeloperoxidase (0.09 U/ 
ml) and H20 2 (58 µmol/1) in PBS were incubated at room tempera-
ture (23°C). Absorbance at 234 nm was monitored. The figure shows 
results of a representative experiment from two separate experiments. 
separate experiments. In another experiment, maximum 
absorbance at 234 nm increased linearly (r 2'= 0.994) as 
increasing concentrations (0.017-0.070 µmol/ml) of 
HepLDL were oxidised with HRP-'H20 2. 
Fig. 3 shows the effect of the antioxidants ascorbic 
acid and vitamin E on oxidation of HepLDL by HRP-
H202. In the presence of ascorbate, conjugated diene 
formation increased within the -first 2 min and then 
declined toward zero during the 30 min incubation 
period. Optical density at 234 nm also increased rapidly 
when ascorbate was treated with the oxidants. Produc-
tion of TBARS was inhibited by 98% in each of two 
separate experiments when HepLDL was oxidised with 
HRP-H20 2 in the presence of79 µmol/1 ascorbate. The 
rate of diene formation during oxidation of HepLDL 
that had been isolated from serum enriched in vitamin 
E and contained increased levels of vitamin E, was 
similar to the rate in control HepLDL isolated from 
serum incubated with ethanol. In separate experiments 
(n = 3) with materials from different subjects, addition 
of vitamin E in ethanol at concentrations of 1, 2 and 3 
µmol/1 and a final ethanol concentration of 0.9% did 
not significantly affect t112 max (control: 2.7 ± 0.3 min; 1 
µmol/1 vitamin E: 3.0 ± 1.3; 2 µmol/1 vitamin E: 3.3 ± 
1.2 min; 3 µmol/1 vitamin E: 3.0 ± 1.0 min, ANOVA 
P = 0.88) and the ratio maximum absorbance in the 
presence of vitamin E/control maximum absorbance in 
the absence of vitamin E and with added ethanol 
(ANOV A P = 0.29). Added BHT (18.9 µmol/1) signifi-
cantly (P < 0.001) decreased the maximum amount of 
conjugated dienes formed ( - 75 ± 13%, n = 3) and the 
production of TBARS to 2% of control values (n = 2) 
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(48 µmol/1) inhibited the early rapid formation of con-
jugated dienes during oxidation of HepLDL (Fig. 4). 
After 30 min, the amounts of dienes formed were 
similar in the presence or absence of tyrosine . 
Fig. 5 plots the effect of increasing concentrations 
of ELPDS on the formation of TBARS during oxida-
tion of HepLDL with HRP and myeloperoxidase. Ox-
idation was followed by measuring TEARS formation 
because conjugated dienes cannot be readily measured 
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Fig. 3. Effect of ascorbic acid and vitamin E on oxidation of 
HepLDL by HRP and H20 2• (A) Ascorbate (79 µmo!/!), HepLDL 
(0.047 µmo! cholesterol/ml), HRP (0.56 U/ml) and hydrogen peroxide 
(58 µmol/1) in PBS were incubated at room temperature (23°C). Also, 
ascorl:iate (79 µmol/1) was incubated with the oxidants. (B) Vitamin E 
solution in ethanol (27.2 mmol/1) was added to serum (10 µI and 272 
nmol vitamin E/ml serum) and the mixture was incubated at 37°C for 
1.5 h. A control incubation of serum with added ethanol (IO µI/ml 
serum) was also performed. HepLDL was isolated from serum and 
0.047 µmo] HepLDL cholesterol/ml was oxidised with HRP (0.56 
U/ml) and H20 2 (58 µmol/1). The mean ( ± S.D.) vitamin E content 
of control HepLDL was 1.3 ± 1.0 nmol/µmol cholesterol and of 
vitamin E enriched HepLDL was 107.7 nmol/µmol cholesterol. Opti-
cal density at 234 nm was monitored. The results are representatives 




















Fig. 4. Effect of added tyrosine on oxidation of HepLDL by HRP 
and H20 2• HepLDL (0.047 µmo! cholesterol/ml), tyrosine (48 µmo!/ 
1), HRP (0.56 U/1) and H20 2 (58 µmol/1) in PBS were incubated at 
room temperature (23°C). The stock solution (20.44 mmol/1) of 
tyrosine was prepared by dissolving tyrosine in dilute hydrochloric 
acid. The addition of 5 µI tyrosine solution to the PBS did not 
appreciably alter the pH of the incubation medium (pH 7.39). Optical 
density at 234 nm was monitored. The figure shows the results from 
a representative experiment from a total of three independent experi-
ments. 
234 nm. Added ELPDS significantly inhibited TBARS 
formation (ANOVA P < 0.0001) particularly at con-
centrations between 7.5-14.9%. The rate of TBARS 
formation increased (0.1-1.2 nmol/30 min) with in-
creasing concentrations of BLPDS alone and the 
quantities of TBARS produced were markedly smaller 
than the levels, when HepLDL was also present. The 
levels of TBARS derived from BLPDS alone were 
subtracted from the values obtained during oxidation 
of HepLDL in the presence of BLPDS. Oxidation of 
HepLDL by myeloperoxidase-H20 2 was also inhib-
ited by increasing concentrations of ELPDS. This in-
hibition was less marked compared with the 
corresponding inhibition of HRP-catalysed oxidation 
of HepLDL. 
The effect of BLPDS (14.9%, v/v) that had been 
dialyzed or gel-filtered to remove small water soluble 
molecules and the addition of magnesium ions, ascor-
bate, tyrosine and cysteine hydrochloride to gel-
filtered BLPDS on the formation of TEARS during 
oxidation of HepLDL by HRP-H20 2 is summarised 
in Table 1. Both dialyzed and gel-filtered BLPDS 
failed to inhibit . this oxidation significantly. Gel-
filtered ELPDS with added magnesium ions (equiva-
lent to the level in ELPDS) and physiological levels of 
ascorbate, tyrosine and cysteine hydrochloride did not 
inhibit TEARS formation. Added urate (19.2-76.9 
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tion during oxidation of HepLDL-catalysed by HRP. 
The inhibitory effect was still present in BLPDS that 
was prepared from serum that had been heated for 1 h 
at 58°C and had only 3% of its initial activity of 
paraoxonase, an enzyme which metabolises oxidised 
lipids (control: 23.5 ± 0.7 nmol/µmol/30 min; heated 
BLPDS: 2.1 ± 1.9 nmol/µmol/30 min; n = 3 experi-
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Fig. 5: Effect of BLPDS on oxidation of HepLDL by HRP and 
myeloperoxidase. (A) HepLDL (0.14 µmo! cholesterol/ml), BLPDS 
(1.9, 7.5, 11.2 and 14.9%, v/v), HRP (0.85 U/ml) and H20 2 (87 
µmo!/!) in PBS were incubated at room temperature (23°C) for 30 
min and then TBARS were measured in the incubation mixture. 
Similar incubations but without HepLDL were also performed and 
the TBARS formed were subtracted from levels measured when 
HepLDL was also present. Values are mean± S.E.M. (n = 3 experi-
ments). (B) A similar experiment in which myeloperoxidase (0.14 
U/ml) replaced HRP is displayed. Values are the averages of two 
separate experiments and the bars represent the range of values. 
Table I 
Effect of dialysis and gel-filtration of BLPDS and the addition of 
magnesium ions, ascorbate, tyrosine and cysteine hydrochloride to 
gel-filtered BLPDS on TBARS formation during HepLDL oxidation 
by HRP-H20/ 
Additions 
BLPDS (14.9%, v/v) 
Dialysed BLPDS (14.9%, v/v) 
Gel-filtered BLPDS (14.9%, v/v) 
+Mg2+ (54 mmol/1) 
+ Ascorbate (84 µmo!/!) 
+ Tyrosine (48 µmol/1) 





100 ± I 
101 ± 8 
122 ± 23 
98 ±2 
• Values are mean± S.D. of three separate experiments. 
* P<0.0001 compared with control. 
4. Discussion 
Our data· indicate that LDL which has been resolu-
bilised from complexes with glycosaminoglycans is 
more susceptible than native LDL to peroxidase-
catalysed oxidation that is only partially inhibited by 
BLPDS when myeloperoxidase is the catalyst. This 
enhanced susceptibility to oxidation may contribute to 
increased levels of myeloperoxidase-modified LDL and 
oxidised LDL that are present in atherosclerotic arteries 
[13,18]. 
The increased susceptibility of HepLDL (and other 
glycosaminoglycan treated LDL) to peroxidase oxida-
tion appears to be specifically due to changes in LDL as 
a result of the interaction with a glycosaminoglycan 
and not as a result of precipitation and resolubilisation 
of LDL. Precipitation with polyethyleneglycol which 
sterically excludes LDL from solution [33] and does not 
form a complex with the lipoprotein, did not increase 
the oxidisability of the resolubilised LDL by HRP. 
Levels of lipid oxidation products were low in freshly 
isolated HepLDL suggesting that the isolation proce-
dure did not oxidatively stress HepLDL and thereby 
increase its susceptibility to peroxidase-catalysed 
oxidation. 
Changes in lipoprotein structure caused by the inter-
action of LDL with glycosaminoglycans may underlie 
the rapid rate of lipid peroxidation in HepLDL com-
pared with native LDL when they are incubated with 
peroxidases. These structural changes may increase the 
efficiency of peroxidase induced formation of radicals 
from apo B and vitamin E which mediate oxidation of 
LDL lipids by myeloperoxidase and HRP. Also, the 
altered molecular structure in HepLDL may increase 
the proximity of . the radicals to oxidisable lipids. 
Camejo and coworkers [9-11] have reported that inter-
action with arterial proteoglycans and glycosaminogly-
cans in vitro alters the structure of both lipid and 
protein components of LDL. Low angle X-ray kinetic 
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tion of the cholesteryl ester core [9] and apo B in the 
lipoprotein [3,6,34]. Thus, it is possible that altered 
protein confonnation may increase the accessibility of 
sites on apo B to peroxidase-catalysed radical forma-
tion and may place apo B radicals in a better position 
to attack oxidisable lipid substrate in HepLDL. In-
creased access of the peroxidase enzymes to apo B in 
glycosaminoglycan treated LDL seems to be in keeping 
with previous reports that protein in LDL which has 
interacted with proteoglycans has an increased suscepti~ 
bility to tryptic fragmentation [11,34]. It has also been 
suggested previously that the physical state of lipids 
and their proximity to radicals generated in the lipo-
protein may be important in the oxidation by peroxi-
dases [22]. 
Glycosaminoglycan induced changes in the lipo-
protein structure may also alter the effect of vitamin E 
on LDL lipid oxidation by HRP. A previous study has 
reported that the addition of small amounts of vitamin 
E accelerates peroxidase oxidation of native LDL ap-
parently by increasing the numbers of a-tocopherol 
radicals [22]. At higher levels of vitamin E, the oxida-
tion is inhibited, suggesting that sufficient free vitamin 
E may remain to inhibit lipid oxidation [22,23]. In 
contrast, the present data indicate that HRP-H20 2 
oxidation of LDL that has interacted with heparin 
glycosaminoglycan is unaffected not only by additions 
of small quantities of vitamin E to the incubation but 
also by massive prior enrichment of HepLDL with 
vitamin E. It is possible that molecular disorganisation 
[9] may allow HRP increased access to vitamin E in the 
cholesteryl ester-rich hydrophobic core of HepLDL, 
resulting in faster production of a-tocopherol radicals 
and decreased levels of free vitamin E. The HRP-
catalysed lipid oxidation in HepLDL is probably near 
or at a maximal rate and may therefore be unaffected 
by any extra a-tocopherol radicals generated from 
added vitamin E. Lipid oxidation in HepLDL was 
markedly inhibited by BHT, a lipophilic antioxidant 
whose radicals are sterically hindered and may be inac-
cessible for propagation of the radical chain reaction 
[22]. Thus, increased generation of a-tocopherol radi-
cals that are not sterically hindered and can accelerate 
lipid oxidation [22] may contribute to the inefficiency of 
vitamin E as an antioxidant in the HepLDL-HRP-
H202 system. Whether rapid oxidation reduces free 
vitamin E to levels that no longer inhibit lipid oxidation 
in HepLDL that has been massively enriched with 
vitamin E remains to be determined. 
Ascorbate markedly inhibited HepLDL oxidation by 
HRP possibly by decreasing levels of apo B and vita-
min E radicals. The protein component of LDL is 
largely at the surface of LDL and therefore readily 
accessible to the water soluble antioxidant. HRP may 
oxidise ascorbate to products which react with LDL 
protein and decrease the formation of apo B radicals. 
This proposed mechanism is essentially analogous to 
that which governs the inhibition of copper ion-
catalysed oxidation of LDL by ascorbate. Retsky et al. 
[35] have reported that during copper ion oxidation of 
LDL in the presence of ascorbate there is oxidation of 
ascorbate to dehydroascorbate (and other products) 
which reacts with LDL protein and inhibits subsequent 
copper ion-catalysed lipid oxidation. In the present 
study, ascorbate appeared to have been oxidised before 
it appreciably inhibited the oxidation of HepLDL. 
There was a large and rapid increase in absorbance at 
234 nm when ascorbate and oxidants were incubated in 
PBS, suggesting that ascorbate had been modified. The 
momentary increase in absorbance at 234 nm, when 
HRP and H20 2 were added to a solution of HepLDL 
in the presence of ascorbate, may be due mainly or 
solely to the formation of oxidation product(s) of 
ascorbic acid that absorb at this wavelength and not to 
increased lipid conjugated diene production. The grad-
ual decline of this early peak in absorbance at 234 nm 
may reflect reaction between the ascorbate oxidation 
product(s) and HepLDL which not only reduces the 
increased absorbance due to oxidation of ascorbate but 
also inhibits the oxidation of HepLDL lipids. Incuba-
tion of ascorbate with copper ions does not result in an 
increase in absorbance at 234 nm (data not shown). 
This finding suggests that there may be differences in 
the antioxidant mechanism of ascorbate in the presence 
of transition metal ions and HRP. The reduced form of 
ascorbate can convert a-tocopherol radicals to free 
Cl-tocopherol in LDL [36]. However, it is uncertain 
whether this regenerating activity of ascorbate remains 
after it has been modified by HRP-H20 2• 
Free tyrosine also inhibited the oxidation of Hep-
LD L by HRP' but only during the early stages of the 
incubation. Tyrosine may have initially competed with 
HepLDL for oxidation until eventually levels of the 
amino acid were decreased and no longer competed 
effectively for oxidation. In a previous study, oxidation 
of native LDL by myeloperoxidase was inhibited by 
high levels of added tyrosine [22]. Some studies [37], but 
not others [22], have reported that oxidation of native 
LDL by myeloperoxidase requires the presence of free 
tyrosine. It has been suggested that added tyrosine may 
be required only when lipoprotein vitamin E content is 
low [22]. In the present study, myeloperoxidase readily 
oxidised HepLDL in the absence of free tyrosine. 
Freshly isolated HepLDL is not depleted of vitamin E 
[17] which may mediate myeloperoxidase-catalysed lipid 
oxidation. Also, altered lipoprotein structure may ·allow 
the oxidation of HepLDL by myeloperoxidase in the 
absence of tyrosine. 
Added BLPDS markedly decreased oxidation of 
HepLDL-catalysed by HRP, but even at the highest 
concentration only partially inhibited the corresponding 
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hibitor(s) in BLPDS was a small, water soluble 
molecule which did not appear to be ascorbate, urate, 
tyrosine or reduced thiols. The mechanism underlying 
the greater sensitivity of HRP oxidation to inhibition 
by BLPDS is uncertain but may relate to the position 
of the catalytic heme unit in HRP. In HRP the heme 
unit is relatively exposed whereas in myeloperoxidase, 
by contrast, it is buried deep in a hydrophobic cleft [38] 
and may be less accessible to components of BLPDS. 
Our finding that BLPDS only partially inhibited the 
oxidation of HepLDL by myeloperoxidase appears to 
be consistent with evidence that myeloperoxidase oxi-
dises LDL in the artery wall [18] where components of 
extracellular fluid can modulate the process. The levels 
of BLPDS used in the present study were in a range 
which may correspond with the concentration of many 
compounds in extracellular fluid [39]. 
In conclusion, the present data suggest that LDL 
from complexes with glycosaminoglycans is abnormally 
susceptible to oxidation by peroxidases including 
myeloperoxidase which is a physiological oxidant. 
These experiments support the hypothesis that LDL 
which becomes trapped in the artery wall by interaction 
with proteoglycans may be susceptible to oxidation by 
myeloperoxidase. Our data also suggest that this perox-
idase oxidation of LDL may be favoured at low levels 
of water-soluble antioxidants. Proteoglycans and gly-
cosaminoglycans are negatively charged and may at-
tract myeloperoxidase which has a basic pKa and wi11 
be positively charged at physiological pH. An interac-
tion of this type could bring the enzyme and LDL into 
close proximity and potentiate lipoprotein modification. 
Oxidation of LDL-proteoglycan complexes by 
myeloperoxidase may increase levels of myeloperoxi-
dase-modified LDL and accelerate lesion development. 
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Appendix C 




























Clinical characteristics of the patients at entry to the study 
Age, years 
Gender, male/female 
Duration of diabetes, years 
BMI, Kg/m2 
Glycated haemoglobin, % 
Plasma glucose, mmol/1 
Diastolic blood pressure, mmHg 
Systolic blood pressure, mmHg 
Systolic blood pressure ~ 90 mmHg 
Clinical heart disease, n (%) 
Control of hyperglycaemia 
Diet only, n (%) 






31.2 ± 6.2 
6.48 ± 1.13 
8.6 ± 1.18 
141 ± 25 





Values are mean ± SD; except in the case of high blood pressure, heart disease and 
control of hyperglycremia where number of patients (%) are reported. 
Medication taken by patients at baseline 
Biguanides, n (%) 
Sulphonylureas, n (%) 
Gliclazide, n (%) 
ACE Inhibitor, n (%) 
~-andrenoceptor blocking agent, n (%) 
Calcium blocking agent, n (%) 
Aspirin, n (%) 






































Apolipoprotein Al, g/1 
Apolipoprotein B, g/1 
a-tocopherol, µmol/1 
Lycopene, µmol/1 
Vitamin C, .!:!_mol/1 
Values are mean ± SD 
Diabetic Patients 
n=52 
6.00 ± 1.09 
1.06 ± 0.24 
0.26 ± 0.13 
0.81 ±0.16 
2.41 ± 1.21 
1.17 ± 0.22 
0.97 ± 0.27 
24.4 ± 5.9 
0.37 ± 0.24 
36.0 ± 20.3 
Products of inflammation and oxidation at baseline 
Plasma sICAM-1, ng/ml 
Plasma sVCAM-1, ng/ml 
Plasma C-RP, mg/I 
Plasma FSB, U/ml 
Plasma TBARS, ng/ml 
RBC TBARS, nmol MDA/ml PC 
Abbreviations: MDA, malondialdehyde; PC, packed cells 
Values are mean ± SD 
Diabetic Patients 
n=52 
263 ± 91 
592 ± 233 
5.6 ±5.3 
10.1 ± 2.3 
102.6 ± 27.8 





















Composition of LDL isolated from patients at baseline 
Free cholesterol, % 
Cholesterol ester, % 
Phospholipids, % 
Triglycerides, % 
a-tocopherol, nunol/mol cholesterol 
Peroxides, nunol/mol cholesterol 
Values are mean ± SD 
Diabetic Patients 
n=52 
9.02 ± 1.46 
29.93 ± 2.51 
23.79 ± 4.09 
8.19 ± 1.83 
2.64 ± 0.66 
9.59 ± 2.73 
Intrinsic resistance of LDL isolated from patients at baseline 
Lag time, minutes 
Rate conjugated diene formation, 
nmol/µmol/min 
Total conjugated diene formation, 
nmol/µmol 
3 hour TEARS, 
nmol MDA/µmol cholesterol 
5 hour TEARS, 
nmol MDA/g_mol cholesterol 
Values are mean ± SD 
Diabetic Patients 
n=52 
70.2 ± 20.1 
8.4 ± 2.3 
1055.6 ± 133.7 
17.92±4.12 
18.11 ± 40.01 
,, 
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Tomato product consumption by the patients at baseline and 
at the end of the study 
Food Baseline End of study 
Tomatoes-raw 82% 77% 
Tomatoes-canned 13% 18% 
Tomatoes-cooked 5% 3% 
Tomato juice 0 1% 
Tomato soup 5% 3% 
Tomato sauce 67% 64% 
Baked beans/tomato sauce 37% 38% 
Spaghetti/tomato sauce 21% 17% 
Tomato paste (in cooked meal) 2% 3% 
Pizza (with tomato) 8% 6% 
Percentage of the group consuming item once over 4 day period. 
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Concentrations of plasma alpha and beta carotene (mean ± SD) 
a-Tocopherol Vitamin C Tomato Juice 
n=l2 n=12 n=15 
a-carotene, µmol/1 
Baseline 0.05 ±0.04 0.12±0.11 0.07 ± 0.04 
End of placebo 0.06 ± 0.05 0.12 ± 0.11 0.07 ±0.05 
End of study 0.04 ± 0.04 0.10 ± 0.09 0.06 ± 0.04 
~-carotene, µmol/1 
Baseline 0.31 ± 0.16 0.51 ± 0.38 0.33 ± 0.19 
End of placebo 0.32 ± 0.17 0.49 ± 0.36 0.36 ± 0.26 
End of study 0.26 ± 0.17 0.42 ± 0.29 0.47 ± 0.21 t 




0.08 ± 0.05 
0.09 ±0.05 
0.08 ± 0.04 
0.31 ± 0.2 
0.30 ± 0.24 
0.28 ± 0.22 
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Formation of TSARS in LDL after copper stimulated oxidation (mean ± SD) 
a-Tocopherol Vitamin C Tomato Juice Placebo p• 
n=12 n=12 n=15 n=13 
3 hour TBARS, 
mmol MDA/mol cholesterol 
Baseline 15.27 ± 3.45* 17.40 ± 3.13 19.12 ±4.59 19.48 ± 3.98 
End of placebo 13.00 ± 3.61 14.23 ± 3.64 18.22 ± 3.85 20.25 ±4.29 
End of study 13.62 ± 5.65 12.79 ± 4.05 18.35 ± 4.22 18.73 ± 4.14 0.463 
5 hour TBARS, 
mmol MDA/mol cholesterol 
Baseline 15.53 ± 3.48* 17.62 ± 2.75 19.18 ± 4.57 19.71 ± 3.87 
End of placebo 12.38 ± 4.38 14.74 ± 3.33 18.32 ± 5.89 20.42 ±4.30 
End of study 12.95 ± 6.06 11.65 ± 3.84 18.51 ± 4.48 18.96 + 4.62 0.134 
a Repeated measures ANOV A by treatment and group with baseline covariate correction. 
* ANOVA comparing antioxidant groups with placebo group at baseline, with level of significance P<0.05. 
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Formation of conjugated dienes in LDL after copper stimulated oxidation 
(mean± SD) 
a-Tocopherol VitaminC Tomato Juice 
n=12 n=12 n=15 
Maximal conjugated dienes, 
nmol/µmol LDL cholesterol 
Baseline 139 ± 26 137 ± 12 146 ± 17 
End of placebo 127 ± 16 132 ±29 144 ± 17 
End of study 138 ± 22 137 ± 22 149 ± 16 
Rate conjugated dienes, 
nmol/µmol LDL cholesterol/minute 
Baseline 1.10 ± 0.34 1.09 ± 0.38 1.13 ± 0.32 
End of placebo 1.13 ± 0.34 1.09 ± 0.39 1.12 ± 0.32 
End of study 1.12 + 0.34 1.10 + 0.39 1.12 + 0.32 





142 ± 15 
147 ± 15 
147 ± 19 
1.15 ± 0.39 
1.15 ± 0.40 
1.14 ± 0.38 
* ANOV A comparing antioxidant groups with placebo group at baseline, with level of significance P<0.05. 
',' V \.' 
P" 
0.501 
0.693 
